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CHAPTER 1 INTRODUCTION
1.1 Introduction to the ribosome
According to the central dogma of molecular biology, the genetic information stored in
DNA molecules is first transcribed into messenger RNA (mRNA) molecules and then translated
into proteins.1 The ribosome, which is a ribonucleoprotein complex, plays a significant role in
the translation process in all living organisms.2 The bacterial ribosome was first described as a
small particulate component by a cell biologist, George Palade, in 1955.3 The term "ribosome"
was proposed by scientist Richard B. Roberts at the end of the 1960s.4 In 1974, the Nobel Prize
in physiology was shared by Palade and two other scientists, Albert Claude and Christian de
Duve, for their work focusing on the discovery of the ribosome.5 Although it was known that the
ribosomes consist of ribonucleic acids (RNA) as well as proteins and they were capable of
synthesizing proteins, the main challenge was to determine the exact mechanistic steps of
translation.
In 1967, Carl Woese, Francis Crick, and Leslie Orgel were the first to suggest that RNA
could act as a catalyst, based on their determination of complex RNA secondary structures.6 In
the early 1980s, Thomas Cech and Sidney Altman independently demonstrated the catalytic
properties of RNA.7,8 In 1989, they won the Nobel Prize in Chemistry for their discovery.7,8 The
breakthroughs in RNA catalysis helped advance ribosomal RNA-focused research as well.9-12 By
this time, it was clear that the ribosome, composed of RNA and protein, was capable of
performing protein translation with the RNA component acting as the catalyzing force for
function.9,10 In 2009, Venkatraman Ramakrishnan, Thomas A. Steiz, and Ada E. Yonath won the
Nobel Prize for their invaluable contributions to determining the structure and function of the
ribosome.13-15 With these exciting discoveries and a greater appreciation from the scientific
community, the ribosome research field has been growing fast with still much to be learned
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about this fascinating organelle. A detailed view of the structure, dynamics, and function of the
bacterial ribosome will be discussed next.
1.2 Components that form the bacterial and eukaryotic ribosome
The ribosome is composed of two major subunits, referred to as large and small, which
are characterized by the sedimentation rate known as the Svedberg unit (S).16 One Svedberg (S)
is equal to 10-13 s. The bacterial ribosome is about 25 nm in diameter with a molecular mass of
2.4×106 Da and a sedimentation coefficient of 70S.17,18 As shown in Figure 1.1, the 70S
bacterial ribosome contains a large subunit known as 50S and a small subunit known as 30S.
Association of the 50S and 30S subunits leads to the complete 70S ribosome.

Figure 1.1 E. coli bacterial ribosome. (A) The large 50S subunit19 is composed of 23S rRNA in
yellow, 5S rRNA in pink, and 34 rproteins in green. (B) The small 30S subunit is composed of
16S rRNA in grey and 21 rproteins in cyan. (C) Association of the large and small subunits
forms the complete 70S ribosome (PDB ID: 2AW4).
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The eukaryotic ribosome is larger than the bacterial ribosome with 60S and 40S subunits
that together form the 80S ribosome.20 The ribosome is a ribonucleoprotein complex. Each
subunit of the ribosome can be further broken down into individual components, ribosomal RNA
(rRNA) and ribosomal proteins (rproteins). In bacterial ribosomes, the 50S subunit comprises 5S
rRNA, which contains 120 nucleotides, and 23S rRNA, which contains 2904 nucleotides.18 The
50S contains 34 rproteins. The 30S subunit comprises 16S rRNA, which contains 1542
nucleotides and 21 rproteins.19 The eukaryotic ribosome is about 25 nm in diameter with a
molecular mass of 4.2 × 106 Da.21 The 60S subunit comprises 28S rRNA containing 4718
nucleotides, 5.8S rRNA with 160 nucleotides, and 5S rRNA with 120 nucleotides. The 60S
contains 49 rproteins. The small subunit 40S contains 18S rRNA with 1874 nucleotides and 33
rproteins.20 Although the bacterial and eukaryotic ribosomes differ in overall size, they have
many highly conserved regions that are essential for the ribosomal functions.22 Since this thesis
work mainly focuses on the bacterial ribosome, all figures and explanations will be in reference
to the E. coli system.
1.3 Function and significance of the bacterial ribosome
In the late 1950s, Francis Crick proposed the central dogma of molecular biology.1 As
illustrated in Figure 1.2, the flow of genetic information is from "DNA to RNA to protein".
During the first step, DNA produces complementary DNA through a process called replication. 1
Following replication, the genetic information in DNA is transcribed into a messenger RNA
(mRNA) molecule. Finally, the genetic information encoded by the mRNA is translated into a
polypeptide chain. The ribosome is the machinery responsible for protein synthesis.9,10 In the
translation process, the ribosome can be considered as the working station, with mRNA as the
template and tRNA carrying the building blocks required for the synthesis.9,10
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The ribosome translation process involves four important steps: mRNA decoding,
peptidyl transfer, translocation, and termination. Each ribosomal subunit plays an important and
distinct role in the process. The major function of the large ribosomal subunit is to catalyze
peptide-bond formation between the amino acid on the aminoacyl transfer RNA (aa-tRNA) in
the aminoacyl site (A site) and the nascent polypeptide chain on the peptidyl site (P site),
whereas the main function of the small subunit is mRNA decoding in which the sequence is
"read" by the machinery.9,10 In the following section, these steps of bacterial protein translation
will be discussed in more detail.

Figure 1.2 The central dogma of molecular biology. This chart shows the flow of genetic
information from DNA to proteins. The genetic information in DNA is first transcribed into
RNA and then translated into proteins. DNA can undergo replication to produce more DNA, and
RNA can undergo reverse transcription to make DNA.
1.3.1 Translation initiation
As shown in Figure 1.3, translation initiation begins when the 30S subunit encounters a
single-stranded mRNA transcript. The initiator fMet-tRNAfMet is positioned over the start codon
of mRNA in the P site. Correct placement of the start codon on the ribosome is accomplished by
base pairing between the Shine-Dalgarno sequence upstream of the start codon and the antiShine-Dalgarno sequence at the 3' end of the 16S rRNA.23,24
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Figure 1.3 Translation initiation of the bacterial ribosome. A) An inactivated 70S ribosome is
approached by IF-3, which promotes subunit dissociation. IF-3 remains bound to the 30S
subunit. B) The mRNA with the start codon AUG and Shine-Dalgarno sequence upstream of the
start codon is recruited to the 30S subunit along with IF-1 and IF-2-GTP-fMet-tRNAfMet
complex. This combination forms the 30S initiation complex. C) IF-1 and IF-3 are released,
allowing for subunit association, and hydrolysis of GTP releases IF-2. The 70S initiation
complex is formed, allowing for elongation to begin.
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The initiation step is facilitated by additional proteins called initiation factors. The first
step in initiation is recycling of the 30S subunit, which dissociates from the 50S in the previous
translation cycle (described more in Section 1.3.3). Initiator factor 3 (IF-3) binding releases the
mRNA and deacylated tRNA on 30S remaining from the previous translation cycle. 24 The 30SIF-3 complex binds to mRNA, initiator factor 1 (IF-1), initiator factor 2 (IF-2), and initiator
tRNA (fMet-tRNAfMet) to form the 30S initiation complex. Initiation factor 2 (IF-2) promotes
binding of the 50S subunit to form the 70S initiation complex accompanied by IF-3 release.
After GTP hydrolysis of IF-2, fMet-tRNAfMet moves to the peptidyl transferase center (PTC) and
the ribosome is ready for the elongation phase. 25-27
1.3.2 Translation elongation
The intact ribosome has three compartments as follows. The A site binds incoming
aminoacyl-tRNAs (aa-tRNAs). The P site binds tRNAs carrying the growing polypeptide chain.
The E site is important for dissociation of the tRNAs so that they can be recharged with amino
acids. The initiator tRNA, fMet-tRNAfMet, binds directly to the P site. This creates an initiation
complex with a free A site ready to accept the aa-tRNA corresponding to the next codon after the
AUG start codon.25,27 The second stage of protein translation is known as elongation. In the
elongation cycle, the polypeptide chain is extended in the N to the C terminus direction by
sequential addition of amino acids. As shown in Figure 1.4, the elongation cycle is composed of
three main steps: decoding, transpeptidation, and translocation. The elongation process is
facilitated by two proteins called elongation factors. Elongation factor Tu (EF-Tu) delivers the
aa-tRNA to the ribosomal A site, and elongation factor G (EF-G) catalyzes translocation of the
tRNA and mRNA with respect to the ribosome.18 The aa-tRNA is delivered as a ternary complex
with EF-Tu and GTP.
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Figure 1.4 Translation elongation of the bacterial ribosome. Elongation is broken down into
three steps: decoding, transpeptidation, and translocation. These steps work in a cyclic fashion in
conjunction with the three elongation factors (EF-Tu, EF-Ts, and Ef-G; not pictured) until the
polypeptide sequence is complete.
The initial binding of the aa-tRNA ternary complex to the ribosome involves WatsonCrick base pairing between the mRNA codon and aa-tRNA anticodon. The mRNA and cognate
aa-tRNA interaction induces a conformational change of the universally conserved residues
A1493, A1492, and G530 in the 16S rRNA in order to stabilize the codon-anticodon interaction.
The complete accommodation of tRNA in the A site requires GTP hydrolysis on EF-Tu.28,29 This
process takes place at the GTPase center on the 50S subunit.30 After transmitting information
regarding the correct codon-anticodon interaction, GTP hydrolysis leads to dissociation of EF-Tu
from the ribosome. The tRNA aminoacyl end orients towards the PTC, which is located entirely
on the 50S subunit.31 The next step of elongation is transpeptidation, in which peptide-bond
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formation occurs. In the peptidyl-transferase reaction, the α-amino group of the aa-tRNA in the
A site attacks the carbonyl carbon of the ester linkage of the peptidyl tRNA in the P site.32-34 As a
result of the peptide bond formation, the nascent polypeptide chain on the P-site tRNA is
transferred to the A-site tRNA. After peptidyl transfer, the P site contains deacylated tRNA and
the A site contains peptidyl-tRNA. In order to empty the A site for the next incoming aa-tRNA
ternary complex, the P-site tRNA and A-site peptidyl tRNA have to move to the E site and P site,
respectively. This process is known as translocation, which is facilitated by EF-G.35 During each
translocation step, tRNAs shift from the P to E site and A to P site. During this process, the
ribosome undergoes a ratchet-like intersubunit rotation, in which the 30S subunit rotates counterclockwise with respect to the 50S subunit.35-38
During translocation, tRNAs go from classical A/A and P/P configurations to A/P and
P/E hybrid configurations. The E site traps the hybrid P/E tRNA efficiently and facilitates the
translocation.39 GTP hydrolysis occurs on EF-G, which triggers back-ratcheting of the 30S
subunit into the unrotated ribosome conformation.39,40 Upon complete back-ratcheting of the 30S
subunit, the entire ribosome moves by three nucleotides (one codon) on the mRNA. The
ribosome is now translocated to the next codon on the mRNA and ready for the next incoming
aa-tRNA into the open A site.
1.3.3 Translation termination
The final step of protein translation is termination. The addition of amino acids to the
polypeptide chain continues until a stop codon reaches the A site. When the ribosome encounters
a stop-codon sequence —UAA UAG, or UGA— on the mRNA, termination occurs. Stop codons
are recognized by a protein called release factor (RF) instead of a tRNA. RF-1 decodes UAA and
UAG stop codons whereas RF-2 decodes UAA and UGA stop codons (Figure 1.5). RF-3 forms
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a complex with GTP, then binds to the ribosome and induces hydrolysis of the nascent
polypeptide chain from the P-site tRNA. The cleaved polypeptide chain then exits the ribosome
through the exit tunnel.41,42 Ribosome recycling factor (RRF) can then bind to the A site in
conjunction with EF-G/GTP complex.43 The hydrolysis of EF-G allows RRF to be translocated
to the P site, in a similar fashion described in the elongation step, which shifts the remaining
tRNAs out and into the E site. This process ultimately releases the RRF and hydrolyzed EFG/GTP complex with mRNA, leaving behind an inactive 70S ribosome.
1.4 Ribosomal RNA structure and modifications
Ribosomal RNA has a primary functional role in all stages of protein synthesis. The
discovery of the catalytic activity of RNA provided support for rRNA as the basic functional
element of the ribosome. Previous studies in which ribosomal proteins were removed from
ribosomes followed by activity assays indicated catalytic activity of the rRNA.44,45
Determination of the secondary structures of the 5S, 16S, and 23S rRNAs expanded their
possible functional roles.22,46,47 Most importantly, solving the crystal structures of ribosomes
vastly increased our understanding of the protein synthesis machinery and verified the role of
rRNA as the catalytic domain for translation.14,48
Ribosomal RNA is post-transcriptionally modified in several sites by a variety of
ribosome-related enzymes. The sites and the number of rRNA modifications vary across
phylogeny.19,49,50 The E. coli ribosome contains a total of 36 of modifications, 11 in 16S rRNA
and 25 in 23S rRNA.22 The list of all nucleotide modifications present in E. coli 16S rRNA and
responsible enzymes are shown in Table 1.1. The same information for 23S rRNA is given in
Table 1.2. There are three main types of nucleotide modification in rRNA: 1) isomerization of
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uridine to pseudouridine (Ψ); 2) methylation of 2' hydroxyls (Nm); and 3) alterations to bases,
most of which undergo methylation at different positions (mN).49,51

Figure 1.5 Translation termination of the bacterial ribosome. Release factor one (RF-1) or
release factor two (RF-2) recognize the stop codon (e.g., UAA). This stimulates the recruitment
of RF-3 bound to GTP, which, upon hydrolysis, recruits EF-G bound to GTP and the ribosome
recycling factor (RRF) upon its release. Upon a second hydrolysis of the GTP bound to EF-G,
the mRNA, remaining tRNA, and termination factors are released, leaving an inactivated 70S
ribosome.
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According to the secondary structural maps (Figures 1.6 & 1.7) and high-resolution xray crystal structures of the ribosome, modified nucleotides are highly localized in the most
functionally important regions of the ribosome.19,50 In particular, regions such as the A site, PTC,
polypeptide exit channel, and intersubunit bridge region are highly modified. Their occurrence in
functionally important regions of the ribosome suggests possible roles of modified nucleotides in
protein translation.19,50
Table 1.1 Nucleotide modifications in E. coli 16S rRNA
Modification

Position

Enzyme

Enzyme class

References

m2 G

966

RsmD

MT

52-55

m7 G

527

RsmG

MT

56-58

m2 G

1207

RsmC

MT

53,54,59,60

m2 G

1516

RsmJ

MT

53, 61,62

m5 C

967

RsmB

MT

63-65

m5 C

1407

RsmF

MT

66,67

m4Cm

1402

RsmH

MT

66-73

m26A

1518

RsmA

MT

39

m26A

1519

RsmA

MT

74-76

m3 U

1498

RsmE

MT

74,75

Ψ
516
RsmA
MT: methyltransferase; PS: pseudouridine synthase

PS

76-78

The importance of post-transcriptional modification for protein synthesis was first
revealed by carrying out in vitro protein translation with E. coli ribosomes reconstituted with
unmodified 16S and 23S rRNA.79 In these experiments, the greater ability of fully modified
ribosomes to carryout protein synthesis compared with unmodified ribosome was revealed.
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Therefore, it is suggested that rRNA modifications play an important role in structure and
function of the ribosome.
Table 1.2 Nucleotide modifications in E. coli 23S rRNA
Base

Modification

Position

Enzyme

G
m1G
745
RlmA(l)
G
m2G
1835
RlmG
7
G
mG
2069
RlmKL
G
Gm
2251
Mrm1
5
C
mC
1968
Rlml
C
Cm
2498
RlmM
2
C
sC
2501
6
A
mA
1618
RlmF
6
A
mA
2030
RlmJ
2
A
mA
2503
Cfr
U
Ψ
746
RluA
5
U
mU
747
RlmCD
U
Ψ
955
RluC
U
Ψ
1911
RluD
U
Ψ
1915
RluD
3
U
mΨ
1915
RluH
U
Ψ
1917
RluD
5
U
mU
1939
RlmD
U
D
2446
U
Ψ
2457
RluE
U
Ψ
2504
RluC
U
Um
2552
RlmE
U
Ψ
2580
RluC
U
Ψ
2604
RluB
U
Ψ
2605
RluF
MT: methyl transferase; PS: pseudouridine synthase

Enzyme
Class

References

MT
MT
MT
MT
MT
MT
MT
MT
MT
PS
MT
PS
PS
PS
PS
PS
MT
MT
PS
PS
MT
PS
PS
PS

80-82
53,83
83-87
87
88-90
67,91
51
92
93-99
93-99
76,100-104
105,106
106,107
108
109-113
88,109-114
108,115-117
111,118-121
122
106-108
123-126
127
121,128-130
121,131
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Figure 1.6 Secondary structure of E. coli 16S rRNA. 14 Modified RNA nucleotides are labeled
with arrows.
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Figure 1.7 Secondary structure of E. coli 23S rRNA (shown in two pages).14 Modified RNA
nucleotides are labeled with arrows.
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Figure 1.7 continued
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Half of the currently available antibiotics target the functionally important regions of the
bacterial ribosome.132 Therefore, it would not be surprising if those rRNA modifications played
an important role in mediating ribosome-antibiotic interactions. Modifications such as
methylation in bacterial rRNA are known to confer resistance to antibiotics.49 Therefore, posttranscriptional modifications appear to play an important role in modulating structure and
function of rRNA.
1.5 The bacterial ribosome as a dug target
The key roles in protein biosynthesis, structural complexity, easy accessibility, and high
abundance in the cell make the ribosome an ideal target for the development of antibacterial
drugs.132,133 Therefore, it is not surprising that half of the currently available antibiotics target the
different functional centers within the bacterial ribosome. Based on the binding site in the
ribosome, antibiotics can be classified into three major types: 1) the decoding-region antibiotics;
2) PTC and exit tunnel antibiotics; and 3) other types, including those targeting the translationrelated protein factors.
1.5.1 Decoding-region targeting antibiotics
The decoding region of the ribosome involves mRNA translation and provides fidelity of
codon-anticodon interactions during protein translation.28,134 It is part of the bacterial A site and
resides in the helix 44 (h44) region of the 30S ribosomal subunit. Aminoglycosides with a 2deoxystreptamine ring (Figure 1.8) are known to inhibit protein translation by binding to the 30S
ribosomal subunit.135,136 Neomycin, paraomomycin, kanamycin, and gentamicin are some
examples in this class. The initially identified primary binding site of this family of antibiotics is
the decoding region, namely the intersubunit bridge B2a.137-139 Upon binding to h44,
aminoglycosides stabilize the A site in an extra-helical conformation. This conformational
change shifts the position and dynamics of two universally conserved residues, A1492 and
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A1493, which are responsible for recognition of the mRNA codon-aminoacyl-tRNA
complex.138,140,141 This stabilized conformational state leads to incorporation of incorrect aatRNAs, and decreased translation fidelity.134,142 However, decreased translation fidelity alone has
little effect on cell growth. Literature reports revealed that bacteria strains harbouring error-prone
ribosomes are still viable.143,144Also, evidence of specific aminoglycosides inhibiting protein
synthesis without exhibiting miscoding suggests that miscoding is not the only mechanism of
action of aminoglycosides.145 Furthermore, these combined observations suggest that
aminoglycosides may interact with more than one functional site in the bacterial ribosome.
Interestingly, crystal structures have shown that neomycin, paramomycin, and
gentamincin are able to interact with the major groove of helix 69 (H69) of 23S rRNA as well.
138,146,147

The interaction with H69 provides a possible mechanism for how aminoglycosides

inhibit the recycling and translocation steps of protein synthesis.33, 46 However, the bactericidal
nature of 2-deoxystreptamine aminoglycoside antibiotics is still poorly understood despite
decades of clinical use and biochemical studies. The emergence of strains with antibacterial
resistance as well as impaired hearing and kidney functions at high doses of aminoglycosides
make them less effective in clinical applications. Viomycin and capreomycin (Figure 1.8) are
cyclic peptides belong to tuberactinomycin family antibiotics.148 Recent studies have shown that
these cyclic peptides target the bacterial ribosome. According to crystal structures, both cyclic
peptides bind to the same site of the ribosome, which lies at the interface between h44 of the 30S
and helix 69 (H69) of the 50S subunits. These peptide antibiotics are known to inhibit the
translocation step of protein synthesis by stabilizing the tRNA in the A site in the pretranslocation state.147,149
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Figure 1.8 Aminoglycoside antibiotics. Chemical structures of the decoding-region targeting
antibiotics are shown with the common 2-deoxystreptamine motif highlighted in red. The cyclic
peptide capreomycin is shown for comparison.
1.5.2 Peptidyl-transferase center and exit-tunnel targeting antibiotics
The ribosomal PTC resides in the 50S subunit and catalyzes the two principle chemical
reactions of protein translation, peptide bond formation and peptide release.24 As the key
functional domain of the ribosome, it is not surprising that different classes of antibiotics target
this site on the ribosome. These antibiotics include clinically important antibiotics such as
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macrolides, lincosamides, streptogramins, chloramphenicol, and the oxazolidinones.17,132 Among
these, macrolides are the clinically most important class of antibiotics. Macrolides are naturally
occurring polyketide compounds that consist of a large macrocyclic lactone ring to which one or
more deoxy sugars are attached.150 Crystal structures of various macrolides bound to the 50S
ribosomal subunit were solved.150 According to the crystal structures, macrolides bind within the
peptide exit tunnel, adjacent to the PTC. This binding sterically blocks the peptide exit channel,
which in turn inhibits entrance of the nascent polypeptide chain and causes premature
dissociation of the peptidyl-tRNA from the ribosome.150,151 The binding sites of lincosamides
and streptogramins overlap with macrolides and their mechanisms of action are proposed to be
the same.17,132 Even though the binding site overlaps, the mechanism of action of the
oxazolidinones is different from all existing PTC-targeting antibiotics.152,153 Recently, it was
shown that oxazolidinones inhibit fMet-tRNAfMet binding to the P site and inhibit the formation
of initiation complex.152,153 On the bacterial ribosome, chloramphenicol binds at the PTC in a
position that overlaps with the amino-acyl moiety of the A-site tRNA and inhibits peptide-bond
formation by blocking aa-tRNA binding this site.154
1.5.3 Other antibiotics
On the bacterial ribosome most of the antibiotic binding sites are clustered at or near the
PTC region and the decoding center.132 However, there are a few exceptions. Evernimicin
(Figure 1.9), an oligosachcharide antibiotic isolated from Micromonospora carbonaceae,
exclusively binds to the 50S subunit.155 Although crystal structures of evernimicin bound to the
ribosome are not available, chemical footprinting and mutagenic studies showed that the drug
binds to the helix 89 and helix 92 regions of 23S rRNA155. Furthermore, evernimicin forms
additional contacts with the ribosomal protein L16 as suggested by mutation studies.156,157
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Figure 1.9 Peptidyl-transferase center and exit-tunnel targeting antibiotics. Chemical
structures of the PTC and exit-tunnel targeting and other type of antibiotics are shown.
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Interestingly, the binding site of evernimicin on the 50S subunit does not overlap with the
binding site of other antibiotics, which may be the reason why cross-resistance is not prevalent
with these clinical isolates. Thiostrepton is an antibiotic from the thiopeptide family.
Biochemical and NMR studies showed that thiostrepton binds to 23S rRNA at the GTPaseassociated domain of the 50S subunit.158 The drug interacts with the ribosomal protein L11 and
residues A1067 and A1095 of 23S rRNA.158,159 Upon binding, thiostrepton interferes with EF-G
binding to the ribosome and inhibits the ribosome translocation.158,159 Fusidic acid is another
antibiotic that is known to target EF-G. Upon binding to the protein, fusidic acid prevents its
release from the ribosome after GTP hydrolysis.159 As a result, the ribosome is trapped as the EFG/GDP ribosome complex, which inhibits the next step of protein translation, namely the aatRNA selection step.160
1.6 The emergence of antibiotic resistance
Antibiotics have been used for the past 70 years to treat infectious diseases.161,162
Although antibiotics were thought to be the perfect solution to bacterial infections, the
emergence of resistance has become a global health issue.132,163 The ability of bacteria to oppose
the inhibitory effects of these drugs is known as antibiotic resistance. Antibiotic resistance is
accelerated by overuse of antibiotics as well as poor infection prevention and control.164 In 2013,
the United States Center of Disease Control and Prevention reported that each year in the United
States at least two million people become infected with bacteria and 23,000 people die as a result
of these infections.165,166 The World Health Organization (WHO) has named antibiotic resistance
as one of the three most important public health threats of the 21st century.163,165 Therefore,
WHO has been leading multiple initiatives to address the problem of antibiotic resistance.165,166
A global action plan on antibiotic resistance was endorsed at the World Health Assemble in May
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2015.163 The global action plan on antimicrobial resistance has five strategic objectives: 1)
improve awareness and understanding of antimicrobial resistance; 2) strengthen surveillance and
research; 3) reduce the incidence of infection; 4) optimize the use of antimicrobial medicines;
and 5) ensure sustainable investment in countering antimicrobial resistance.167,168 Antibiotic
resistance is a global health problem requiring efforts from all nations and all levels of society to
prevent and control.
1.7 Resistance mechanisms in bacteria
Understanding the underlying mechanisms of antibiotic resistance is essential for novel
therapeutic development. There are three fundamental antibiotic resistance mechanisms in
bacteria.169 Modifications of the antibiotic molecules are some of the most effective resistance
mechanisms. This can be a chemical alteration or destruction of the antibiotic molecule through
the production and action of specific enzymes.161 There are many types of modifying enzymes
that catalyze acetylation (aminoglycosides, chloramphenicol, streptogramins), phosphorylation
(aminoglycosides, chloramphenicol), and adenylation (aminoglycosides, lincosamides) of the
antibiotic molecule.161 The best examples are the aminoglycoside modifying enzymes that
covalently modify the amino or hydroxyl groups of the aminoglycoside molecule.161
Aminoglycoside

modifying

enzymes

have

become

the

predominant

mechanism

of

aminoglycoside resistance worldwide.170,171 The best example of deactivation of an antibiotic
molecule is the mechanism shown by penicillin-resistance bacteria.172 Penicillin is a β-lactam
antibiotic that targets the bacterial cell wall. Production of the β-lactamase enzyme deactivates
the antibiotic. The enzyme destroys the amide bond of the β-lactam ring, which is responsible for
the antibiotic activity, therefore rendering the antibiotic ineffective.173
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The next antibiotic resistance mechanism involves reduced antibiotic penetration or
export of the drugs using efflux systems.174,175 Most of the clinically used antibiotics have
intracellular drug targets. Therefore, the drug must penetrate the outer membrane and accumulate
inside bacterial cells in order to exert its antimicrobial activity. In gram-negative bacteria, the
outer membrane acts as the first line of defense against the penetration of hydrophilic antibiotic
molecules.176,177 For example, vancomycin, a glycopeptide antibiotic, is not active against gramnegative bacteria due to its lack of penetration through the outer membrane.178 Efflux-mediated
antibiotic resistance is another common mechanism found in both gram-negative and grampositive bacteria.179,180 Bacterial efflux pumps are proteins that are localized in the plasma
membrane. 180,181 The function of efflux pumps is to recognize and extrude toxic compounds out
of the bacterial cell. Tetracycline resistance is one of the best examples of efflux-mediated
resistance in gam-negative bacteria.180,181 Gram-positive bacteria show efflux-mediated
resistance to macrolides, lincosamides, and strepogramins.180,182
Target-site modification is the most common antibiotic resistance mechanism found in
pathogenic bacteria, affecting almost all families of antibiotics.132 Target alterations may consist
of enzymatic modifications of the binding site (addition of methyl group) or point mutations in
the genes encoding the target site. Macrolide resistance, which is caused by rRNA methylation,
is a well-characterized example of target-site modification.183 Methyltransferase Erm catalyzes
methylation of the adenine residue at position A2058 of 23S rRNA.184 As a result of this methyl
modification, binding of the antibiotic molecule to its target is impaired. Expression of the erm
genes confers resistance not only to macrolides, but also to lincosamides and streptogram B,
since these antibiotics have overlapping binding sites on the 23S rRNA.183,184 In the case of
aminoglycoside antibiotics, methylation of the N7 position of G1405 or N1 position of A1408
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confers resistance to the geneticin or neamine, respectively.185,186 Besides enzymatic
modifications, a site-specific mutation of the target site is enough to confer resistance to
antibiotics. For example, A1408G mutation in 16S rRNA confers resistance to aminoglycosides
such as neomycin.187 Studies with model rRNA showed that the A1408G mutation reduces
binding affinity of the antibiotic molecule to the A site, which causes antibiotic resistance.188
As mentioned earlier, half of the currently available antibiotics target the bacterial
ribosome.132 However, bacteria have developed resistance to most of these drugs.132,189
Therefore, development of unique antibiotics targeting functionally important regions of rRNA is
one promising way to overcome this issue. Most currently used antibiotics target key functional
domains of the ribosome, such as the PTC and decoding center. Discovery of new drugs
targeting these key functional domains is difficult, since a variety of resistance mechanisms
involving these locations may already exist. Therefore, identification of novel druggable targets
in the bacterial ribosome and discovery of compounds that selectively target those regions is a
possible approach to combat antibiotic resistance.190-193
1.8 Helix 69 region of 23S rRNA as a novel drug target
Structural information obtained from x-ray crystallography has indicated that there are
many key regions of ribosomal RNA (rRNA) that could serve as antibacterial drug targets.132
The specific conserved region of the ribosome under investigation in this study is helix 69
(H69).22 Helix 69 is a 19-nucleotide hairpin-loop structure that is located in domain IV of the
23S rRNA in the 50S subunit.22,194 It interacts with helix 44 (h44) of the 16S rRNA to form
intersubunit bridge B2a (Figure 10), which plays significant roles in various ribosomal
functions, including subunit association, translocation, peptide release, and ribosome
recycling.50,195 The nucleotide sequence of H69 contains three post-transcriptionally modified
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nucleotides, or pseudouridines (), at positions 1911, 1915, and 1917 (Figures 1.11 and Figure
1.12).196

Figure 1.10 The location of H69 in the 70S full
ribosome. H69 (in purple) is located at the
junction between the 30S and 50S ribosomal
subunits. It makes a direct interaction with helix
44 (h44), known as the aminoacyl tRNA site (A
site) (in cyan), of the 30S subunit. Its proximity
to essential translational machinery and at the
interface of the two subunits makes H69 a
potentially important antibacterial drug target.
(PDB ID: 2AW4).19,50

The nucleotide sequence of H69 is highly conserved in bacteria, archaea, and
eukaryotes.22 However, there are some noticeable differences between the H69 sequences of
bacteria (E. coli) and eukaryotes (H. sapiens) (Figure 1.11). The 1915 position of H69 in E. coli
is a methylated , whereas in human it is unmethylated.196,197 The nucleotide at the 3' end of the
loop is an adenosine (A) in E. coli and guanosine (G) in H. sapiens.22,198 Thirdly, the H. sapiens
H69 has two extra s in the stem region of the hairpin.194 Considering the variety of functions of
this motif in protein biosynthesis as well as the sequence conservation and key differences
between bacterial and human H69, it is an attractive antibacterial drug target.
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Figure 1.11 The secondary structures and sequences of modified and unmodified H69. The
secondary structures of unmodified (UUU) and modified E. coli (m3) and modified human
H69 show sequence differences (, pseudouridine; m3, 3-methylpseudouridine). Nucleotides
in upper case letters in the E. coli H69 sequence have >95% conservation and those in lower case
have 88–95% conservation across phylogeny.22

Figure 1.12 Chemical structures of pseudouridine, 3-methylpseudouridine, and uridine.
Pseudouridine (Ψ, left) is a post-transcriptional modification of uridine (U, right). The difference
between these two structures is a 120° rotation of the base in pseudouridine, forming a C–C
glycosidic bond versus the canonical C–N glycosidic bond shown in uridine. Threemethylpseudouridine (m3Ψ, middle) differs from Ψ only by a methylation on the 3-position of
the base.
1.9 Antimicrobial peptide research
In order to provide effective treatments for future bacterial infections, innovative
approaches to antimicrobial drug development are necessary, preferably with novel modes of
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action or discovery of new drug classes. Recently, antimicrobial peptides (AMPs) have become
promising compounds for drug development.199-201 AMPs are essential components of the innate
immune system.199,202 Being “nature’s antibiotics”, AMPs form the first line of host defense
against pathogenic infections.202-204 During the past few decades, AMP research has grown
rapidly in response to the demand for novel antibacterial agents to treat multi-drug resistance
pathogens.199,204 To date, the AMP database lists 2848 peptides with antimicrobial activity,
which have been synthesized or discovered in natural sources.205 This list includes AMPS from
six kingdoms, three hundred and one peptides from bacteria (bacteriocins), four from archaea,
eight from protista, thirteen from fungi, 343 from plants, and 2179 from animals.205-207 AMPs are
usually made up of between 12 to 50 amino acid residues and differ widely in their sequence and
structure.201,204 Most of the AMPs are polycationic and about 50% of their amino acids are
hydrophobic.200,207 The amphipathic nature enables AMPs to preferentially target the anionic
bacterial membranes. Therefore, in contrast to small molecule antibiotics, most of the AMPs
target the bacterial cell membrane and kill bacteria by lytic mechanisms.203,208,209
The bacterial cell membrane is an evolutionary conserved component of bacteria and
rarely undergoes mutations. Therefore, AMPs are less likely to develop bacterial resistance.
Interestingly, most of the AMPs are bactericidal and kill bacteria more rapidly than conventional
small molecule antibiotics.199 Compared to the bacterial cell membrane, the human cell
membrane is dominated by phospholipids and cholesterols. The differences in membrane
composition are the major reason for the selectivity of AMPs. However, the lytic activity of
AMPs is a major concern when it comes to AMP-based therapeutic development. Higher peptide
concentrations might cause toxic effects on mammalian cell membranes, which limit the clinical
potential of the drug.162,210 Therefore, during the past few decades, there have been efforts to
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discover AMPs that kill bacteria by targeting intracellular processes rather than lytic
mechanisms. Recent studies suggest that a number of AMPs are able to act on intracellular drug
targets as their major mechanism of action.211,212 For example, many cationic AMPs have been
shown to interact with nucleic acids. Buforin II and indolicidin are well-characterized cationic
AMPs that are known to interact with DNA.213,214 Most recently, it was shown that proline-rich
AMPs (PrAMPs) inhibit protein translation by strongly binding to the 70S ribosome.215,216 The
identification of intracellular targets of antimicrobial peptides provides more therapeutic options.
1.9.1 Peptides as ribosome-targeting ligands
The development of peptide ligands that specifically bind to higher-order structures of
ribosomal RNA is one promising way to address the problem of antibiotic resistance. Since
peptides are the natural building blocks of proteins, they do not identify as foreign invaders by
the host immune system.199,212,217 Therefore, compared to conventional antibiotics, the
development of drug resistance would be harder with peptide antibiotics. In addition, peptides
can be easily modified by incorporating additional functional groups or directly modifying the
peptide backbone. Such modifications would enhance the structural stability, cell permeability,
as well as affinity and selectivity of peptide antibiotics.
Viomycin and capreomycin are cyclic peptides that belong to the tuberactinomicin family
of antibiotics (Figure 1.8). These two cyclic peptides are among the most effective antibiotics
against multi-drug resistance tuberculosis.149 Recently, it was found that both of these cyclic
peptides bind to the highly conserved intersubunit bridge B2a region of the ribosome and interact
with H69 of the 50S subunit and h44 of the 30S subunit simultaneously.148 These antibiotics are
known to inhibit ribosome translocation by stabilizing the A-site-tRNA interaction.149 Prolinerich antimicrobial peptides (PrAMPs) have attracted considerable attention in recent years as
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promising candidates to combat multidrug resistance gram-negative pathogens.210,215,218
Interestingly, recent studies in several laboratories showed that two insect-derived PrAMPs,
oncocin and apidaecin, inhibit protein translation both in vitro and in vivo by strongly binding to
the 70S ribosome.215,216 Shortly afterwards, it was shown that a mammalian-derived PrAMP,
bactenecin Bac7, also targets the 70S ribosome.219,220 In 2015, the crystal structure of oncocinbound Thermus thermophilus ribosome was solved.221,222 According to the crystal structure,
oncocin binds to the 50S ribosomal subunit where it blocks the PTC and destabilizes the
initiation complex.221-223 Further structural and biochemical studies indicate that PrAMPs inhibit
the transition from the initiation to elongation phase of protein translation.223 However,
apidaecin-type peptides show a different translational inhibition mechanism by blocking
assembly of the 50S subunit of the ribosome.224,225 Several research groups and companies are
optimizing PrAMPs as promising compounds to treat systemic infections caused by gramnegative bacteria.226 More details about PrAMPs will be discussed in Chapter 2.
The binding sites of most of the newly discovered antimicrobial peptides overlap with the
binding sites of conventional antibiotics.199,210 For example, the binding site of PrAMPs on the
50S subunit overlaps with that of many clinically important antibiotics such as the macrolides,
chloramphenicols, lincosamides, and pleuromutilins.222,223 Therefore, the resistance mutations
that arise against currently used antibiotics will also confer cross-resistance to these newly
identified antimicrobial peptides. As such, the development of peptide ligands targeting novel
druggable sites of the bacterial ribosome is a different strategy to overcome the problem of
antibiotic resistance. Recent studies in several laboratories have identified short peptides
targeting new sites of the bacterial ribosome.190,216,221-223,227 In these studies, phage display was
used to identify unique peptides against rRNA regions of interest. Short peptides with moderate
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affinity (µM) and selectivity towards relatively unexplored regions of the bacterial ribosome
such as helix 31 (970 loop) and h18 pseudoknot of 16S rRNA, or helix 69 of 23S rRNA were
identified from random peptide libraries.190-193 Some of these selected peptides showed inhibition
of bacterial protein translation in cell-free translation systems and displayed desirable features
for development as lead compounds for novel antimicrobials.190,192,193 In fact, these selected
peptides can be used as tools to validate novel antibiotic binding sites in the ribosome and to
develop drug leads using peptidomimetic approaches.
1.9.2 The challenges and future of the antibiotic peptide research
AMPs display remarkable structural and functional diversity and rapidly attracted
attention as novel antibiotic candidates. The broad spectrum of activity, low propensity to
develop bacterial resistance, higher target specificity, and strong bactericidal activity make
AMPs promising drug candidates. However, there are still some limitations in antibiotic peptide
research that need to be addressed before AMPs can be applied clinically.
The poor correlation between in vitro antimicrobial activity and in vivo efficacy is one of
the major obstacles that has limited the progression of AMP candidates towards clinical
development.162,228,
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Most commonly, the identification of therapeutic peptides starts with in

vitro screening of peptide libraries. This can be done with a random peptide library or peptide
library derived from a known AMP.191,215 For example, with the phage display technique,
random phage-displayed peptide libraries are incubated with a target of interest to select for
those specifically bind the target.230 Typically, the target is immobilized on a solid support before
addition of the phage library. However, in these in vitro screening techniques, the most crucial
peptide-target interaction step occurs in a simulated environment, which is very different than the
actual cellular environment.228,229 This process also requires identification and synthesis or
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isolation of the target prior to the experiment, as well as the assumption that the target is in its
bioactive conformation under these in vitro conditions. Another important concern is that targets
such as DNA, RNA, or proteins have numerous conformations in vivo that are influenced by
their environment. Peptides are also highly sensitive to their environmental conditions, which
results in discrepancies between their in vitro and in vivo activity. The development of in vivo
peptide libraries would be an alternative approach to overcome the limitations of in vitro peptide
library screens.231-234
Solid-phase peptide synthesis (SPPS) is the most commonly used method for chemical
synthesis of therapeutic peptides. However, the relatively high cost of SPPS compared to
bacterial production is considered as one of the major limitations in AMP research.200,229,235
Recent evidence suggests that the production cost of a 5000 Da molecular mass peptide exceeds
the production cost of a 500 Da molecular mass small molecule by more than 10-fold.235
Therefore, the high cost of SPPS for clinical applications is a challenge in the AMP optimization
process. After identifying an AMP from a natural source or from a peptide library screen, the
next critical step is to obtain optimized structural analogs. Usually the optimization process is
done by minimizing the peptide length and systematically substituting each amino acid
residue.235 This process is typically expensive and time consuming due to the need to employ
SPPS. As a result of the above-mentioned limitations, out of thousands of identified AMPs, only
a few have actually been studied in any great detail.
1.10 Objectives associated with this thesis work
The development of short peptides that specifically bind to higher-order structures of
ribosomal RNA is one promising way to address the problem of antibiotic resistance. These
peptides could potentially be developed into small molecule drugs. Recent studies in several
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laboratories including ours have identified heptamer peptide sequences targeting rRNA
motifs.191,192,215,216,221-223 Most of these studies were confined to in vitro systems, including
binding studies with small model rRNAs,191,192 in vitro chemical footprinting studies with
isolated ribosomes,221 or elucidation of crystal structures of peptide-bound ribosomes.221-223 The
poor correlation between in vitro and in vivo activities of these peptides is one of the major
limitations in antibiotic peptide research. Therefore, in contrast to these in vitro methods, one of
the main objectives of my dissertation work was to utilize a plasmid-based system to in vivo
express ribosome-targeting peptides and study their direct inhibitory effects on bacteria. There
are some additional applications of the plasmid-based in vivo expression system. For example,
we can utilize this system to in vivo probe peptide-ribosome interactions, express peptide
mutants, generate peptide libraries, or study a variety of other biologically interesting peptides
(e.g., anti-freeze peptides).
In my dissertation research, the main focus was on helix 69 (H69) of the 50S subunit.
Helix 69 is proposed to be a potential drug target based on its pivotal role in ribosome protein
synthesis at multiple stages and its unique higher-order RNA structure. Helix 69 could
potentially be targeted by small molecules such as peptides or DNA/RNA aptamers to interfere
with the naturally occurring intersubunit interaction. In previous studies, the phage-display
method was used to identify peptides that target the H69 region.192,236 In vitro binding studies
have shown that these selected peptides have moderate affinity towards H69.191 In a second
approach, peptide variants with higher affinity and enhanced selectivity were identified by doing
alanine and arginine scans of the parent peptide sequence derived from phage display.191
Specificity, stoichiometries and binding affinities of these peptides to H69 were determined by
using in vitro methods. Our working hypothesis was that the selected peptides will bind to H69
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and disrupt ribosome function. However, the in vivo activity of these peptides was not
determined. Therefore, we hoped that in vivo expression of peptides would allow us to study the
behavior of selected peptides in the actual cellular environment.
Another important type of small molecule considered in this thesis work is the
aminoglycoside, a well-known antibiotic that targets the bacterial ribosome. The initially
identified primary binding site of the 2-deoxystreptamine family of antibiotics is the h44 region
of the small subunit adjacent to the decoding site.132,139 Recent x-ray crystal structures have
shown that neomycin, paromomycin, and gentamicin are able to interact with the major groove
of H69.138,140,146,147 However, the bactericidal nature of 2-deoxystreptamine aminoglycoside
antibiotics is still poorly understood.140,146 Previous work in our lab revealed that 
modifications are important for efficient binding of aminoglycosides to H69.237,238
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However,

the effects of  modifications on the bactericidal activity of aminoglycosides have not been
examined. The work presented in the fourth chapter of this thesis discusses the effects of s in
H69 on the bactericidal nature of 2-deoxystreptamine aminoglycoside antibiotics. The
information gained from these studies provides deeper insight into the underlying mechanism of
action of aminoglycosides, which is important for the development of unique antibiotics that
target the bacterial ribosome at novel sites such as H69.
In contrast to in vitro methods, most of the work I did for my dissertation is focused on
the in vivo activity of antibacterial drugs targeting the bacterial ribosome. In fact, the methods I
developed are not confined to ribosome-targeting drugs. We can expand this work to study the in
vivo activity of other drugs as well. In order to achieve the main goals of my dissertation work,
three specific aims were developed:
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Aim 1) Optimized a specific plasmid system to in vivo express a ribosome-targeting peptide,
oncocin, in bacteria and map its rRNA binding sites
The specific plasmid system I utilized for this study was developed by Dr. Phillip
Cunningham's lab in the Department of Biological Sciences at Wayne State University.231 In the
Cunningham lab, they developed a series of plasmid systems to in vivo express random peptide
libraries to identify inhibitory peptides. I optimized one of their plasmid systems to in vivo
express the ribosome-targeting peptide oncocin (VDKPPYLPRPRPPRRIYNR) and its variants
in bacteria. The interaction of the peptide with the bacterial ribosome was studied by doing in
vivo chemical footprinting experiments.
Aim 2) Utilized the plasmid system to in vivo express H69-targeting peptides
The optimized-plasmid system was utilized to in vivo express H69-targeting peptides in
bacteria. In the first approach, H69-targeting peptide were in vivo expressed as Green
Fluorescent Protein (GFP)-tagged fusion peptides. In order to further characterize the selected
peptides as potential drug leads, it is essential to determine their activity outside the context of
the fusion protein. Therefore, in the second approach a different plasmid system was used to
express H69-targeting peptides as free peptides in bacteria. The effects of these peptides on
bacterial protein translation and growth were monitored through fluorescent intensities and
optical densities of cultures expressing the peptides.
Aim 3) Evaluated the effects of pseudouridine modifications on the antibacterial activity of
2-deoxystreptamine class aminoglycosides
Minimum inhibitory concentration (MIC) studies were carried out with Ψ-deficient and
wild-type E. coli strains using the broth micro dilution method. E. coli MC 415 (wild-type,
ΨΨΨ) and E. coli MC 416 (RluD(–), UUU) were utilized in the study (Michael O'Connor's lab,
University of Missouri). MIC experiments were carried out with a series of aminoglycosides that
are known to target the H69 and A site of the ribosome.
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CHAPTER 2 MOLECULAR BIOLOGICAL AND BIOCHEMICAL METHODS
USED IN THE DISSERTATION WORK
2.1 Abstract
In contrast to in vitro methods, most of the work I did for my dissertation is focused on
the in vivo activity of antibacterial drugs targeting the bacterial ribosome. The details of the
molecular biological, microbiological, and biochemical methods I utilized in my dissertation
work are discussed in this chapter. The main focus of Chapter 3 and 4 is in vivo expression of
antibacterial peptides in E. coli. In this work, specific plasmid systems developed in Dr. Phillip
Cunningham's lab were utilized. Basic molecular cloning techniques and methods such as the
polymerase chain reaction (PCR), ligation, transformation, colony PCR, and DNA sequencing
were employed in this work. Activities of the peptides were assessed using bacterial growth
assays. Moreover, an in vivo dimethyl sulfate footprinting technique was used to study peptideribosome interactions. The main focus of Chapter 5 is evaluation of the effects of pseudouridine
modifications on antibacterial activity of the 2-deoxystreptamine class aminoglycosides. In this
work, a series of MIC experiments were carried out using the broth micro dilution method. A
brief description of each experimental method followed by detailed protocols are summarized in
this chapter. In fact, the methods described are not confined to ribosome-targeting drugs. We can
expand this work to study the in vivo activity of other drugs.
2.2 In vivo expression of peptides in bacteria
Molecular cloning techniques were used to in vivo express peptides in E. coli (Figure
2.1). In the first approach, peptides were in vivo expressed as GFP-tagged fusion peptides
(Figure 2.2a). In order to further characterize the selected peptides as potential drug leads, it is
essential to determine their activities outside the context of the fusion protein. Therefore, in the
second approach a different plasmid system was used to express free peptides in bacteria (Figure
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2.2b). The effects of these peptides on bacterial protein translation and growth were monitored
through fluorescent intensities and optical densities of cultures expressing the peptides.

Figure 2.1 Cloning experiment. This schematic diagram illustrates the basic steps involved in
the molecular cloning experiment. The DNA insert of peptide is synthesized using primer
extension PCR. The insert and vector are digested with the appropriate restriction enzymes and
then ligated. The ligated plasmid is electrotransformed into bacterial cells. The insertion is
confirmed by DNA sequencing. Peptides are in vivo expressed by adding arabinose and utilized
in bacterial growth assays.
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Figure 2.2 A schematic diagram of the two approaches used in the in vivo peptide
expression methodology. a) In the first approach, peptides are cloned at the N-terminus of GFP
and expressed as a fusion protein. The effects of peptides on bacterial growth and protein
translation are monitored by measuring OD600nm and fluorescence intensities of cultures
expressing peptides. b) In the second approach, free peptides are expressed and the effects on
bacterial growth are monitored by measuring OD600nm of cultures expressing peptides.
2.2.1 Synthesis of the peptide DNA insert
In both GFP and free plasmid systems, primer extension PCR was used to generate the
desired peptide DNA sequences. As illustrated in Figure 2.3, PCR to produce the peptide insert
does not use a template, but the 3' ends of the two primers, universal forward and peptidespecific reverse, overlap to allow extension. During PCR, primers anneal with each other and
extend to give the full-length DNA product. Restriction digestion of the PCR product with
appropriate enzymes provides peptide inserts for the cloning experiments.
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Figure 2.3 Peptide insertion by PCR. The design of the PCR experiment is shown. The
nucleotide sequences of the universal forward and the peptide specific reverse primer sequence
are shown. During PCR, the primers anneal with each other and extend to give the full-length
DNA product. The nucleotides from the PCR product are shown with the restriction sites in
orange. The amino acid sequences of the TEV protease recognition sequence, ENLYFQ (green)
and the peptide, AAAAAAA (red), are in letters shown below the DNA sequence.
2.2.2 Cloning of peptides into the GFP plasmid system
The genes were cloned behind the PBAD promoter of the plasmid such that the peptides
could be expressed by inducing with L-arabinose. Dr. Wes Colangelo prepared the plasmid,
pBacEmtvec3, for this experiment (Figure 2.4). The restriction enzyme sites Kas I and Nhe 1
were used to clone the peptide insert into the plasmid. In previous studies, it was shown that
cloning of peptides at the N-terminus of the GFP gene shut down its own translation, and this
could be overcome by cloning peptides a few amino acids away from the start codon. 193,231
Therefore, a normalizing sequence (g10 leader sequence) was added at the 5' end of the GFP
gene and then a TEV (Tobacco Etch Virus) protease recognition sequence (ENLYFQG/S) was
added after the normalizing sequence (Figure 2.5).
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Figure 2.4 Plasmid map of pBACEmtvec3. pBACEmtvec3 is derived from the commercial
plasmid pCC1BAC. The plasmid shows chloramphenicol resistance. The restriction enzyme sites
Nhe I and Kas I are used to clone the peptide insert into the plasmid. Therefore, the lambda insert
in the plasmid vector is replaced by the peptide sequence in the ligated plasmid. After insertion
of the peptide sequence, its expression is controlled by the PBAD and the ParaC promoters. The
PBAD promoter is adjacent to the ParaC promoter, which transcribes the araC gene in the opposite
direction. The araC gene encodes AraC protein, which regulates activity of both the PBAD and
ParaC promoters.240,241
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Figure 2.5 In vivo expression of GFP-peptide fusion proteins. A schematic diagram for the
production of GFP-tagged peptides using the TEV protease expression system is shown. A
normalizing sequence (g10 leader sequence) was added at the 5' end of the construct. The
peptides are cloned behind the TEV protease recognition sequence. A peptide linker, EGGG, is
placed before GFP to provide flexibility of the peptide. The expression of the peptide and TEV
protease is induced by adding arabinose and anhydrotetracycline (ATC), respectively. Upon
expression of TEV protease, the peptides are exposed at the N-terminus of GFP.
The expression of GFP tagged-peptides in the TEV protease system was carried out in E.
coli strain EPI300. The ligated plasmids were electrotransformed into E. coli EPI300, which
contained two plasmids for the expression of TEV protease and the tetracycline repressor protein
(TetR). Therefore, the expression was done in a three-plasmid system (Figure 2.5) in which the
first plasmid (pBacEmpep, chloramphenicol resistance) was used for expression of GFP-tagged
peptides, the second (pRK603) for Tet-inducible TEV protease with kanamycin resistance, and
the third (pZS4int-tetR, spectinomycin resistance) for constitutive tetracycline repressor protein
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(TetR) expression.242 Figure 2.6 illustrates the mechanism that controls the in vivo expression of
TEV protease from pRK603 in the presence and absence of the inducer, anhydrotetracycline
(ATC). The expression of TEV protease from the pRK603 plasmid is under control of the P Tet
promoter. When co-transformed with pRK603, constitutive expression of TetR from pZS4inttetR represses the expression of TEV protease from the PTet promoter by binding to its operator.

Figure 2.6 In vivo expression of TEV protease. A schematic diagram for the production of
TEV protease is shown. The expression of TEV protease is under control of the PTet promoter.
The binding of TetR to the promoter inhibits the expression of TEV protease. Upon the addition
of ATC, it binds to TetR and causes a conformational change in the protein lowering its affinity
for the PTet. With TetR removed, expression from PTet proceeds and produces TEV protease.
When ATC is added to a cell culture containing both plasmids, ATC binds to TetR and
causes a conformational change in the protein lowering its affinity for the P Tet operator. With
TetR removed, expression from PTet proceeds and produces TEV protease. During the bacterial
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growth assay, once the cells enter early log phase growth, ATC is added to induce TEV protease
expression and allow it to accumulate in the cytoplasm. After an additional hour of incubation,
L-arabinose was added to induce the expression of peptide-EmGFP fusion.
In this plasmid system, the peptide sequence was cloned behind the TEV protease
recognition sequence. TEV protease is a 27-kDa catalytic domain of the Nuclear Inclusion a
(NIa) protein encoded by the Tobacco Etch Virus.243,244 Waugh’s lab developed methods for in
vivo processing of fusion proteins by this enzyme.242,245 The expression of TEV protease from
another plasmid in the same cell would lead to cleavage of the TEV recognition peptide
sequence between residues Q and G, and the resulting peptide was exposed at the N-terminus of
GFP.242,245 TEV protease cleavage occurs between Q and G, leaving an extra glycine (G) at the
N-terminus of the peptide sequence (Figure 2.7). Although the wild-type TEV protease
recognition sequence is ENLYFQG/S, recent studies have shown that any amino acid after Q in
the sequence could cleave efficiently such that the exact peptide sequence could be exposed after
TEV cleavage.231,242,246,247

Figure 2.7 TEV cleavage site. The TEV protease has a 7 amino acid recognition sequence and
cleaves between amino acids 6 and 7 (Q and G). This leaves a G residue attached to the desired
peptide sequence, in this case producing GAAAAAAA at GFP end.
Therefore, later in this project peptide primers were designed excluding the codon
corresponding to the C-terminus G residue. Therefore, after TEV protease cleavage the exact Nterminus sequence of the peptide is exposed. TEV cleavage of fusion proteins is typically more
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efficient than thrombin or enterokinase. Furthermore, it is easy to overproduce and is resistant to
many protease inhibitors.246,247
2.2.3 Free peptide expression system
In this approach, a single plasmid expression system pKan5tvVec (8243 bp) with an
inducible PBAD promoter and kanamycin resistance was used as the vector (Figure 2.8).
Therefore, the peptides could be expressed by inducing with L-arabinose. The restriction enzyme
sites Hind III and Nhe I were used to clone the peptide insert into the plasmid (Figure 2.9).

Figure 2.8 In vivo expression of free peptides. A schematic diagram for the production of free
peptides using the TEV protease expression system is shown. The peptides are cloned behind the
TEV protease recognition sequence and under control of the PBAD promoter. Therefore, the
expression of peptides and TEV protease is induced by adding arabinose. After TEV protease
cleavage, free peptides are available in the cell.
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Figure 2.9 Plasmid map of pKan5tvVec. The restriction enzyme sites Nhe I and Hind III are
used to clone the peptide insert into the plasmid. Therefore, the lambda insert in the plasmid
vector is replaced by the peptide sequence in the ligated plasmid. The expression of the peptide
and TEV-protease is controlled by the PBAD and ParaC promoters. The plasmid shows kanamycin
resistance.
The peptide insert was generated by using the non-template PCR method as described
earlier (Figure 2.3). The ligated plasmids were transformed into E.coli DH5 cells. Expression of
TEV protease from the same plasmid would cleave the TEV recognition peptide sequence
leaving free peptides.
2.3 Materials and Methods
Materials
Plasmid maxi-prep purification was performed using a plasmid maxi-prep kit #12162
from Qiagen. Gotaq Green Master Mix (2×, #M712B) was purchased from Invitrogen (Carlsbad,
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CA). NEB Buffer 2.1 restriction enzymes, Hind III, Nhe I, and Kas I, were obtained from New
England Biolabs (lpswich. MA). Quantum Prep Freeze ‘N Squeeze DNA Gel Extraction Spin
Columns were acquired from Bio-Rad Laboratories (Hercules, CA). OPTIZYME T4 DNA ligase
is a product of Fisher BioReagents (Fair Lawn, NJ). Thermo Scientific (Lafayette, CO)
manufactures the GeneJet Plasmid Miniprep Kit. Escherichia coli DH5, Escherichia coli EPI
301 cells, and plasmid vectors, pBACEmtvec3 and pKan5tvVec, were provided by the
laboratory of Dr. Philip Cunningham. Lysogeny broth (LB) was purchased from Sigma-Aldrich
(St. Louis, MO). All other chemicals used to make buffers were purchased from Sigma-Aldrich
(St. Louis, MO) or Fisher BioReagents (Fair Lawn, NJ). DNA sequencing was done by the DNA
Sequencing Lab Applied Genomics Technology Center at Wayne State University (Detroit, MI).
The PCR primers to generate the inserts, universal forward primers and reverse primers
corresponding to each peptide sequence and sequencing primers were synthesized by Integrated
DNA Technologies.
The list of primers used in the cloning experiments are as follows:
GFP-tagged peptide expression system
Universal forward primer
5'-CATGGTAT GCTAGCATGACTGGTGGACAGCAAATG GGTCGG GAAAACCTGTAC
TTCCAGGGC-3'
RQVANHQ reverse primer
5'-CCCTTGCTCACCATGGCGCCGCCGCCTTCCTGGTGGTTCGCAACCTGACGCCCT
GGAAGTACAGGTTTTCCCG-3'
TARHIY reverse primer
5'-CCCTTGCTCACCATGGCGCCGCCGCCTTCGTAGATGTGACGCGCGGTGCCCTG
GAAGTACAGGTTTTCCCG-3'
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NQAANHQ reverse primer
5'-CCCTTGCTCACCATGGCGCCGCCGCCTTCTGGTGGTTAGCCGCCTGGTTACCC
TGGAAGGTTTTCCCG-3'
AAAAAAAA reverse primer
5'-CCCTTGCTCACCATGGCGCCGCCGCCTTCGTAGATGTGACGCGCGGTGCCCTG
GAAGTACAGGTTTTCCCG-3'
Sequencing forward primer
5'-AACTCTCTACTGTTTCTCC-3'
Sequencing reverse primer
5'-GTGCAGATGAACTTCAGG-3'
Free peptide expression system
Universal forward primer
5'-CATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGAAAACCTGTA
CTTCCAG-3'
AAA reverse primer
5'-TTAAAGTTAAAGCTTTTACGCCGCCGCCGCCGCCGCCGCACCCTGGAAGTACA
GGTTTTCCCGAC-3'
Oncocin reverse primer
5'-CTAAAGTTAAAGCTTTTAGCGGTTATAGATGCGGCGTGGTGGGCGTGGGCGT
GGCAGATATGGTGGCTTATCAACCTGGAAGTACAGGTTTTCCCGACCC-3'
Oncocin 3A reverse primer
5'-CTAAAGTTAAAGCTTTTAGCGGTTATAGATGCGGCGTGGTGGGCGTGGGCG
TGGCAGATATGGTGGCGCATCAACCTGGAAGTACAGGTTTTCCCGACCC-3'
Oncocin 6A reverse primer
5'-CTAAAGTTAAAGCTTTTAGCGGTTATAGATGCGGCGTGGTGGGCGTGGGCG
TGG CAGCGCTGGTGGCTTATCAACCTGGAAGTACAGGTTTTCCCGACCC-3'
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Oncocin 7A reverse primer
5'-CTAAAGTTAAAGCTT TTAGCGGTTATAGATGCGGCGTGGGGGCGTGGGCGTGGCGCATA
TGGTGGCTTATCAACCTGGAAGTACAGGTT TTCCCGACCC -3'
Oncocin 11A reverse primer
5'-CTAAAGTTAAAGCTTTTAGCGGTTATAGATGCGGCGTGGTGGCGCTGGGCGTGGCAGTAT
GGTGGCTTATCAACCTGGAAGTACAGGTTTTCCCGACCC-3'
Oncocin 36711A reverse primer
5'-CTAAAGTTAAAGCTTTTAGCGGTTATAGATGCGGCGTGGTGGCGCTGGGCGTGGCGCC
GCTGGTGGCGCATCAACCTGGAAGTACAGGTTTTCCCGACCC-3'
Sequencing forward primer
5'-CAACTCTCTACTGTTTCTCCATGC-3'
Sequencing reverse primer
5'-GCCCAAATCCAATACCATACACG-3'
Methods

All of the experimental methods used for the GFP and free plasmid system are the same
except for the plasmid vector and the E.coli strain used in each system. Therefore, in this chapter,
the experimental methods are explained in detail for the free plasmid system, which also applies
to the GFP system. The specific information for each system is explained in detail in Chapter 3
for the free plasmid and the Chapter 4 for GFP system.
2.3.1 Preparation of Escherichia coli DH5 electrocompetent cells
E. coli DH5 cells were streaked from frozen stocks onto Luria-Bertani (LB) agar plates
and incubated overnight at 37 °C. An overnight culture (3 mL) of LB broth was inoculated with
a single isolated colony of the DH5 cells and incubated overnight (16 h) at 37 °C with shaking.
In each of four flasks (2 L), 250 μL from a single overnight culture was added to 250 mL of
preheated (37 °C) Super Optimal Broth (SOB) and incubated at 37 °C with vigorous shaking
(350 rpm) until the OD550nm = 0.8. The cultures were cooled to 4 °C on ice for 15 min before the
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cultures were transferred to four Sorvall tubes (250 mL) on ice, then centrifuged (5000 rpm) at 4
°C for 15 min to harvest the cells. The supernatant was discarded and each pellet was washed
with ice-cold 10% glycerol (250 mL) and the cells were centrifuged (5000 rpm) at 4 °C for 15
min. The wash and centrifugation steps were repeated a second time. The supernatant was
decanted off and the cells were resuspended in the small volume (1 mL) of supernatant left in
each tube. The cells were stored in 25 μL aliquots at -80 °C.
2.3.2 Preparation of pKan5tvVec vector
The vector DH5 strain for pKan5tvVec (8243 bp) was streaked from a frozen stock onto
a fresh LB-agar plate with kanamycin (50 μg/mL) and incubated overnight at 37 °C. A single
colony was used to inoculate a 5 mL culture using LB broth and kanamycin (50 μg/mL), which
was incubated for 8 h at 37 °C with shaking (275 rpm). The 5 mL culture was added to LB broth
(495 mL) with kanamycin (50 μg/mL) and incubated for 16 h overnight at 37 °C with shaking
(275 rpm). The culture was divided into two Sorvall (250 mL) tubes and centrifuged (6000 rpm)
at 4 °C for 15 min. The following steps were completed using a QIAGEN Plasmid Maxi Kit. The
tubes were inverted to remove the media and the pellets were resuspended by swirling using
buffer P1 (10 mL) with RNase A (10 mg/mL), and the resuspension was transferred to new
Sorvall tubes. Lysis buffer P2 (10 mL) was added and the solution was mixed by inversion (6×),
then incubated at room temperature for 5 min. Neutralization buffer P3 (10 mL, 4 °C) was added
and mixed by inversion (6×), and the mixture was left on ice for 20 min. The mixture was
centrifuged (13,000 rpm) at 4 °C for 30 min, and the supernatant was transferred to a new tube
before a second centrifugation (13,000 rpm) at 4 °C for 15 min. To equilibrate the QIAGEN tip
500, buffer QBT (10 mL) was added to the column and emptied by gravity flow during
centrifugation. All steps using the QIAGEN tip 500 empty by gravity flow. After centrifugation,
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the supernatant was transferred to the column. The column was washed with buffer QC (2 × 30
mL). The plasmid DNA was eluted from the column using buffer QF (15 mL) and eluate was
collected in a fresh tube. The DNA was precipitated by adding room temperature isopropanol
(10.5 mL), which was mixing by inversion, then centrifuging (11,000 rpm) at 4 °C for 30 min.
The supernatant was discarded. Two washes were carried out using 70% ethanol (5 mL) each
time and centrifuging (11,000 rpm) at 4 °C for 15 min. After removing the ethanol, the pellet
was allowed to air dry for 20 min. The DNA was resuspended in sterile ddH2O (1 mL). The
purity of DNA was checked by running it on an agarose gel.
2.3.3 Synthesis of DNA inserts of peptides
The non-template PCR method was used to generate constructs for the desired peptides.
The following forward and reverse primers were used to amplify the PCR products. A universal
forward primer (5 µM, 10 µL), reverse primer (5 µM, 10 µL), Gotaq-master mixture (2×, 50 µL),
and ddH2O (30 µL) were combined in a PCR tube. The PCR reaction was heated in a
thermocycler to 95 °C for 5 min to denature, then 55 °C for 1.5 min to anneal the DNA, and 72
°C for 30 S to carry out extension. The reaction was held at 72 °C for 7 min after all 30 cycles
were completed, and the sample was cooled to 4 °C. The PCR products were checked on an
agarose gel and purified before restriction digestion.
2.3.4 Insert and vector digestion
To produce the peptide insert from the PCR product, 20 μL of the PCR product (1 μg)
was combined with 1 μL Hind III (20 U/μL), 1 μL Nhe I (10 U/μL), 5 μL NEB Buffer 2.1 (10×),
and sterile ddH2O (23 μL). To digest the pKan5tvVec plasmid (8243 bp) to produce the vector
DNA (5371 bp), 2.5 μL pKan5tvVec plasmid (1 μg) was combined with 1 μL Hind III (20
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U/μL), 1μL Nhe I (10 U/μL), 5 μL NEB Buffer 2.1 (10×), and sterile ddH2O (8 μL). The
reactions were incubated overnight for 16 h at 37 °C.
2.3.5 DNA gel extraction with ethanol precipitation on digested products
Quantum Prep Freeze ‘N Squeeze DNA Gel Extraction Spin Columns were used to
purify the digested samples for both the vector and insert. The samples were separated by
electrophoresis using TBE agarose 1% gels at 95 V, 1 h for the insert gel and 2 h for the vector
gel. The gels were stained with 1 drop ethidium bromide (0.5 μg/ml) in water with shaking for 20
min. The insert band (78 bp) and vector band (5371 bp) were each excised from their respective
gels using a scalpel, with sterile technique, sliced into small pieces, and placed into the
individual filter cups. The filter cup was attached to the dolphin tube and the spin column was
cooled in the -20 °C freezer for 5 min. The column was centrifuged (10,000 rpm) for 5 min at
room temperature. The freeze and spin was repeated two more times in an identical manner. The
DNA solution in the collection tube was transferred to a new microcentrifuge tube for each
sample. The two DNA samples were concentrated using ethanol precipitation. For each 100 μL
vector and insert sample, 100% ethanol (250 μL) was added with 3 M NaOAc (10 μL), and
vortexed for 1 min. The samples were incubated on dry ice for 45 min then centrifuged (14,000
rpm) at 4 °C for 45 min. The supernatant was carefully removed. Ice cold 70% ethanol (100 μL)
was added to the pellet and the mixture was incubated on dry ice for 30 min. After the final
centrifugation (14,000 rpm) at 4 °C for 30 min, the pellet was dried in the Speedvac for 15 min.
The DNA was resuspended in sterile ddH2O (10 μL).
2.3.6 Ligation and electrotransformation
Ligation reactions were set up for the vector to insert (V:I) with ratios 1:2, 1:4 ,1:10,
1:100, and 1:250, with T4 DNA ligase (5 U/µL) enzyme, ligase buffer (10×) and sterile H2O.
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The reactions were incubated 1 h at room temperature and heat inactivated for 10 min at 70 °C.
The ligation mixture (1.5 µL) was added to electrocompetent cells (25 µL) on ice and mixed
gently by pipetting. Each sample was transferred into a pre-chilled electroporation chamber and
electroporated. Each sample was used to inoculate LB broth (1 mL). Cultures were incubated 37
°C for 1 h with shaking. Samples were transferred to microcentrifuge tubes. Cells were pelleted
(5000 rpm) at 4 °C for 10 min. The supernatant (800 µL) was removed carefully. Pelleted cells
were resuspended in the remaining supernatant (200 µL) and plated on pre-warmed LB-agar
plates with kanamycin (50 μg/mL).
2.3.7 Sequence confirmation
The peptide clones were confirmed by colony PCR and DNA sequencing. Several
colonies from the plates of transformants were selected and used to streak a new master plate. A
single colony from each master plate was used to inoculate 50 µL of sterile water in a PCR tube.
The samples were boiled at 95 °C for 10 min in a thermocycler. The colony PCR reaction was
prepared for each sample in a PCR tube using 2.5 µL of sequencing forward primer (5 µM),
reverse primer (5 µM), 2.5 µL colony DNA mixture, 12.5 µL Gotaq Green Master mixture and 5
µL of sterile H2O. The PCR reaction was run and products were checked on an agarose gel.
Plasmids were isolated using a GeneJet Plasmid Miniprep kit and sent for DNA sequencing.
Samples were sequenced by the Applied Genomics Technology Center DNA Sequencing
Laboratory, Wayne State University.
2.3.8 Bacterial growth assay – free plasmid system
Ligated plasmids containing peptides were transformed into the E. coli DH5 strain. Cells
were grown in LB/kanamycin medium to prepare an overnight culture. The culture was diluted
1:500 and incubated at 37 °C for 3-4 h until the optical density (OD600 nm) reached ~ 0.2. When
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cells reached early log phase, ~200 min, L-arabinose was added to a final concentration of 0.2%
(w/v) to induce the expression of free peptides. Control experiments were done without adding
inducer. From each culture, 300 µL of cells were transferred to a 96-well plate. Optical densities
(OD600nm) of cultures were measured every 60 min until cells reached the stationary phase.
2.3.9 Bacteria growth and fluorescence assay
Ligated plasmids pep-GFP pBacEmtvec3 were transformed into the E. coli EPI300 strain.
A single colony from each clone was grown in LB/chloramphenicol/kanamycin/spectinomycin
medium to prepare an overnight culture. The culture was diluted 1:500 and incubated at 37 °C
for 3-4 h until the optical density (OD600 nm) reached 0.1 (~ 200 min). Anhydrotetracyclin (ATC)
was added to a final concentration of 250 ng/mL to induce TEV protease expression. When cells
reached early log phase, ~240 min, L-arabinose was added to a final concentration of 0.2% (w/v)
to induce the expression of GFP-tagged peptides. Control experiments were done without adding
inducers to see the difference in cell growth in the presence or absence of GFP-tagged peptides.
After induction of GFP-tagged peptides, the level of GFP expression in each culture was
monitored by measuring fluorescence intensity at 60 min time intervals until cells reached the
stationary phase. From each culture, 600 µL of cells were pipetted out into an Eppendorf tube
and pelleted by centrifuging 2 min in a benchtop micro centrifuge. Cells were washed twice with
600 µL HN buffer (50 mM HEPES, pH 7.5, 150 mM NaCl). Two hundred µL of cells were
transferred into each well of Costar, clear bottom 96-well black plate. The florescence intensity
was measured at 487 nm (excitation) and 509 nm (emission). Optical density of cultures was
measured at 600 nm.
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2.3.10 Purification of the EmGFP-pep fusion protein
Ligated plasmids pep-GFP pBacEmtvec3 were transformed into the E. coli EPI300 strain.
A single colony from each clone was grown in LB/chloramphenicol/kanamycin/spectinomycin
medium to prepare an overnight culture. The culture was diluted 1:500 and incubated at 37 °C
for 3-4 h until the optical density (OD600 nm) reached 0.1 (~ 200 min). Anhydrotetracyclin (ATC)
was added to a final concentration of 250 ng/mL to induce TEV protease expression. When cells
reached early log phase, ~240 min, L-arabinose was added to a final concentration of 0.2% (w/v)
to induce the expression of GFP-tagged peptides. Bacteria culture was grown to 0.4 OD and the
culture was centrifuged at 6,000 g for 20 min to pellet the cells. The pellet was resuspended in
lysis buffer (50 mM Tris-Cl, pH 7.6, 300 mM NaCl, 10 mM imidazole, 1mM DTT, and 0.05% of
Triton-X100) and lysed using a French Press. The lysate was centrifuged twice at 15,000 rpm for
30 min to remove cellular debris. The supernatant was collected. As previously described, the
peptide construct was prepared in which His-tag was placed at the C-terminus of the EmGFP
gene such that the peptide-GFP fusion protein could be purified using Ni-affinity
chromatography. The column was packed with ~ 2 mL Ni-bound IMAC resin and equilibrated
with 50 mM Tris-Cl, pH 7.6, 300 mM NaCl, 10 mM imidazole, 1 mM DTT, and 0.05% of
Triton-X100. The equilibration of the column with 10 mM imidazole helps to remove cellular
proteins having less affinity to nickel ions. To wash and elute of protein, 1× Tris-buffer (50 mM
Tris-Cl, pH 7.6, 300 mM NaCl, 1 mM DTT, and 0.05% of Triton-X100) was used. The specific
concentration of imidazole is mentioned in each step of purification. The crude protein was
mixed with the resin and incubated for 30 min to allow binding. It was washed with 20 column
volumes of equilibration buffer and then with five column volumes of 1× Tris-buffer with 20
mM imidazole. After washing with five column volumes of 1× Tris-buffer with 30 mM
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imidazole, the protein was eluted with 1× Tris-buffer with 50 mM imidazole. The fractions were
collected in 1.5 mL microcentrifuge tubes. The purity of eluted protein was checked by running
the samples on a 12 % SDS-PAGE. After confirming the purity of protein, it was dialyzed
against 50 mM Tris-Cl, pH 7.6, 300 mM NaCl, 1 mM DTT, and 0.05% of Triton X100 to
remove the imidazole. Finally, the protein was quantified by using a standard Bradford assay.
Isolated protein was characterized by matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry.
2.4 Chemical probing of RNA structure
RNAs adopt highly structured biologically active scaffolds to carry out their functions.
Therefore, identifying key RNA structural features at the nucleotide level is crucial for
understanding their biological roles and to develop RNA-targeting therapeutics. Chemical
probing is considered as a powerful technique to study RNA, including the nucleotide sequence,
secondary and tertiary structures, and protein or drug interactions.248-250 Applications of chemical
probing for analyzing ribosome-tRNA interactions were reported by Moazed and Noller in the
late 1980s.39,251 In this work, they proposed the hybrid tRNA state during translocation based on
chemical probing data.39 Furthermore, they found that some clinically important antibiotics also
interact with ribosomal RNAs at specific sites.139 They demonstrated the power of chemical
probing analysis and its broad potential to study RNA biomolecules. Many chemical reagents
have been developed for the purpose of studying nucleic acid structures.250,252 For example,
dimethylsulfate (DMS), diethylpyrocarbonate (DEPC), and hydrazine were used to analyze RNA
sequences and tertiary structures. In this dissertation work, DMS footprinting was employed to in
vivo map the ribosome binding sites of peptide antibiotics. In the following section, the DMS
footprinting technique will be discussed.
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2.4.1 Dimethyl Sulfate (DMS) footprinting
DMS is one of the most versatile chemical reagents used to probe RNA structure. 249
DMS was introduced for RNA structure mapping in 1980 when Peattie and Gilbert adapted
methods that had been used for sequencing DNA and RNA.250,253,254 DMS can directly donate a
methyl group to specific hydrogen-bond-accepting ring nitrogens on A, C, and G residues in
RNA (Figure 2.10). DMS attacks the N1 position of A and the N3 position of C to produce 1methyladenosine (m1A) and 3-methylcytosine (m3C), which inhibit Watson-Crick base-pair
formation with the complementary base. DMS also attacks the N7 of G to produce 7methylguanosine (m7G) (Figure 2.10). In the case of A and C, the methylated base directly
inhibits reverse transcriptase, because the methyl group alters the Watson-Crick face of the base.
In order to map methylation at N7 of G, the RNA must be treated with aniline and borohydride
to cleave the RNA backbone at the methylated Gs prior to reverse transcription (Figure 2.11).
By comparing the pattern of modification-dependent reverse transcription stops to
dideoxynucleoside triphosphate-generated stops using the same labeled primer, the sites of
methylation can be mapped to the RNA sequence (Figure 2.12). Methylation-dependent stops
occur one position before the corresponding dideoxynucleotide stop.
The DMS methylation reaction rate is relatively insensitive to changes in solution
conditions such as pH and monovalent ion concentration and increases only mildly with
increased temperature.255-257 Therefore, the changes in DMS reactivity are typically due to
structural changes rather than changes in reaction conditions. DMS footprinting has been used to
monitor pH-dependent conformational changes in the ribosome, RNA structural changes in
response to changes in ionic conditions or mutations, and to monitor protein binding to
RNA.239,255,258-262 This reagent has also been used to monitor binding of small ligands to RNAs,
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notably the binding of antibiotics to the ribosomal complex.139,239,263,264 If a particular base in
RNA is involved in a secondary or tertiary RNA structure, or interacts with a protein or other
ligand, it may have altered reactivity with DMS. For example, DMS reactivity at the N1 of A or
N3 of C would be diminished when the nucleotide is involved in a Watson-Crick base pair.249 A
similar situation may occur during interactions with proteins or other ligands. If interactions
reduce the reactivity of a particular nucleotide towards DMS, it can be identified by reduced
band intensity on a gel compared to a DMS-only control (DMS protection) (Figure 2.12). If
interactions with a ligand increase the reactivity of a nucleotide towards DMS, the corresponding
gel band intensity increases compared to the DMS-only control (DMS exposed). The intensities
of gel bands can be quantified using Image Quant Software. Therefore, normalized band
intensities provide information about the interaction of ligands with RNA at the nucleotide level.
In this manner, DMS reactivity can be used as a tool to monitor the RNA-ligand interactions.

Figure 2.10 Types of chemical probing and target sites. DMS: dimethylsulfate; DEPC:
diethylpyrocarbonate; NMIA: N-methylisatonic anhydride: CMCT: 1-cyclohexyl-(2orpholinoethyl) carbodiimide metho-p-toluene sulfonate. The blue text shows chemical probing
sites detected by direct reverse transcription analysis; red text shows modification sites detected
after RNA strand scission by aniline treatment; and black text shows chemical probes used
primarily for sequencing rather than structural analysis.

57

Figure 2.11 The use of dimethyl sulfate as a chemical probe. a) The general reaction scheme
involves strand scission following DMS modification at G N7. b) Methylation of adenosine N1
by DMS and c) methylation of cytidine N3 by DMS are illustrated.265
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Figure 2.12 DMS footprinting gel schematic. This illustration shows a reverse transcriptionbased primer extension assay of RNA after DMS probing. The modified site on the gel is one
nucleotide prior to the actual modified site because the dideoxy sequencing stops reverse
transcription after incorporating a complementary base; the DMS modification stops reverse
transcription without incorporation of the complementary base. Dideoxy sequencing lanes are
labeled as C, U, G, and A (reverse transcription with ddGTP, ddATP, ddCTP, and ddTTP, respectively).
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2.4.2 In vivo DMS footprinting
Since the folding of RNA might be different in a more complex environment such as
living cells, it is highly important to study RNA structures in vivo. Methods and probes that are
useful for studying RNA structure in vivo are limited. The most commonly used reagents are
DMS, kethoxal, and lead (II).265,266 Compared to other available chemical reagents, a major
experimental convenience of DMS is its rapid penetration into all compartments of the cell.267
This feature has allowed probing of RNA structure in a wide variety of cells, including gram
negative and gram positive bacteria, yeast, protozoa, and plant, including the nucleus, nucleolus,
and chloroplasts.267-274 Since DMS readily penetrates cells without the need for extended
permeabilization treatments, modification of RNA occurs under nearly in vivo conditions. Also,
short incubation times at physiological temperatures allow for a quick snapshot of RNA structure
in vivo. The method can be applied to many cultures simultaneously, facilitating direct
determination of the effect of different mutations or treatments on folding of the target RNA.
Using primers that are specific for a number of RNAs, the structures of multiple RNAs can be
determined in the same sample. In this dissertation work, I optimized an in vivo DMS
footprinting protocol to map the ribosome binding sites of a peptide antibiotic PrAMP, or
oncocin. In the next section, the in vivo footprinting protocol will be discussed in detail.
2.5 Materials and Methods
Materials
Chemicals used in this experiment such as dimethyl sulfate (DMS), 2-mercaptoethanol
(2-ME), sodium acetate (NaOAc), ethylenediammine tetraacetic acid (EDTA), 2-amino-2hydroxymethylpropane-1,3-diol (Tris), phenol-chloroform-isoamyl alcohol (25:24:1) (PCI), urea,
acrylamide, bisacrylamide, and isoamyl alcohol were purchased from Sigma-Aldrich (St. Louis,
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MO) or Fisher Bioreagents (Fair Lawn, NJ). Lysogeny broth (LB) was purchased from SigmaAldrich (St. Louis, MO). Enzymes such as ImPromII reverse transcriptase (RT) and
polynucleotide kinase (PNK) were purchased from Promega (Fitchburg, WI). Adenosine 5'triphosphate γ-32P (32P-ATP) was purchased from Perkin Elmer Life Sciences Inc (Waltham,
MA). DNA primers for primer extension (5'-GCTCAATGTTCAGTGTCA AGC-3' and 5'GAC
ATCGAGGTGCCAAACAC-3') were synthesized by Integrated DNA Technologies (Coralville,
IA).
Methods
2.5.1 In vivo DMS footprinting experiment
The DH5 strain containing ligated oncocin plasmid was streaked from a frozen stock onto
a fresh LB-agar plate with kanamycin (50 μL/mL) and incubated overnight at 37 °C. A single
colony was used to inoculate a 3 mL culture using LB broth and kanamycin (50 mg/mL), which
was incubated overnight at 37 °C with shaking (250 rpm). From the overnight culture, 60 μL was
added to LB broth (30 mL) with kanamycin (50 μL/mL) and incubated at 37 °C for 3-4 h until
the optical density (OD600 nm) reached ~ 0.2. When cells reached early log phase, ~240 min, Larabinose was added to a final concentration of 0.2% (w/v) to induce the expression of peptide.
The incubation was continued for 1 h. The dimethyl sulfate (DMS) reaction was initiated by
adding 100 μL of DMS, followed by incubation, with vigorous shaking for 5 min at 37 °C. The
reaction was quenched by placing the tube on ice and adding β-mercaptoethanol (0.6 M, 5 mL)
and water-saturated isoamyl alcohol (5 mL). After cooling on ice for 15 min, cells were pelleted
at 5,000 rpm, at 4 °C for 30 min. The upper isoamyl alcohol phase and the lower aqueous phase
was carefully removed from the pellet. The cell pellet was resuspended in β-mercaptoethanol
(0.6 M, 5 mL) and centrifuged again (5000 rpm, at 4 °C for 30 min). The supernatant was
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carefully removed and the cell pellet was washed with 1.5 mL ice-cold Tris-saline buffer (10
mM Tris-HCl, pH 8, 100 mM NaCl, 1 mM EDTA) and centrifuged again (5000 rpm, 10 min).
Control experiments (no DMS, no drug) were carried out simultaneously. The cell pellet was
used for the total RNA isolation as described below.
2.5.2 Total RNA isolation
The cell pellet was resuspended in 200 μL of AE buffer (50 mM sodium acetate pH 5.2,
10 mM EDTA). Sodium dodecyl sulfate (SDS) was added to a final concentration of 1%. An
equal volume of phenol: isoamyl alcohol: chloroform (PCI) was added and the mixture was
incubated at 65 °C for 4 min. The samples were immediately put in -20 °C freezer to cool down
and allowed to thaw at room temperature. Samples were centrifuged (14,000 rpm at 4 °C for 10
min) and the supernatants were transferred to a new tube. The supernatant was subjected to
phenol-chloroform extraction at least two times. Extracted RNA was isolated by doing ethanol
precipitation. The purity of isolated total RNA was checked by agarose gel electrophoresis.
2.5.3 Radiolabeling of DNA at the 5' end
For the labeling of 50 pmol DNA, 10 μCi [γ32P]–ATP and 10 units T4 polynucleotide
kinase were reacted in T4 polynucleotide kinase buffer (50 mM Tris·HCl, pH 7.6, 10 mM
MgCl2, 5 mM DTT, 0.1 mM spermidine, and 0.1 mM EDTA). The total volume was adjusted to
50 μL with ddH2O and the sample was incubated at 37 oC for 45 min. The labeled DNA was
isolated by ethanol precipitation. The dried DNA pellet was redissolved in 50 µL of ddH2O.
2.5.4 Reverse-transcription and primer extension reactions
The appropriate DNA primers were radiolabeled with [ -

32

P] ATP at the 5' end as

described earlier. RNA (500 ng) and 1 µL of radiolabeled primer (60,000-100,000 cpm) were
incubated together at 80 °C for 3 min and then the mixture was cooled to room temperature for 5
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min. The master mixture for a reverse transcription reaction was prepared by combining 24 units
of ImProm-II reverse transcriptase enzyme, 1 μL of 5× reverse transcriptase reaction buffer, and
0.4 μL of 50 mM MgCl2. To the primer-annealed platinated rRNA, 1.65 μL of the master
mixture, 1 μL of dNTP (10 mM), and ddH2O (total volume 5 μL) were added. Primer extension
was carried out at 43 °C for 1 h. For sequencing, total RNA was used with the corresponding
radiolabeled primer. For the sequencing reverse transcription reaction, 1 μL of dNTP: ddNTP 1:4
(0.5 mM:2 mM) was used instead of the dNTP mixture. Termination of the reactions was done
by heating the reaction mixture at 95 °C for 2 min after adding 2 μL of denaturing loading dye
(80% formamide, 1× TBE, 0.02% bromophenol blue, 0.02% xylene cyanol) and quickly placing
on ice. Reactions (50,000 cpm per lane) were loaded onto 10% denaturing polyacrylamide gels
(0.4 mm thick, acrylamide: bisacrylamide 19:1, 0.5× TBE, 7 M urea). Gels were run at 33 V/cm
for approximately 3 h. Gels were exposed to a phosphor screen overnight and imaged on a
Molecular Dynamics Phosphorimager and analyzed using ImageQuant software.
2.6 Evaluate the effects of pseudouridine (Ψ) modifications on the antibacterial activity of
2-deoxystreptamine aminoglycosides
The main focus of Chapter 5 is evaluation of the effects of Ψ modifications in H69 on
the antibacterial activity of the 2-deoxystreptamine class of aminoglycosides. The approach was
to compare the susceptibilities of modified and unmodified bacterial strains to different
aminoglycosides. In this work a series of MIC experiments was carried out using the broth micro
dilution method. A brief description of the MIC methodology and details of the experimental
protocol will be discussed in the following section.
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2.6.1 Minimum inhibitory concentration (MIC) studies
Minimum inhibitory concentration (MIC) is defined as the lowest concentration of an
antibiotic that will inhibit the visible growth of bacteria being investigated. MIC values are used
to determine susceptibilities of bacteria to drugs and also to evaluate the activity of new
antimicrobials agents. In clinical practice, this in vitro parameter is used to classify the tested
microorganisms as clinically susceptible, intermediate, or resistant to the tested drug.275,276 The
interpretative standards for these classifications are published by different national organizations
such as the Clinical and Laboratory Standards Institute (CLSI) in the USA and the European
Committee on Antimicrobial Susceptibility Testing (EUCAST).277,278 MIC determinations can be
used for monitoring the development of antibiotic drug resistance. MIC wild-type distribution
databases are available for relevant species-drug combinations. The highest MIC of the wild-type
population is defined as the epidemiological cut-off value or the wild-type cutoff value.
Organisms that acquired resistance can be easily identified by showing higher MIC values than
the epidemicological cut-off value.279-281 As even slight changes may become clinically relevant,
the determination of MIC is a valuable means for resistance surveillance, as well as providing a
valuable comparator for variants of a given antimicrobial agent and/or species with differential
susceptibility. Indeed for new drug candidates, the MIC determination is one of the first steps to
evaluate antimicrobial potential.
In this dissertation work, the MIC method was utilized as a tool to study the effects of
rRNA modifications on the in vivo activities of antibiotics. In previous studies, the MIC method
together with in vitro binding studies was employed to evaluate the effects of rRNA
modifications on the antibacterial activity of aminoglycosides. For example, in one study it was
shown that mutations in 16S rRNA distrupt in vitro binding of aminoglycosides.282 In this work,
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in vitro binding studies were done by chemical probing experiments with mutant and wild-type
ribosomes. In the same study, in vivo activity was measured by MIC experiments with mutant
and wild-type bacterial strains. In this manner, altered drug interactions with the target can be
implied if the in vitro data correlate with resistance observed in vivo. Binding studies are often
carried out with model RNAs or isolated ribosomes and therefore confined to in vitro systems. In
contrast, MIC data allow direct effects of rRNA modifications on the antibacterial activities of
drug to be assessed. Higher MIC values may indicate that rRNA modifications cause drug
resistance, whereas lower MIC values indicate that rRNA modifications increase susceptibility of
bacteria to the drugs. Therefore, it is important to carry out in vitro binding and MIC studies
together to evaluate the effects of rRNA modifications on drug activity.
2.6.2 Agar and broth dilution methods
Agar and broth dilution are the most commonly used techniques to determine the MIC
values of antimicrobial agents.275,276,283 For agar dilution, solutions with defined numbers of
bacterial cells are spotted directly onto the nutrient agar plates that have incorporated different
antibiotic concentrations. After incubation, the presence of bacterial colonies on the plate
indicates growth of the organism. Broth dilution uses liquid growth media containing
geometrically increasing concentrations (typically a two-fold dilution series) of the antimicrobial
agents, which is inoculated with a defined number of bacteria cells. The final volume of the test
defines whether the method is termed macro dilution, (< 2 mL), or micro dilution (microtiter
plates using > 500 µL per well) (Figure 2.13).
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Figure 2.13 Broth dilution methods. a) Broth macro dilution and b) broth micro dilution results
are shown for neomycin as an example. The MIC value is represented by a red circle in each
experiment. SC is the sterility control and GC is the growth control.
After incubation, the presence of turbidity indicates growth of the organism. In both agar
and broth dilution approaches, the MIC is defined as the lowest concentration (in mg/L) of the
antimicrobial agent that prevents visible growth of a microorganism under defined conditions.
Broth macro dilution method has been widely used to determine MIC.283 However, the tedious
procedure and need for large amounts of drugs make the macro dilution method undesirable for
studying expensive compounds such as antimicrobial peptides.283,284 Therefore, the broth micro
dilution method has become the most common and popular and practical method for MIC
experiments. In this dissertation work, broth micro dilution was employed to determine the MIC
of different antibiotics. The protocol was adapted from a standard protocol for antimicrobial
susceptibility testing that was published by CLSI.275,277

66

2.7 Materials and Methods
Materials
Mueller Hinton broth (MHB) was purchased from Becton, Dickinson, and Company. All
of the antibiotics used in the study, neomycin sulfate, paromomycin sulfate, kanamycin sulfate
capreomycin sulfate, gentamicin, streptomycin sulfate, spectinomycin sulfate, and carbenicillin
were purchased from Sigma-Aldrich (St. Louis, MO). Clear bottom 96-well plates were
purchased from Sigma-Aldrich (St. Louis, MO). E. coli MC415 (wild-type, ΨΨΨ) and E. coli
MC416 RluD(–), UUU) were provided by Professor Michael O'Connor’s lab, University of
Missouri (Kansas City, MO).
Methods
2.7.1 Preparation of the bacterial suspension
Bacterial isolates to be tested were streaked from a frozen stock onto LB-agar plates
without antibiotics to obtain single colonies. Plates were incubated overnight at 37 °C. Mueller
Hinton broth (3 mL) was inoculated with a single colony of bacteria. The inoculated broth was
incubated for 4 to 6 h at 37 °C in a shaker at 225 rpm until it reached a visible turbidity. The
turbidity of the bacterial suspension was verified by measuring the absorbance of the suspension
spectrophotometrically (OD600 nm at 0.08 to 0.13). The bacterial suspension was adjusted to 1 
108 cfu/mL and diluted by a factor of 1:100 by adding 200 µL bacterial suspension to 19.8 mL
sterile Muller Hinton broth. After turbidity adjustment, the bacterial suspension was used within
30 min, as the cell number might otherwise change.
2.7.2 Broth micro dilution method
Antibiotic dilutions were prepared in sterile Mueller Hinton broth 96-well plate.
Antibiotic concentrations ranged from 43 to 0.02 mg/L. As the antibiotic solution was inoculated
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with an equal amount of bacteria in broth, the dilutions were prepared at a concentration twice
the desired level. Each well of the microtiter plate was labeled with the respective antibiotic
concentration. The sterility and growth control wells were filled with 100 and 50 μL,
respectively, of the sterile broth. After turbidity adjustment of the bacteria suspension, the
microtiter plate was inoculated by adding 50 μL of bacteria to each well (with the exception of
negative control). The optical density (OD600 nm) of bacteria was taken after initial treatment. The
plate was incubated at 37 °C for 24 h. The bacterial growth was monitored by measuring optical
density (OD600

nm).

Percent inhibition of bacterial growth in the presence of different drug

concentrations was calculated and normalized to the growth control using formula below.285
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CHAPTER 3 IN VIVO EXPRESSION AND RIBOSOME MAPPING OF A PROLINERICH ANTIMICROBIAL PEPTIDE, ONCOCIN, IN ESCHERICHIA COLI
3.1 Abstract
The development of short peptides that specifically bind to higher-order structures of
ribosomal RNA is one promising way to address the problem of antibiotic resistance. Recent
studies in several laboratories, including ours, have identified short peptide sequences targeting
the bacterial ribosome.191,192,215,216,221-223 The poor correlation between in vitro and in vivo
activities of these peptides is one of the major questions in antibiotic peptide research. Therefore,
one of the main objectives of my dissertation work was to utilize a plasmid-based system to in
vivo express ribosome-targeting peptides and study their direct inhibitory effects on bacteria. In
this chapter, the main focus is oncocin, a proline-rich antimicrobial peptide known to target the
bacterial ribosome.215,221-223,225 A specific plasmid system was optimized to in vivo express
oncocin and its variants in bacteria. The direct inhibitory effects of in vivo-expressed peptides
were measured by doing bacterial growth assays. Our data show that the in vivo-expressedpeptide completely inhibits bacterial growth and displays bactericidal activity. According to
previous biochemical and structural data, oncocin is known to inhibit bacteria by targeting the
bacterial ribosome.221,223,225 Since our system allows us to in vivo express the bioactive peptide, it
is of interest to probe its interactions with the ribosome in an actual cellular environment. The
dimethyl sulfate (DMS) footprinting protocol was optimized to in vivo map the ribosome binding
sites of oncocin. Our footprinting data revealed interactions of oncocin with the PTC region of
the bacterial ribosome. To the best of our knowledge, this is the first effort to use DMS
footprinting to in vivo probe peptide-ribosome interactions.
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3.2 Introduction
Antimicrobial peptides (AMPs) are essential components of the innate immune
system.199,202 Being “nature’s antibiotics”, AMPs form the first line of host defense against
pathogenic infections.202-204 During the past few decades, AMP research has grown rapidly in
response to the demand for novel antibacterial agents to treat multi-drug resistance
pathogens.199,204

Although most of these AMPs inhibit bacteria by permeabilizing the

membrane, the action of AMPs is not limited to the surface of pathogens.212 Recently, subclasses
of AMPs have been identified that inhibit bacterial growth by targeting fundamental intracellular
processes.286 The proline-rich AMPs (PrAMPs) belong to one such subclass that targets the
ribosome and interferes with protein translation in bacteria.218,222,225 The activity of PrAMPs
against gram-negative bacteria was discovered more than 25 years ago with the isolation of
apidaecins from honey bee (Apis melifera)287 and bactenecins from cattle (Bos taurus)288 in the
late 1980s. Initially, PrAMPs were found in mammals and insects. They include cathelicidinderived peptides bactenecin and PR-39 from mammals and oncocin, drosocin, pyrrhocoricin, and
apidaecin from insects. Subsequently, they were also found in other animal species, such as
crustaceans, amphibians, and molluscs.218 Even though PrAMPs have different origins, all of
them are characterized as cationic AMPs with a high content of proline (typically 25 to 50%) and
arginine, often arranged in conserved patterns (Table 3.1).
Oncocin (VDKPPYLPRPRPPRRIYNR) is a PrAMP derived from Oncopeltus fasciatus
(milkweed bug),215,289 which has been optimized to be effective against gram-negative human
pathogens.215 Interestingly, recent studies have shown that PrAMPs such as oncocin target the
bacterial ribosome and inhibit protein translation.216,221 Most recently, two groups independently
identified the binding site of oncocin to the 50S subunit of the Thermus thermophilus 70S
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ribosome, where it blocks the peptidyl transferase center (PTC) and destabilizes the initiation
complex.222,223 These structures reveal peptide binding to the PTC region of the ribosome
(Figure 3.1). Upon binding to the upper region of the peptide exit tunnel, oncocin interferes with
binding of the aminoacyl-tRNA in the A site. Although it allows formation of the initiation
complex, the steric occlusion caused by the 19-mer peptide destabilizes the initiation complex
and causes dissociation.216,222,223 Therefore, oncocin inhibits protein translation by inhibiting the
transition from initiation to elongation (Figure 3.2).216,222,223
Table 3.1 Amino acid sequences of some selected PrAMPs
Peptide

Sequence

References
219
Bac7
RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFP
290
Pyrrhocoricin
VDKGSYLPRPTPPRPIYNRN
291
Metalnikowin
VDKPDYRPRPRPPNM
Oncocin

VDKPPYLPRPRPPRRIYNR

215,292

Oncocin112

VDKPPYLPRPRPPRrIYNr

223,289

Oncocin72

VDKPPYLPRPRPPROIYNO

216,289

r =D - Arg ; O = Ornithine
The conserved residues of selected PrAMPs are highlighted in blue. The underlined residues
correspond to the common core region.
Previous structural and biochemical data suggest that the N-terminal residues of oncocin
are responsible for targeting this peptide to the ribosome.216,223 The positively charged amino
acid residues distributed along the entire peptide sequence are necessary for efficient cellular
uptake of the peptide.221,223 The inner membrane protein SbmA, which is a part of the ABC
transporter system, is responsible for the cellular uptake of oncocin. SbmA transporters are
specific to gram-negative bacteria.293 Therefore, oncocin does not penetrate through mammalian
cell membranes, which makes it non-toxic to mammalian cells even at high concentrations.170,210
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Recent studies have shown that PrAMPs such as oncocin can be shuttled into mammalian cells
by cell-penetrating peptide penetratin.294

Figure 3.1 A crystal structure of the oncocin-ribosome complex. The structure of oncocin
(red) and the P-site tRNAfMet (purple) bound to the 70S ribosome (PDB: 5HCR) is shown.221 The
50S and 30S subunits are shown in grey and blue, respectively.
Oncocin was optimized to treat gram-negative pathogens such as Escherichia coli,
Pseudomonas aeruginosa, and Acinetobacter baumannii.215 Its minimal inhibitory concentrations
range from 0.125 to 8 μg/mL for 34 different strains and clinical isolates from Escherichia coli,
Pseudomonas aeruginosa, and Acinetobacter baumannii.215 The amino acid sequence of oncocin
was optimized to produce derivatives with improved antibacterial activity and stability. Onc112
and Onc72 are examples of optimized oncocin derivatives (Table 3.1).289 The pharmacokinetic
profiles explain the high in vivo efficacies in models of systemic infection and indicate the
potential use of these oncocin derivatives for the treatment of urinary tract infections.295
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Figure 3.2 Inhibition of protein synthesis by oncocin. a) Model for the mechanism of action of
oncocin is shown. The upper panel shows the main steps involved in canonical translation in the
absence of protein synthesis inhibitors. Translation begins with initiator tRNA (green) binding to
the ribosomal P site. During elongation, the aa-tRNA is delivered by EF-Tu to the A site,
followed by tRNA accommodation into the A site on the large subunit and subsequent departure
of EF-Tu. In the presence of PrAMPs, such as oncocin, aminoacyl tRNA (aatRNA) delivery can
occur, but the aa-tRNA accommodation step is blocked. The initiation complex is destabilized,
thus leading to dissociation from the P site.
In 2015, two groups independently identified the binding site of oncocin 112 to the 50S
subunit of the Thermus thermophilus 70S ribosome, where it blocks the PTC and destabilizes the
initiation complex.222,223 According to the crystal structure, the binding site of oncocin within the
ribosomal exit tunnel overlaps with the binding site of many clinically important classes of
antibiotics such as the macrolides (e.g., erythromycin), which aborts translation by interfering
with movement of the nascent polypeptide chain through the ribosomal exit tunnel.221-223
Chloramphenicols, pleuromutilins (e.g., tiamulin), and lincosamides (e.g., clindamycin) sites also
overlap; these compounds inhibit peptide-bond formation by preventing correct positioning of
the tRNA substrates.221-223 Even though it is very promising for the development of novel
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antibiotics, it is unclear whether resistance mutations that arise against currently used antibiotics
will also confer cross-resistance against oncocin. The development of novel antimicrobial
compounds based on PrAMPs such as oncocin is a possible approach to overcome multi-drug
resistant pathogenic bacteria.
3.3 Objectives of this project
The poor correlation between in vitro and in vivo activities of antimicrobial peptides is
one of the major questions in antibiotic peptide research. Therefore, in contrast to in vitro
methods, the main objectives of my dissertation work were to develop a biological approach for
in-cell synthesis of peptide antibiotics. I optimized a specific plasmid system to in vivo express
the ribosome-targeting peptide oncocin and studied its direct inhibitory effects on bacteria. Since
the system allows us to synthesize peptides inside bacteria, it has several other downstream
applications (Figure 3.3). The system was utilized to in vivo express oncocin variants and study
their inhibitory activities. Furthermore, in vivo DMS footprinting experiments were carried out to
map the ribosome binding sites of oncocin. The objective of this chapter is to emphasize the
different applications and advantages of the in vivo peptide expression approach using oncocin as
a model peptide. The in vivo peptide expression approach provides important information about
the biological function and peptide-target interactions in actual cellular environment.

74

Figure 3.3 Different applications of in vivo peptide expression in bacteria. As explained in
Chapter 2, the pKantvec plasmid system was utilized to in vivo express oncocin as a free peptide
in bacteria. After expression, its direct inhibitory effects on bacterial growth were measured by
doing growth assays. Oncocin-ribosome interactions were determined by doing in vivo DMS
footprinting experiments. An in vivo alanine scan was carried out by expressing alanine mutants
of oncocin followed by growth assays. In order to identify oncocin-derived AMPs, an oncocinbased in vivo peptide library was constructed.
3.4 Results and discussion
3.4.1 Cloning of oncocin peptide into the plasmid system
The proline-rich antimicrobial peptide oncocin was chosen for this study. A single
plasmid expression system, pKan5tvVec (8243 bp) with an inducible PBAD promoter and
kanamycin resistance, was used as the vector. Dr. Wesley Colangelo (Cunningham lab) prepared
the plasmid for this experiment. The restriction enzyme sites Hind III and Nhe I were used to
clone the peptide insert into the plasmid. As explained in the experimental methods section in
Chapter 2, the primer extension PCR method was used to generate the corresponding DNA
sequences that code for the desired peptide sequences. The size of the DNA product
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corresponding to 19-mer peptide sequence is 135 bp. The PCR product was checked on an
agarose gel before the restriction digestion (Figure 3.4).

Figure 3.4 Plasmid vector and peptide-insert preparation. a). Plasmid pkan5tvec (8243 bp)
was digested using Nhe I and Hind III restriction enzymes and the gel band corresponding to the
desired vector fragment (5371 bp) was purified before ligation. b) The insert was synthesized
using the non-template PCR method and purified before and after restriction digestion. The size
of the PCR prodcut of oncocin is 135 bp. The control lane contains a 113 bp DNA product for
comparison.
The DNA products were gel purified and ligated to obtain the new plasmid pPep-oncocin
(5485 bp) (Figure 3.5). The genes were cloned behind the PBAD promoter of the plasmid
pKan5tvVec such that the peptides could be expressed by inducing with L-arabinose. The ligated
plasmid was transformed into E. coli DH5 electrocompetent cells. The sequence of the peptide
clone was confirmed by doing DNA sequencing (Figure 3.6).
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Figure 3.5 Plasmid map of pPep-oncocin. The restriction enzyme sites Nhe I and Hind III were
used to clone the peptide insert into the plasmid. The expression of the peptide and TEV-protease
was controlled by the PBAD promoter. The plasmid shows kanamycin resistance.
In a previous study, it was shown that cloning of the peptide sequence right after the start
codon completely inhibited translation of the peptide.193 Therefore, in this study the peptide
sequence was cloned behind the TEV (Tobacco Etch Virus) protease recognition sequence
(ENLYFQG/S). The protease enzyme specifically cleaves between residues Q and G/S of its
recognition sequence, resulting in an extra G or S amino acid at the N-terminus of the peptide
sequence.242,245 Although the wild-type TEV protease recognition sequence is ENLYFQG/S,
studies have shown that any amino acids after Q in the ENLYFQ/S sequence could cleave
efficiently such that the exact peptide sequence is exposed after TEV cleavage. 231,242,243,246
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Therefore, a primer was designed that excluded the codon corresponding to the C-terminal G
residue of the oncocin peptide. Therefore, after TEV protease cleavage the exact N-terminus
sequence of the oncocin peptide would be exposed (Figure 3.7).

a)

b)

Figure 3.6 Peptide sequence confirmation. a) The peptide clones were confirmed by doing
colony PCR, which gave 361 bp PCR products for the 19-mer peptide in colony PCR. Control
lanes contain a 329 bp DNA product for comparison. b) The sequence alignment of ligated
plasmid pPep-oncocin. The full alignment is 1020 bp, whereas this section only shows the
nucleotide sequence of the TEV recognition sequence in the first box (green) with the amino acid
sequence labeled in green. The amino acid sequence of oncocin is shown in red and the
corresponding nucleotides are in box 2 (red).
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Figure 3.7 TEV cleavage site. Oncocin primers were designed excluding the C-terminal G
residue of the wild-type TEV recognition sequence (ENLYFQG). Therefore, TEV protease
cleavage occurs between Q and V, resulting in the exact oncocin peptide sequence.
3.4.2 Study the effects of oncocin on bacterial growth (bacterial growth assay)
After confirming the sequence of each peptide clone, they were used in bacterial growth
assays as described earlier. Bacteria were grown in LB/kanamycin medium. When cells reached
late lag phase or OD600nm = 0.2, (~200 min), L-arabinose was added to induce the expression of
peptides. Cell growth was measured with and without adding inducer. The bacterial growth was
monitored by measuring the optical density of all bacteria cultures every 60 min (Figure 3.8). In
growth assays, DH5 strain CSL011 from the Cunningham lab, which expresses peptide
KGTRAFATTNSH, was utilized as a positive control. In previous studies in the Cunningham
lab, this 12-mer peptide inhibited bacterial growth.231 The 7-mer peptide AAAAAAA was used
as a negative control, and did not show growth inhibition in previous experiments. All of the
induced cultures, including the controls, showed slower growth rates as compared to the uninduced cultures (Figure 3.8a). This effect was likely due to the high stress on cells created by
the over-expressed mRNA or proteins. Compared to the negative control peptide GAAAAAAA,
complete inhibition of bacterial growth was observed in the cultures that expressed oncocin
(Figure 3.8a).
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Figure 3.8 Oncocin impacts on growth assay. a) Effects of the expression of different peptides
on bacterial cell growth were assessed. Oncocin-UI is the uninduced growth curve for the pPeponcocin plasmid, whereas, Oncocin-IN is its induced partner. Peptide-induced cultures show
slower growth compared to the uninduced cultures. b) Percent inhibition of bacterial growth after
540 min (9 h) (left), or 24 h (right) upon expression of different peptides was measured and
normalized to the negative control (induced GAAAAAAA). All growth assays were performed
at least three times independently and results were averaged.
After 540 min (9 h) of incubation, both oncocin and the positive control peptide showed
~ 80% inhibition of growth (Figure 3.8b). Interestingly, even after overnight incubation oncocin
showed complete inhibition of bacterial growth, which was not observed with the positive
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control peptide. This behavior suggests strong bactericidal activity of oncocin compared to the
positive control peptide. After 9 h of incubation, 50 µL of bacteria was taken out and plated in
LB/agar medium and incubated at 37 °C. After overnight incubation, we did not observe
colonies on plates incubated with bacteria expressing oncocin. However, an average of 60
colonies were observed on plates incubated with bacteria expressing the positive control peptide.
This observation demonstrated the bactericidal activity of oncocin directly compared to the
positive control peptide. Therefore, our data are in a good agreement with the previously
reported information about oncocin as an antimicrobial peptide.221,289 Furthermore, our data
suggest that the plasmid-based system can be utilized to identify in vivo antibacterial activities of
peptides. In previous studies, this system was utilized to in vivo express only 7-mer
peptides.193,231 However, by in vivo expressing oncocin, we showed that the system can be used
for the recombinant expression of even larger peptides.
After optimizing the plasmid system to in vivo express peptides, we considered the
possible applications of the plasmid system. The in vivo peptide expression approach could be
useful in AMP optimization processes. After identifying an AMP from a natural source or from a
peptide library screen, the next critical step is to obtain optimized structural analogs. Usually the
optimization process is done by minimizing the peptide length and systematically substituting
each amino acid residue.235 This process is typically expensive and time consuming due to the
need to employ solid-phase peptide synthesis (SPPS).235 For example, the bioactive oncocin
peptide sequence we utilized in this study was obtained after a very long optimization process. 215
Oncocin is the optimized peptide sequence of Oncopeltus antibacterial peptide 4, which was
originally isolated from Oncopeltus fasciatus (milkweed bug) together with three other AMPs.292
Since, the original peptide sequence isolated from milkweed bug did not show considerable
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antimicrobial activity, its sequence was optimized to obtain a bioactive peptide sequence.215 In
this process, peptide variants were chemically synthesized using SPPS and utilized in MIC
studies with different bacteria strains. Finally, they came up with the bioactive 19-mer peptide
sequence of oncocin (VDKPPYLPRPRPPRRIYNR-NH2), which was found to be active against
37 different isolates of E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, E. cloacae, and
Proteus vulgaris.215 Despite the favorable antibacterial spectrum of AMPs, there are multiple
obstacles to be overcome in their further development for therapeutic consideration.
Recently, one research group in Germany used rational design to optimize the oncocin
sequence. In this work, they found several oncocin derivatives with improved protease stability
and antibacterial activity.289 The relatively high cost of SPPS compared to bacterial production is
considered as one of the major limitations in AMP research. Recent evidence suggests that the
production cost of a 5000 Da peptide exceeds the production cost of a 500 Da small molecule by
more than 10-fold.235 Therefore, the high cost of SPPS for clinical applications is a challenge in
the AMP optimization process.200,229 This in vivo peptide expression approach has several
advantages in AMP optimization. The bacterial production of peptides is cost effective and less
time consuming compared to SPPS. On the other hand, in vivo approaches allow the study of
peptide activities in actual cellular environments which is not possible with in vitro experiments.
Considering these facts, one of the possible applications of this plasmid system is in vivo
expression of AMP variants and the study of their in vivo activities. In this dissertation work, an
in vivo alanine scan experiment of oncocin was carried out. The main focus of the next section of
this chapter is in vivo expression and evaluation of the activities of the alanine mutants of
oncocin.
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3.4.3 In vivo expression of alanine mutants of oncocin
Previous structural and biochemical data suggested that the N-terminal residues of
oncocin are responsible for targeting this peptide to the ribosome, whereas the positively charged
amino acid residues distributed along the entire peptide sequence are necessary for efficient
cellular uptake of the peptide.216,221,223 After the discovery of oncocin, scientists were curious to
study the role of each amino acid residue of oncocin. In one study, a positional alanine scan was
carried out to identify critical residues for antibacterial activity. In this work, all possible 19
peptides resulting from a positional alanine scan were chemically synthesized and utilized in
MIC studies.289 In this work, they showed that alanine substitutions at positions 3, 6, 7, and 11
completely abolished the antibacterial activity.
According to previous structural and biochemical data, Lys3, Tyr6, Leu7, and Arg11 of
oncocin are critical for the ribosome binding and antibacterial activity of oncocin. 216,289
However, all of these studies were confined to in vitro systems and entirely depended on SPPS.
Therefore, it was of interest to examine the activities of oncocin mutants in an actual cellular
environment. Each critical amino acid residue of oncocin was substituted with alanine to obtain
four single alanine mutants of oncocin (oncK3A, oncY6A, onc7LA, oncR11A). In addition, all
four positions were substituted with alanine to obtain the onc3KAY6AL7AR11A mutant. DNA
inserts corresponding to each alanine mutant (Figure 3.9a) were cloned into the plasmid vector
and transformed into DH5α cells as described in Chapter 2 (Methods section). The ligation was
confirmed by doing colony PCR (Figure 3.9b), and individual peptide clones were confirmed by
DNA sequencing. The bacterial growth assays were carried out with oncocin and alanine mutants
to evaluate the antibacterial activities.
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Figure 3.9 Cloning of alanine mutants of oncocin. a) The peptides inserts were generated
using the non-template PCR method and gel purified before and after restriction digestion. The
size of the 19-mer peptide PCR product was 135 bp. The control lane contains a PCR product of
a 15-mer peptide (123 bp) for comparison. b) The peptide clones were confirmed by doing
colony PCR, which gave 361 bp PCR products. The control lane contains a colony PCR product
of a 15-mer peptide (349 bp) for the comparison
Figure 3.10 shows the growth curves for the oncK3AY6AL7AR11A mutant and wildtype oncocin. When all four amino acid residues were substituted with alanine, a complete loss
of antibacterial activity was observed. After 540 min (9 h) of incubation, more than 80%
inhibition was observed with wild-type oncocin, whereas only 3% growth inhibition was
observed in the cultures expressing the mutant peptide. After 9 h of incubation, 50 µL of bacteria
was taken out and plated in LB/agar medium and incubated at 37 °C. After overnight incubation,
we did not observe colonies on plates incubated with bacteria expressing oncocin. However,
more than 100 colonies were observed in plates incubated with bacteria expressing the alanine
mutant. This observation demonstrated the bactericidal activity of oncocin directly compared to
the mutant peptide. According to our in vivo data, substitution of Lys3, Tyr6, Leu7, and Arg11
with alanine led to complete loss of the antimicrobial activity of oncocin. This observation is
consistent with one or more of these residues being critical for the antibacterial activity of
oncocin.
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Figure 3.10 OncK3AY6AL7AR11A mutant growth assay. Effects of expression of the
OncK3AY6AL7AR11A mutant on bacterial cell growth compared to the wild-type oncocin.
Peptide uninduced growth curves are shown as UI, whereas its induced partner is shown as IN.
The growth inhibition is completely abolished for the alanine muatant compared to oncocin
(induced). All growth assays were performed at least three times independently and results were
averaged.
Our in vivo data are in a good agreement with previous observations for the mutant
peptide onc3KA6YA7LAR11A. Previously, it was shown that alanine substitution of Lys3,
Tyr6, Leu7, and Arg11 severely reduced the antimicrobial activity of oncocin and decreased its
binding affinity to the 70S ribosome by more than 30-fold.216,296 Altogether, previous in vitro
data with chemically synthesized mutant peptides and our data with in vivo expressed mutant
peptides support Lys3, Tyr6, Leu7, and Arg11 as critical residues for the antibacterial activity of
oncocin.
In the next step, we wanted to look at the contributions of individual amino acid residues
on the antibacterial activity of oncocin. Therefore, single alanine mutants of oncocin (oncK3A,
oncY6A, onc7LA, and oncR11A) were expressed and utilized in bacterial growth assays as
explained previously. In this experiment, onc3AY6AL7AR11A and wild-type oncocin were used
for comparison as inactive and active variants, respectively. Previous structural and biochemical
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data suggested that N-terminal residues of oncocin were responsible for targeting this peptide to
the ribosome.222,223 Previous mutational studies also showed that substitution of Val1, Asp2, and
especially Lys3, by alanine in oncocin led to a loss of antimicrobial activity. The effect was
significant with the Lys3 substitution.216 Therefore, we examined the in vivo activity of the
oncK3A mutant.

Figure 3.11 OncK3A mutant growth assay. Effect of the expression of oncK3A mutant on
bacterial growth compared to the wild-type oncocin and oncK3AY6AL7AR11A mutant
peptides. All growth assays were performed at least three times independently and results were
averaged.
In growth assays with the K3A mutant, we observed a loss of antimicrobial activity
compared to oncocin. However, compared to the mutant peptide, K3AY6AL7AR11A, complete
loss of activity was not observed at shorter times (Figure 3.11). For example, after 3 h of
induction (at 360 min), oncK3A showed 22% inhibition, whereas oncocin showed 77%
inhibition. However, after 6 h of induction (at 540 min) oncK3A showed complete loss of
antibacterial activity (no inhibition), and oncocin showed more than 80% growth inhibition. In
previous studies with the oncK3A mutant peptide, it was shown that upon alanine substitution,
the MIC value for the mutant peptide increased by 10-fold compared to the wild-type peptide. In

86

the same study, it was shown by fluorescence polarization method that ribosome binding of the
mutant peptide decreased 5-fold compared to the wild-type peptide sequence.216 Collectively,
previous in vitro data and our in vivo data suggest that Lys3 of oncocin is important for
antibacterial activity.

Figure 3.12 Interactions of oncocin within the PTC. a) The middle part of oncocin occupies
the A-site cleft in the PTC. Residues Leu7 and Tyr6 form a three-layer stack with the nucleotide
base of C2452. b) Interactions of the C-terminus of oncocin with the peptide exit tunnel are
shown. Arg9 and Arg11 form a stacking interaction with the nucleotide bases of C2610 and
A2062, respectively (PDB ID: 5HCR).221
The second set of oncocin-ribosome interactions involves the side chains of Tyr6 and
Leu7. According to a crystal structure,221 the aromatic side chain of Tyr6 establishes a π-stacking
interaction with C2452 of the 23S rRNA (Figure 3.12a). The backbone of Leu7 forms two
hydrogen bonds with U2506. The compact hydrophobic core formed by Tyr6 and Leu7 is likely
to be key in anchoring the peptide to the exit tunnel. Previous mutagenesis experiments showed
that alanine substitution of either residue in oncocin reduced the ribosome binding affinity by a
factor of 7 and resulted in a complete loss of inhibitory activity on in vitro translation.216 In order
to look at in vivo activities, a bacterial growth assay was performed with oncY6A and oncL7A
mutants. Complete loss of antibacterial activity with both mutant peptides was observed
compared to the wild-type oncocin (Figure 3.13).
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Figure 3.13 OncY6A and oncL7A mutants growth assay. Effects of the expression of mutant
peptides on bacterial cell growth compared to the wild-type oncocin. The growth inhibition is
completely abolished upon the induction of alanine muatant compared to oncocin. All growth
assays were performed at least three times independently and results were averaged.
After 3 h of induction (at 360 min), the growth curves of both mutant peptides overlapped
with the negative control peptide, onc3KAY6AL7AR11A and showed complete loss of
antibacterial activity. Our data are in a good agreement with previous observations of these
mutant peptides in vitro and support roles for Tyr6 and Leu7 in the antibacterial activity of
oncocin. In addition to the above-mentioned interactions, the crystal structure revealed that the
C-terminal PRPRP motif of oncocin interacts with 23S rRNA.221-223 This includes π-stacking
interactions between the guanidino groups of Arg9 and Arg11 with nucleotides of 23S rRNA
(Figure 3.13b). Previous mutagenesis experiments showed that substitution of Arg11 with
alanine in oncocin reduced the ribosome binding affinity by a factor of 6 and increased the MIC
and IC50 of the peptide by 8- and 14-fold, respectively.

216

Therefore, it was of interest to

examine the in vivo activity of the onc11A mutant. In the growth assay, loss of antibacterial
activity was observed with onc11A cultures compared to oncocin-expressing bacterial cultures
(Figure 3.14). However, onc11A did not show complete loss of activity as did
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onc3KAY6AL7AR11A peptide. After 3 h of induction (at 540 min) compared to the
onc3KAY6AL7AR11A mutant, oncR11A showed only 24% inhibition.

Figure 3.14 OncR11A mutant growth assay. Effects of the expression of the oncR11A mutant
on bacterial cell growth compared to the wild-type oncocin. All growth assays were performed at
least three times independently and results were averaged.
Therefore, the antibacterial activity of the mutant peptide was retained to a certain extent
even with the alanine substitution. From our alanine scanning experiment, it appears that all four
residues, Lys3, Tyr6, Leu7, and Arg11, are important for the antibacterial activity of oncocin.
Out of them, Tyr6 and Leu7 seem to be the most important, because the growth of Y6A and L7A
mutants was similar to the K3AY6AL7AR11A mutant. Our observations with the oncocin
alanine mutants are in good agreement with previously observed in vitro activities of these
mutants.216,221,223 The purpose of this alanine scan experiment was to determine whether we can
utilize the plasmid-based system as a tool to study the in vivo activities of peptide variants. The
in vivo activities of oncocin mutants correlated well with the previously observed in vitro
activities of these peptides. Therefore, our in vivo approach has promising applications in peptide
optimization processes. However, there are some limitations. Since the peptides are expressed in
an actual cellular environment, there is a possibility for them to undergo proteolytic degradation
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by bacteria proteases. However, we have the same issue when chemically synthesized peptides
are utilized in MIC experiments, since peptides act inside bacterial cells. The advantage of the in
vivo approach is the overexpression of the peptide. Although some amount of peptide undergoes
degradation, the cell can produce enough peptide to show activity. In-cell synthesis can also help
to overcome cell permeability issues associated with short peptides. With our data, we propose
that for the initial optimization process of an AMP (such as alanine scanning), the plasmid-based
system could be used as an alternative to SPPS and MIC studies. It saves both money and time
during the initial optimization process. At later stages of AMP optimization, in vivo approaches
can be used together with in vitro experiments to obtain more information about the behavior of
selected peptide variants. Similarly, mutants can be chemically modified by SPPS following
sequence optimization.
3.4.4 In vivo probing of oncocin-ribosome interactions
In 2015, two research groups independently solved the x-ray crystal structures of onc112bound Thermus thermophilus ribosomes.221,223 According to these crystal structures, the peptide
binds to the PTC region and interferes with binding of the aminoacyl-tRNA in the A site.
Furthermore, these x-ray crystal structures reveal that several 23S rRNA nucleotides in the PTC
region undergo different conformation changes upon peptide binding. X-ray crystallography is a
powerful technique for understanding the structures, biological functions and ligand interactions,
of many biomoleules. A major use of this technology is the identification and study of drug
targets. For example, in the ribosome research field, x-ray crystallography is a commonly use
technique. Crystal structures represent time and space averages of all molecules present within
the crystal lattice and often exhibit significant conformational variations in their structures.297
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Despite their utility, crystal structures of ribosome complexes show that some regions of
the ribosome are dynamic, and these motifs can have significantly different conformations in the
crystal from those in solution.298 The intrinsic dynamics of the ribosome in solution could lead to
alternative or additional binding modes.262 Even though high-resolution crystal structures of
oncocin bound ribosome are available, in order to better understand the rRNA-oncocin
interactions it is important to look at the rRNA dynamics in solution. Chemical footprinting is a
commonly used biochemical tool to examine such conformational changes of rRNA nucleotides
upon drug binding.139,263 Alterations in reactivities of rRNA nucleotides towards chemical
modifications provide valuable information about the rRNA-drug interactions.139,239,263 In a
previous study, in vitro chemical footprinting was employed to study ribosome-oncocin
interactions in solution.221 In this study, the authors observed that several nucleotides in the PTC
region were protected by oncocin from chemical modifications. These observations in in vitro
probing experiments were consistent with binding of oncocin to the PTC region. Even though it
provided information about rRNA dynamics in solution, the experiment was confined to an in
vitro system. In in vitro footprinting experiments, the most crucial peptide-target interaction step
occurs in a simulated environment, which is very different than the actual cellular
environment.228,229 This process also requires synthesis or isolation of the target prior to the
experiment, as well as the assumption that the target is in its bioactive conformation under these
in vitro conditions. For example in previous studies, the fooprinting experiment was carried out
with isolated ribosomes and it was not clear if they used activated ribosomes for the experiment.
Another important concern is that targets such as DNA, RNA, or proteins have numerous
conformations in vivo that are influenced by their environment. Peptides are also highly sensitive
to environmental conditions, which may result in discrepancies between their in vitro and in vivo
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activity. Considering these facts, it is of interest to probe the ribosome-peptide interactions in
actual cellular environments.
The development of a tool that could monitor ongoing rRNA conformational states in
actual cellular environments would be significant. Since this plasmid system allows us to
produce AMPs inside bacteria, it was of interest to in vivo probe the binding sites of oncocin and
confirm its interactions with the PTC region of the bacterial ribosome. In this dissertation work, I
optimized an in vivo DMS footprinting protocol to map the ribosome binding sites of oncocin.
The details of the in vivo DMS footprinting technique and the experimental protocols are
described in Chapter 2. In this in vivo footprinting experiment, oncocin-expressing bacterial cells
were treated with DMS, followed by isolation of chemically modified RNA. In order to look at
ribosome-oncocin interactions, reverse transcription-based primer extension analysis of the PTC
region was performed by using of 5'-32P-labeled DNA primers. The objective of our experiment
was to identify oncocin-ribosome interactions under in vivo conditions and compare with
previously reported in vitro data.221 The in vivo footprinting provides additional information
regarding altered binding interactions of oncocin with the ribosome relative to in vitro
conditions. To the best of our knowledge, this is the first effort to use in vivo DMS footprinting
to study ribosome-drug interactions. Unlike most known antibiotics, a single oncocin molecule
interacts with not just one, but with two adjacent functional sites of the ribosome. Its N-terminus
binds near the PTC of the 50S subunit, where it interferes with the A-site tRNA and the peptidyltRNA in the P site.222,223 The other portion of oncocin interacts with the peptide exit tunnel of the
50S subunit and blocks it completely.221,223 We carried out two DMS footprinting experiments to
monitor 23S rRNA nucleotides in the peptide exit tunnel and the PTC region.
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3.4.4.1 Interactions of oncocin in the peptide exit tunnel region
Previous structural and biochemical data revealed that several nucleotides in the upper
chamber of the peptide exit tunnel undergo conformational changes upon oncocin binding.218,221
Nucleotide A2062 adopts a conformation that allows the base to form a favorable stacking
interaction with Arg11 of oncocin. A similar interaction was also observed between Arg9 and
C2610 (Figure 3.15).222,223 The binding site of oncocin in the peptide exit tunnel overlaps with
the binding sites of macrolide antibiotics, erythromycin and azithromycin.223 Interestingly, a
crystal structure of the macrolide antibiotic erythromycin bound to ribosomes revealed that
nucleotide A2062 undergoes different conformational changes upon drug binding.299-301 Previous
studies showed that mutations of A2062 and C2610 substantially reduced antibiotic-dependent
ribosome stalling.302,303 Moreover, alanine scan experiments showed that substitution of Arg11 in
oncocin with alanine decreased its binding affinity to the ribosome by about 6-fold.216 For this
dissertation work, I performed an in vivo alanine scan experiment and observed loss of
antimicrobial activity upon substitution of Arg11 with alanine (data explained in Section 3.4.3).
These observations explained the important role of A2062 in oncocin-ribosome interactions.

Figure 3.15 Interactions of oncocin within the PTC. a) The middle part of oncocin occupies
the A-site cleft in the PTC. Residues Leu7 and Tyr6 form a three-layer stack with the nucleotide
base of C2452. b). Interactions of the C-terminus of oncocin with the peptide exit tunnel are
shown. Arg9 and Arg11 form a stacking interaction with the nucleotide bases of C2610 and
A2062, respectively. (PDB ID: 5HCR).221
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In in vivo footprinting experiments, strong protection of A2062 by oncocin is observed
(Figure 3.16). This observation is consistent with A2062 undergoing a conformational change
upon oncocin binding. In addition to A2062, strong DMS protection is observed at A2058 and
A2059, which was not previously observed by in vitro oncocin footprinting experiments.221

Figure 3.16 In vivo DMS footprinting of oncocin-PTC interactions. The autoradiogram (left)
shows reverse transcription mapping of oncocin binding sites in the peptide exit tunnel region.
Dideoxy sequencing lanes are labeled as C, U, G, and A (reverse transcription with ddGTP,
ddATP, ddCTP, and ddTTP, respectively). The strong DMS reactive sites are labeled with black
arrows and circled on the secondary structure map of the PTC region (right). The primer site is
indicated with p2083.
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Figure 3.17 In vivo DMS footprinting analysis of oncocin-PTC interactions. a)
Autoradiogram for DMS footprinting followed by primer extension analyses of oncocin binding
to peptide exit tunnel. Reverse transcription stops before the DMS modification site, so the
product mobility differs from the sequencing lane by one nucleotide. b) Quantification of DMS
reactivity of each nucleotide in the presence and absence of oncocin is shown. Band intensities
were normalized to a non-specific stop site labeled as the standard. Three independent
footprinting experiments were carried out and results were averaged.
The reduced band intensities of the reverse transcription stop sites compared to the DMSonly control indicate low DMS reactivity of these nucleotides in the presence of oncocin. The gel
bands were quantified using Image Quant software, and normalized intensities were determined
(Figure 3.17b). Compared to the no drug control, 20-fold decreased DMS reactivity was
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observed for A2062, with 12-fold decreased reactivity for both A2058 and A2059. The DMS
protection of A2058 and A2059 by oncocin was not observed in previous in vitro footprinting
studies.221 In addition, the oncocin-ribosome crystal structure did not show any direct
interactions of the peptide with either A2058 or A2059.222,223 Despite lack of interactions with
oncocin, all currently available crystal structures of 14-membered-ring macrolide-ribosome
complexes revealed significant interactions with A2058 and A2059 of 23S rRNA (Figure
3.18).304-306 These two nucleotides are recognized as the main constituents of the macrolidebinding pocket. The high binding affinities of macrolides originate mainly from hydrophobic
interactions of their lactone rings and hydrogen bonds of their desosamine sugars with
nucleotides A2058 and A2059.306
A crystal structure of erythromycin bound to ribosomes indicated that nucleotide 2058
plays a key role in macrolide binding and selectivity, the base component is an adenine in
eubacteria and a guanine in eukaryotes.305 Furthermore, the prominent macrolides-lincosamidesstreptograminB (MLS) resistance mechanisms, an A to G substitution or erm-gene methylation,
are related to the increasing size of A2058.17,305,307 Moreover, previous in vitro DMS footprinting
studies with erythromycin showed strong DMS protections of A2058 and A2059.305 In this
previous study, the footprinting experiments were done with ribosomes isolated from four
different species, archaea (H. halobium) and three different bacterial species (D. radiodurans, E.
coli, or S. aureus), and in all cases strong DMS protection was observed at A2058 and A2059.
Collectively, these data indicate that A2058 and A2059 play crucial roles in macrolide antibiotic
binding to the PTC region. Therefore, it was not surprising that we observed strong protection of
A2058 and A2059 by oncocin. The extended arginine side chains of oncocin span across the
peptide exit tunnel and completely block the upper chamber. Even though in x-ray structures the
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peptide did not show direct interactions with A2058 and A2059, Leu7 of oncocin forms Hbonding interactions with the neighboring nucleotide G2061, which provides additional
stabilization of the peptide inside the peptide exit tunnel (Figure 3.15).222

This indirect

interaction may induce conformational changes of A2058 and A2059, nucleotides which could
reduce their reactivity towards DMS.

Figure 3.18 Crystal structure of macrolide antibiotic bound ribosomes. Macrolide, antibiotic
erythromycin (shown in orange) binds to the PTC. Nucleotide positions at which mutation
confers resistance for erythromycin are labeled in red (PDB ID: 4V7Y).50
Crystal structures of ribosome complexes are static and some regions of the ribosome
could have significantly different conformations in the crystal from those in solution.298 The
intrinsic dynamics of the ribosome in solution, especially in the more complex cellular
environment, could lead to alternative or additional binding modes.262 This could be a possible
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explanation for the observed DMS protection of A2058 and A2059 nucleotides in the in vivo
footprinting experiment. With these data, we can argue that compared to in vitro probing studies,
antibiotic footprinting in cellular environments provides additional information about AMPribosome interactions.
3.4.4.2 Interactions of the oncocin N-terminus with the ribosome
The structures of Pr-AMP bound ribosomes revealed that the N-terminus of peptides
form several interactions with helix 92 (H92), which forms the A loop of 23S rRNA.221-223
According to a crystal structure, the first three amino acids of oncocin (VDK) form multiple
interactions with H92 (Figure 3.19).222

Figure 3.19 Interactions of the N-terminus of oncocin with 23S rRNA. The side chain of
Asp2 forms two H-bonding interactions with G2553, a residue located helix H92 (H92) of 23S
rRNA, termed the A loop (PDB ID: 5HCR).221
The main chain peptide backbone of Val1 forms two H-bonding interactions with C2573
(Figure 3.19). In addition to that, the side chain of Asp2 also forms H-bonding interactions with
G2553.221 The nucleotide G2553 is part of the A loop and forms a Watson-Crick base pair with
C75 of the aa-tRNA.308 The interactions of oncocin with H92 interfere with binding of the CCA

98

end of aa-tRNA in the PTC region. Although a crystal structure is available, it was of interest to
examine the interactions of H92 nucleotides with oncocin in the cellular environment, which
would provide additional insight into the oncocin-ribosome interaction and mechanism of action
of oncocin.
In our in vivo footprinting experiment, we observed that several nucleotides in the H92
region undergo conformational changes upon oncocin binding (Figure 3.20). Nucleotide C2556
located in the loop region (A loop) of H92 shows strong DMS protection upon drug binding.
Compared to the DMS-only control, a 50-fold decrease in DMS reactivity is observed (Figure
3.21b). In addition, C2551 in the loop and A2560 and C2559 in the stem region of H92 are also
protected by oncocin from DMS modification. According to the crystal structure, none of these
nucleotides have direct interactions with oncocin.222 However, the direct interaction of G2553
with Asp2 of oncocin might cause indirect structural effects on neighboring nucleotides.
According to the crystal structure, Val1 of oncocin also forms two H-bonding interactions with
C2573 (Figure 3.19). This interaction may cause conformational changes of C2573, which leads
to changes in DMS reactivity of this nucleotide. Consistent with that report, our footprinting
experiment reveals DMS protection at nucleotide C2573. Compared to the DMS-only control,
we observe a 12-fold reduced DMS reactivity at this residue (Figure 3.21b). This observation
supports the interaction of C2573 with oncocin in vivo.
The goal of our in vivo footprinting experiment was to evaluate the oncocin-ribosome
interactions in a cellular environment. Collectively, our in vivo footprinting analysis supported
the interaction of oncocin with the PTC region of the bacterial ribosome. Our data are in good
agreement with previous observations regarding oncocin-ribosome interactions. Under in vivo
conditions, we observed additional binding information in the PTC, which was not obtained from
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in vitro experiments. With these data, it is apparent that our plasmid system can provide
important contact identification of ribosome-peptide interactions by in vivo probing. To the best
of our knowledge, this is the first effort to use DMS footprinting method to in vivo probe drugribosome interactions.

Figure 3.20 In vivo DMS footprinting of oncocin-H92 interactions. The autoradiogram (left)
shows reverse transcription mapping of oncocin binding sites in the H92 region of 23S rRNA.
Dideoxy sequencing lanes are labeled as C, U, G, and A (reverse transcription with ddGTP,
ddATP, ddCTP, and ddTTP, respectively).. The corresponding reactive sites are labeled with
black arrows and circled in the secondary structure map of the PTC region (right). Nucleotide
G2553 of the A loop is shown in red. The primer site is indicated with p2594.
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Figure 3.21 In vivo DMS footprinting analysis of oncocin-PTC interactions. a)
Autoradiogram for DMS footprinting followed by primer extension analyses of oncocin binding
to PTC. Reverse transcription stops before the DMS modification site, so the product mobility
differs from the sequencing lane by one nucleotide. b) Quantification of DMS reactivity of each
nucleotide in the presence and absence of oncocin is shown. Band intensities were normalized to
a non-specific stop site labeled as the standard. Three independent footprinting experiments were
carried out and results were averaged.
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3.5 Summary and conclusions
The development of short peptides that specifically bind to higher-order structures of
ribosomal RNA is one promising way to address the problem of antibiotic resistance.191
However, the poor correlation between in vitro and in vivo activities of peptides is one of the
major limitations in antibiotic peptide research. Therefore, in contrast to in vitro methods, one of
the main objectives of my dissertation work was to utilize a plasmid-based system to in vivo
express ribosome-targeting peptides and to study their direct inhibitory effects on bacteria. In this
chapter, the main focuses was in vivo expression of the PrAMP oncocin, and study its direct
inhibitory effects on bacterial growth. The 19-mer oncocin peptide sequence was cloned into a
plasmid vector and in vivo expressed as a free peptide. The antibacterial activity of the peptide
was confirmed by doing bacterial growth assays. After induction of the peptide, complete
inhibition of bacterial growth (~ 80%) was observed. Data for our growth assays confirmed the
strong antibacterial activity of oncocin.
Since this system allows us to produce peptides inside bacterial cells, there are some
additional applications of the plasmid-based in vivo expression system. For example, we utilized
the system to in vivo express alanine mutants of oncocin. According to previous structural and
biochemical data, Lys3, Tyr6, Leu7, and Arg11 of oncocin are critical for ribosome binding and
antibacterial activity of oncocin.216,289 However, all of these studies were confined to in vitro
systems and based on tedious SPPS and individual peptide testing. Therefore, we carried out an
in vivo alanine scan experiment. Each critical amino acid residue of oncocin was substituted with
alanine to obtain four single alanine mutants of oncocin (oncK3A, oncY6A, onc7LA, oncR11A).
At the same time, all four positions were substituted with alanine to obtain the
oncK3AY6AL7AR11A mutant. According to our in vivo data, substitution of Lys3, Tyr6, Leu7,
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and Arg11 with alanine leads to loss of antimicrobial activity of oncocin. The effect was
significant with the oncK3AY6AL7AR11A mutant. Results of our in vivo alanine scan
experiment supported the critical roles of Lys3, Tyr6, Leu7, and Arg11 residues of oncocin in
ribosome binding and antibacterial activity.
Even though crystal structures of the ribosome complexed with prAMPS such as oncocin
are available, molecular details of the peptide-rRNA interactions on the full ribosome were still
unclear, especially in solution. On the other hand, the folding of RNA might be different in a
more complex environment such as living cells. Therefore, it is important to study ribosomepeptide interactions in vivo. One additional application of our plasmid system is in vivo probing
of ribosome-peptide interactions. In vivo chemical footprinting studies were carried out using
dimethyl sulfate (DMS) as the probe to monitor oncocin-ribosome interactions. Our in vivo
footprinting experiments identified several nucleotides in the peptide exit tunnel that undergo
conformational changes upon oncocin interactions. Residues A2058, A2059, and A2062 of the
peptide exit channel were protected by oncocin from DMS modification. Nucleotides A2058 and
A2059 are the main constituents in the macrolide binding pocket.305,306 Even though literature
reports suggested that oncocin overlaps with the macrolide binding site, under in vitro
footprinting conditions DMS protection was not observed at A2058 and A2059.221 In contrast,
our in vivo footprinting analysis showed strong protection at both A2058 and A2059. In addition,
our in vivo footprinting analysis revealed that several nucleotides in the H92 region were also
protected by oncocin. Together these data support the interaction of oncocin with the PTC region
of the ribosome. Collectively, we showed in this work that there are several advantages for in
vivo peptide expression compared to in vitro approaches that are entirely dependent on SPPS.
However, there are some limitations to the in vivo method such as possible proteolytic
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degradation of the short peptides. Therefore, further experiments such as mass analysis of the
cell lysate need to be done to confirm the presence of intact peptides inside cells. In this study,
we used oncocin as an example to explore the different applications of our plasmid system.
However, we can expand our plasmid system to study a variety of other AMPs. There are some
additional applications of the plasmid-based in vivo expression system. For example, we can
utilize this system to generate peptide libraries, or study a variety of other biologically interesting
peptides (e.g., anti-freeze peptides).
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CHAPTER 4 IN VIVO EXPRESSION OF HELIX 69-TARGETING PEPTIDES IN
ESCHERICHIA COLI
4.1 Abstract
The specific region of the bacterial ribosome under investigation of this study is helix 69
(H69).22 H69 is a multifunctional and highly conserved hairpin-loop structure that is located in
domain IV of the 23S rRNA in the 50S ribosomal subunit.22 In previous studies, the phagedisplay method was used to identify peptides that target the H69 region. In vitro binding studies
have shown that these selected peptides have moderate affinity towards H69.192 In a second
approach, peptide variants with higher affinity and enhanced selectivity were identified by doing
alanine and arginine scans of the parent peptide sequence selected in the phage-display
method.191 However, the in vivo activities of these peptides were not determined in this initial
study. In contrast to the in vitro methods, the objective of the current study was to in vivo express
the selected peptides in bacteria and study their inhibitory effects on bacterial protein translation
and growth. Plasmid-based, in vivo expression systems were used to express GFP-tagged as well
as free H69 peptides inside bacteria. However, our bacterial growth assays revealed that the
selected peptide sequences do not have considerable antibacterial activity. Proteolytic
degradation of short peptides could be a possible reason for this behavior. Out of the different
peptide sequences we studied, we found out that NQAANHQ peptide shows better inhibition
compared to other H69-targeting peptides. Based on our in vivo and in vitro data, we can
consider NQAANHQ as a potential drug lead that would need further development and
improvement in activity.
4.2 Introduction
The development of peptide ligands that specifically bind to higher-order structures of
rRNA is one promising way to address the problem of antibiotic resistance.190-192,221 Structural
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information obtained from x-ray crystallography has indicated that there are many significant
regions of rRNA that could serve as antibacterial drug targets.132 The specific conserved region
of the ribosome under investigation in this study is H69. Helix 69 is a 19-nucleotide hairpin-loop
structure that is located in domain IV of the 23S rRNA in the 50S subunit. 22 It interacts with
helix 44 (h44) of the 16S rRNA to form intersubunit bridge B2a (Figure 4.1), which plays
significant roles in various ribosomal functions, including subunit association, translocation,
peptide release, and ribosome recycling.50,195 The nucleotide sequence of H69 contains three
post-transcriptionally modified nucleotides, or pseudouridines (), at positions 1911, 1915, and
1917 196 (Figures 4.2 and Figure 4.3).

Figure 4.1 The location of H69 in the 70S full
ribosome. H69 (in purple) is located at the
junction between the 30S and 50S ribosomal
subunits. It makes direct interactions with helix
44 (h44), known as the aminoacyl tRNA site (A
site) (in cyan), of the 30S subunit. Its proximity
to essential translational machinery and at the
interface of the two subunits makes H69 a
potentially important antibacterial drug target.
(PDB ID: 2AW4).19,50

The nucleotide sequence of H69 is highly conserved in bacteria, archaea, and
eukaryotes.22 However, there are some noticeable differences between the H69 sequences of
bacteria (E. coli) and eukaryotes (H. sapiens) (Figure 4.2). The 1915 position of H69 in E. coli is
a methylated , whereas in human it is unmethylated.196,197 The nucleotide at the 3' end of the
loop is an adenosine (A) in E. coli and guanosine (G) in H. sapiens.22,198 Thirdly, the H. sapiens
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H69 has two extra s in the stem region of the hairpin.194 Considering the variety of functions of
this motif in protein biosynthesis as well as the sequence conservation and key differences
between bacterial and human H69, it is an attractive antibacterial drug target.

Figure 4.2 The secondary structures and sequences of modified and unmodified H69. The
secondary structures of unmodified (UUU) and modified E. coli (m3) and modified human
H69 show sequence differences (, pseudouridine; m3, 3-methylpseudouridine). Nucleotides
in upper case letters in the E. coli H69 sequence have >95% conservation and those in lower case
have 88–95% conservation across phylogeny.22

Figure 4.3 Chemical structures of pseudouridine, 3-methylpseudouridine, and uridine.
Pseudouridine (Ψ, left) is a post-transcriptional modification of uridine (U, right). The difference
between these two structures is a 120° rotation of the base in pseudouridine, forming a C–C
glycosidic bond versus the canonical C–N glycosidic bond shown in uridine. Threemethylpseudouridine (m3Ψ, middle) differs from Ψ only by a methylation on the 3-position of
the base.

107

4.3 Objectives of the study
Helix 69 could potentially be targeted by small molecules such as peptides or DNA/RNA
aptamers to interfere with the naturally occurring intersubunit interaction. In previous studies, the
phage-display method was used to identify peptides that target the H69 region.192 In vitro binding
studies have shown that these selected peptides have moderate affinity towards H69. In the
second approach peptide variants with higher affinity and enhanced selectivity were identified by
doing alanine and arginine scans of the parent peptide sequence selected in the phage-display
method.191 The working hypothesis is that the selected peptides will bind to H69 selectively and
disrupt ribosome function. Specificity, stoichiometry and binding affinity of these peptides to
H69 were determined by using in vitro methods.191,192 However, the in vivo activity of these
selected peptides was not determined in this initial study. Therefore, some of the selected peptide
sequences were chemically synthesized using solid-phase peptide synthesis and utilized in
minimum inhibitory concentration (MIC) studies to determine their antibacterial activity. Data in
MIC studies suggested that the peptides likely have penetration problems and cannot cross cell
walls.
In contrast to these in vitro methods, the objective of the current study is to utilize a
plasmid-based system to in vivo express these selected peptides in bacteria and study their
inhibitory effects on bacterial protein translation and growth. In the first approach, H69-targeting
peptide were in vivo expressed as Green Fluorescent Protein (GFP)-tagged fusion peptides
(Figure 4.4a). In order to further characterize the selected peptides as potential drug leads, it is
essential to determine their activity outside the context of the fusion protein. Therefore, in the
second approach a different plasmid system was used to express H69-targeting peptides as free
peptides in bacteria (Figure 4.4a). The effects of these peptides on bacterial protein translation
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and growth were monitored through fluorescent intensities and optical densities of cultures
expressing the peptides. Therefore, we hoped that in vivo expression of peptides would allow us
to study the behavior of selected peptides in the actual cellular environment.

Figure 4.4 A schematic diagram of the two approaches used in the in vivo peptide
expression methodology. a) In the first approach, peptides were cloned at the N-terminus of
GFP and expressed as a fusion protein. The effects of peptides on bacterial growth and protein
translation were monitored by measuring OD600nm and fluorescence intensities of cultures
expressing peptides. b) In the second approach, free peptides were expressed and the effects on
bacterial growth were monitored by measuring OD600nm of cultures expressing peptides.
4.4 Results and discussion
4.4.1 In vivo expression of GFP-tagged H69 peptides
4.4.1.2 Cloning of H69-peptides into the GFP plasmid system
Three peptide sequences (RQVANHQ, TARHIY, and NQAANHQ) were chosen for
these studies. The details of the molecular cloning experiment is explained in the Experimental
Method Section in Chapter 2. Dr. Wesley Colangelo prepared the plasmid vector pBacEmtvec3
for this experiment. The restriction enzyme sites Kas I and Nhe I were used to clone the peptide
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insert into the plasmid. Therefore, the peptide insert and the plasmid vector were digested using
Kas I and Nhe I enzymes (Figure 4.5). The primer extension PCR method was used to generate
the corresponding DNA sequences that code for the desired peptides. The size of the DNA
product corresponding to the 7-mer peptide sequence is 113 pb. The PCR product was checked
on an agarose gel before the restriction digestion (Figure 4.5b).

Figure 4.5 Plasmid vector and peptide insert preparation. a). Plasmid pBacEmtvec (16, 295
bp) was digested using Nhe I and Kas I restriction enzymes and the gel band corresponding to
the desired vector fragment (9865 bp) was purified before ligation. b) The insert was synthesized
using the non-template PCR method and purified before and after restriction digestion. The size
of the PCR product corresponding to the 7-mer peptide sequence is 113 bp.
The DNA products were gel purified and ligated to obtain the new plasmid pBacEmGHpep (9943 bp). The genes were cloned behind the PBAD promoter of the plasmid such that the
peptides could be expressed by inducing with L-arabinose. The ligated plasmids were
electrotransformed into E. coli EPI300, which contained two other plasmids for the expression of
TEV protease. Therefore, the peptide expression was done in a three-plasmid system. The details
of the TEV-protease plasmid system is explained in chapter 2. The correct ligation was
confirmed by doing colony PCR (Figure 4.6a). The sequence of the peptide clones were
confirmed by doing DNA sequencing (Figure 4.6b).
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Figure 4.6 Peptide sequence confirmation. a) The peptide clones were confirmed by doing
colony PCR, which gave a 340 bp PCR product for the 7-mer peptide in colony PCR. b) The
sequence alignment of ligated plasmid. The full alignment is 1040 bp, whereas this section only
shows the nucleotide sequence of the TEV recognition sequence in the first box (green) with the
amino acid sequence labeled in green. The amino acid sequence of 7-mer peptide, RQVANHQ,
is shown in red and the corresponding nucleotides are in box 2 (red).
In this plasmid system, the peptide sequence was cloned behind the TEV protease
recognition sequence. The expression of TEV protease from another plasmid in the same cell
would lead to cleavage of the TEV recognition peptide sequence between residues Q and G, and
the resulting peptide was exposed at the N-terminus of GFP.243,245 TEV protease cleavage occurs
between Q and G, leaving an extra glycine (G) at the N-terminus of the peptide sequence
(Figure 4.7). Although the wild-type TEV protease recognition sequence is ENLYFQG/S, recent
studies have shown that any amino acid after Q in the sequence could cleave efficiently such that
the exact peptide sequence could be exposed after TEV cleavage.243,246,247 However, at the
beginning of this project peptide primers were designed without excluding the codon
corresponding to the C-terminus G residue. Therefore, TEV protease cleavage occurs between Q
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and G, leaving an extra glycine (G) at the N-terminus of the peptide sequence (Figure 4.7).
Therefore, all of the peptide sequences we expressed had an extra G-residue at the N-terminus.

Figure 4.7 The TEV cleavage site. The TEV protease has a 7 amino acid recognition sequence
and cleaves between amino acids 6 and 7 (Q and G). This leaves a G residue attached to the
desired peptide sequence, in this case producing GAAAAAAA at the GFP end.
4.4.1.3 Study the effects of H69-targeting peptides on bacterial growth

Figure 4.8 In vivo expression of GFP-peptide fusion proteins. A schematic diagram for the
production of GFP-tagged peptides using the TEV protease expression system is shown. A
normalizing sequence (g10 leader sequence) was added at the 5' end of the construct. The
peptides were cloned behind the TEV protease recognition sequence. A peptide linker, EGGG,
was placed before GFP to provide flexibility of the peptide. The expression of the peptide and
TEV protease was induced by adding arabinose and anhydrotetracycline (ATC), respectively.
Upon expression of TEV protease, the peptides were exposed at the N-terminus of GFP.
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After confirming the sequence of each peptide clone, they were used in bacterial growth
assays. As explained in Chapter 2 the expression was done in a three-plasmid system in which
the first plasmid (pBacEmpep, chloramphenicol resistance) was used for expression of GFPtagged peptides, the second (pRK603) for Tet-inducible TEV protease with kanamycin
resistance, and the third (pZS4int-tetR, spectinomycin resistance) for constitutive tetracycline
repressor protein (TetR) expression 242 (Figure 4.8).
Bacteria were grown in LB medium containing three antibiotics, chloramphenicol,
kanamycin,

and

spectinomycin.

When

cells

reached

late

lag phase

(~210

min),

anhydrotetracycline (ATC) was added to induce the expression of TEV protease from the
pRK603 plasmid. The L-arabinose was then added (~240 min) to induce the expression of GFPtagged peptides.

Figure 4.9 Bacterial growth assay. Measurement of E. coli growth upon the expression of
peptide-GFP and TEV protease is shown. Optical density (OD600 nm) of cultures expressing
different peptides were measured at every 60 min. Compared to the negative control
GAAAAAAA-GFP, slightly reduced growth was observed in cultures expressing the
GNQAANHQ-GFP.
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Cell growth was measured with and without adding inducers. The bacterial growth was
monitored by measuring the optical density of all bacteria cultures every 60 min (Figure 4.5). In
growth assays, the 7-mer peptide GAAAAAAA-GFP fusion was used as a negative control,
which did not show growth inhibition in previous experiments. Compared to the negative control
fusion protein GAAAAAAA-GFP, we could observe some level of growth inhibition of the cells
bearing GNQAANHQ-GFP, GRQVANHQ-GFP, and GTARHIY-GFP peptide-fusion proteins
(Figure 4.9).

Figure 4.10 GFP translation assay. a) The level of GFP translation by different peptides in the
TEV protease system is shown. The GFP fluorescence was measured for different peptides at
different time intervals after induction. b) Compared to the control (GAAAAAAA-GFP), a
modest decrease in fluorescence intensity was observed in the cultures expressing
GNQAANHQ-GFP, GRQVANHQ-GFP, and GTARHIY-GFP fusion proteins. All growth
assays were performed at least three times independently and results were averaged.
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The amount of GFP translation in the presence of different peptides was monitored by
measuring the fluorescence intensity (excitation at 487 nm and emission at 509 nm) at 60 min
time intervals. The fluorescence intensity was divided by the optical density of the bacteria
culture at each time point to calculate florescence intensity per cell and plotted against the time
(min) (Figure 4.10). The presence of peptides did not completely inhibit GFP translation;
however, compared to the negative control peptide, GNQAANHQ, GRQVANHQ, and
GTARHIY showed 24, 7, and 5% inhibition of GFP translation, respectively. From the results of
growth and fluorescence inhibition, we conclude that the in vivo expression of GNQAANHQ
showed comparatively better inhibition of growth and protein translation of bacteria.
4.4.1.4 Purification of the EmGFP-pep fusion protein

Figure 4.11 Protein purification and characterization. a) A 12 % SDS polyacrylamide gel
shows the purified EmGFP-peptide fusion protein. b) The MALDI spectrum of the purified
EmGFP-peptide fusion protein is given.
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We could successfully utilize this TEV-protease-based, three-plasmid system to in vivo
express H69 peptides as EmGFP fusion proteins. As previously described, the peptide construct
was prepared in which a His-tag was placed at the C-terminus of the EmGFP gene such that the
peptide-GFP fusion protein could be purified for further experiments.
The proteins were purified by Ni-affinity chromatography and the product was checked
by running SDS-PAGE (Figure 4.11a). Isolated protein was characterized by Matrix-assisted
laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (Figure 4.11b).
Purified GFP-tagged peptides can be used in in vitro binding experiments such as surface
plasmon resonance (SPR) to further characterize the binding affinity and specificity of peptides
to the H69 target.
4.4.2 In vivo expression of free peptides
In the first approach, we utilized a TEV-protease based plasmid system to in vivo express
H69 targeting peptides as GFP fusion proteins in bacteria cells. In this system, the display
protein EmGFP serves numerous functions such as stabilizing the structure, reducing proteolysis
and producing a visible means of quantification. However, in order to further characterize
selected peptides as potential drug leads, it is essential to determine their activity outside the
context of the fusion protein. Therefore, in the second approach we utilized a different plasmid
system to express H69- targeting peptides as free peptides in bacterial cells (Figure 4.12). The
H69 targeting peptides NQAANHQ, RQVANHQ, and TARHIY were selected for the study.
4.4.2.1 Cloning of H69 peptides into pKantvec plasmid system
In this approach, a single plasmid expression system pKan5tvVec (8243 bp) with an
inducible PBAD promoter and kanamycin resistance was used as the vector. Therefore, the
peptides could be expressed by inducing with L-arabinose (Figure 4.12).
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Figure 4.12 In vivo expression of free peptides. A schematic diagram for the production of free
peptides using the TEV protease expression system is shown. The peptides were cloned behind
the TEV protease recognition sequence and under control of the PBAD promoter. Therefore, the
expression of peptides and TEV protease was induced by adding arabinose. After TEV protease
cleavage, free peptides would be available in the cell.

Figure 4.13 Plasmid vector and peptide insert preparation. a). Plasmid pkan5tvec (8243 bp)
was digested using Nhe I and Hind III restriction enzymes and the gel band corresponding to the
desired vector fragment (5371 bp) was purified before ligation. b) The peptide inserts were
synthesized using the non-template PCR method and gel purified before and after restriction
digestion. The size of the PCR product corresponding to the 7-mer peptide sequence was 113 bp.
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The details of the pKan5tvVec plasmid system are explained in Chapter 2, Section 2.2.3.
The peptide inserts were generated by using the non-template PCR method as described earlier.
The size of the DNA product corresponding to the 7-mer peptide sequence was 113 pb. The PCR
product was checked on an agarose gel before the restriction digestion (Figure 4.13b). The
restriction enzyme sites Hind III and Nhe I were used to clone the peptide insert into the plasmid.
Therefore, the peptide insert and plasmid vector were digested using Hind III and Nhe I enzymes
(Figure 4.13). The DNA products were gel purified and ligated to obtain the new plasmid
pKantvec-pep (5459 bp). The ligated plasmids were electrotransformed into E. coli DH5 cells.
The correct ligation was confirmed by doing colony PCR (Figure 4.14a). The sequences of the
peptide clones were confirmed by doing DNA sequencing (Figure 4.14b).

Figure 4.14 Peptide sequence confirmation. a) The peptide clones were confirmed by doing
colony PCR, which gave a 329 bp PCR product for the 7-mer peptide in colony PCR. b) The
sequence alignment of ligated plasmid is given. The full alignment was 1020 bp, whereas this
section only shows the nucleotide sequence of the TEV recognition sequence in the first box
(green) with the amino acid sequence labeled in green. The amino acid sequence of 7-mer
peptide, RQVANHQ is shown in red and the corresponding nucleotides are in box 2 (red).
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4.4.2.2 Study the effects of H69-targeting peptides on bacterial growth
After confirming the sequence of each peptide clone, they were used in bacterial growth
assays as described in Chapter 2, Section 2.3.8. Bacteria were grown in LB/kanamycin medium.
When cells reached late lag phase with OD600nm = 0.2, (~200 min), L-arabinose was added to
induce the expression of peptides. The bacterial growth was monitored by measuring the optical
density of all bacterial cultures every 60 min (Figure 4.15). In growth assays, DH5 strain
CSL011 from the Cunningham lab, which expresses peptide KGTRAFATTNSH, was utilized as
a positive control. In previous studies in the Cunningham lab, this 12-mer peptide inhibited
bacterial growth. The 7-mer peptide AAAAAAA with an N-terminus G was used as a negative
control, and did not show growth inhibition in previous experiments. Compared to the negative
control peptide GAAAAAAA, we did not see much difference between the growth curves and
the inhibition profiles of the H69-targeting peptides.
Compared to the negative control peptide, the GNQAANHQ peptide showed only
slightly more inhibition at 360 min. The percent inhibition of growth was calculated and
normalized to the negative control peptide (Figure 4.15b). According to our results, 18, 14, and
7% inhibition was observed with the GNQAANHQ, GRQVANHQ, and GTARHIY peptides,
respectively. In contrast to H69-peptides, the positive control peptide showed complete
inhibition of growth right after induction. Throughout the incubation period it showed more than
80% inhibition of bacterial growth. The growth inhibition with the positive control peptide
support that the peptides can have activities inside bacteria without undergoing proteolytic
degradation or efflux.
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Figure 4.15 Effects of H69-targeting peptides on bacterial growth. a) Measurement of E. coli
growth upon the expression of free peptides and TEV protease is shown. b) Percent inhibition of
growth after 360 min of incubation was calculated and normalized to the negative control,
GAAAAAAA. All growth assays were performed at least three times independently and results
were averaged.
The peptides are overexpressing, but may undergo some level of undergoes degradation.
However; our results suggest that the cell can produce enough peptide to reach the MIC.
Therefore, growth inhibition appears to depend on the MIC of each peptide. The peptides with
lower MICs would achieve cell death faster and display complete inhibition of growth. This idea
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is supported by the complete inhibition by the 12-mer positive control peptide and oncocin
discussed in Chapter 3. Therefore, we can conclude that MICs of the H69-targeting peptides are
much higher than the 12-mer positive control peptide. By in vivo expressing the positive control
peptide and a proline-rich AMP oncocin, we showed that our system can be used as a tool to in
vivo express short peptide sequences and study their antibacterial activity. As mentioned before,
in this TEV-protease-based plasmid system we cloned the 7-mer peptide sequence behind the
TEV protease recognition sequence (ENLYFQG/S). Since TEV protease cleavage occurs
between Q and G, an extra glycine (G) is left at the N-terminus of the peptide sequence.
Therefore, all of the peptide sequences that were expressed have an extra G at the N-terminus.
This may be a possible reason for the lower antibacterial activity of our peptides. However, it is
not known if this small difference in the peptide sequence would affect the potency of the
original peptide. One approach to test this would be to reclone the peptide sequences without G
of the TEV protease recognition sequence. If the peptide sequences are cloned with the altered
TEV protease recognition sequence, then completely free unaltered peptides will be produced
inside bacterial cells. Another approach to test the effect of the extra glycine would be to clone
the 7-mer peptide sequence in front of the TEV protease cleavage site. This approach would give
the peptide with extra G at the C-terminus, NQAANHQG. If this arrangement of peptides shows
enhanced activity, it would confirm that the N-terminus of the peptide is important for its
antibacterial activity. Further cloning experiments with the above-mentioned approaches will
provide a better understanding of the antibacterial activities of H69-targeting peptides as
potential drug leads.
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4.5 Overall summary and conclusions
The poor correlation between in vitro and in vivo activities of peptides is one of the major
questions in antibiotic peptide research. In this work, we successfully utilized a plasmid-based
systems to in vivo express H6-targeting peptides in bacteria. In the first approach peptides were
expressed as GFP-fusion proteins, and in the second approach they were expressed as free
peptides. However, bacterial growth assays revealed that selected peptide sequences do not have
any significant antibacterial activity. The dynamic nature of H69 of differing conformations in
the actual cellular environment compared to in vitro peptide selection conditions may also be a
factor. Therefore, peptides or RNA may not find the active conformations that favor binding.
Proteolytic degradation of these short peptides by bacterial proteases could be another possible
reason for this behavior. In both systems, we found that GNQAANHQ peptide shows better
inhibition compared to other H69-targeting peptides. Based on in vivo and in vitro data, we can
consider NQAANHQ as a potential drug lead, but it will need considerable modifications or
alterations to improve its activity. Further cloning experiments with the above-mentioned
approaches may provide a better understanding of the antibacterial activity of H69-targeting
peptides as potential drug leads.
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CHAPTER 5 EFFECTS OF PSEUDOURIDINE MODIFICATION ON
ANTIBACTERIAL ACTIVITY OF THE 2-DEOXYSTREPTAMINE
AMINOGLYCOSIDES
5.1 Abstract
Aminoglycosides with a 2-deoxystreptamine (2-DOS) motif are known to inhibit protein
translation by binding to the helix 44 (h44) region of the small subunit adjacent to the decoding
site. However, recent x-ray crystal structures have shown that neomycin, paromomycin, and
gentamicin are able to interact with the major groove of the helix 69 region (H69). Previous
work in our lab revealed that  modifications are important for efficient binding of
aminoglycosides to H69. However, the effects of  modifications on bactericidal activity of
aminoglycosides have not been examined. Therefore, the objective of this work was to evaluate
the effects of  modification on the antibacterial activities of 2-DOS class aminoglycosides.
Antibacterial activities were assessed by performing minimum inhibitory concentration (MIC)
studies using wild-type and -deficient bacterial strains. Our data reveal that loss of 
modifications confers resistance to 4,6-linked-2-DOS aminoglycosides, gentamicin and
kanamycin, whereas the effect was not significant with 4,5-linked-2-DOS aminoglycosides,
neomycin and paromomycin. However, bacterial strains carrying partially defective RF2 show
resistance to neomycin and paromomycin in the RluD(–) background. The observed results could
be a combined effect of loss of s and defective RF2 that perturbs the ribosome-drug
interactions. The information gained from these studies provides deeper insight into the
underlying mechanism of action of aminoglycosides, which is important for the development of
unique antibiotics to target the bacterial ribosome at novel sites such as H69.
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5.2 Introduction
The key roles in protein biosynthesis, structural complexity, easy accessibility, and high
abundance in the cells, make the bacterial ribosome an obvious target for antibacterial drug
development.133,309,310 Most of known antibiotics target functional regions within the bacterial
ribosome.17,132 Aminoglycosides belong to a class of compounds effective against gram-negative
bacteria.311,312 These antibiotics inhibit the bacterial ribosome by interacting with rRNA.135,140,313

Figure 5.1 Aminoglycoside antibiotics. Chemical structures of the decoding-region-targeting
antibiotics are shown with the common 2-DOS motif (highlighted in red). The cyclic peptide
capreomycin is shown for comparison.

124

Aminoglycosides with a 2-deoxystreptamine (2-DOS) motif (Figure 5.1) are known to
inhibit protein translation by binding to the 30S ribosomal subunit.135,136 Neomycin,
paraomomycin, kanamycin, and gentamicin are some examples in this class. The initially
identified primary binding site of this family of antibiotics is the decoding region, involving the
intersubunit bridge B2a.137-139 Upon binding to helix 44 (h44), aminoglycosides stabilize the A
site in an extra-helical conformation.28 This conformational change shifts the position and
dynamics of two universally conserved residues, A1492 and A1493, which are responsible for
recognition

of

the

mRNA

codon-aminoacyl-tRNA

complex.138,140,141 This

stabilized

conformational state leads to incorporation of incorrect aa-tRNAs, and decreased translation
fidelity.134,142 However, decreased translation fidelity alone has little effect on cell growth.
Literature reports revealed that bacteria strains harboring error-prone ribosomes are still
viable.143,144 Also, evidence of specific aminoglycosides inhibiting protein synthesis without
exhibiting miscoding suggests that miscoding is not the only mechanism of action of
aminoglycosides.145 Furthermore, these combined observations suggest that aminoglycosides
may interact with more than one functional site in the bacterial ribosome.
Interestingly, crystal structures have shown that neomycin, paramomycin, and gentamicin
are able to interact with the major groove of helix 69 (H69) of 23S rRNA as well (Figure 5.2).
138,146,147

The interaction with H69 provides a possible mechanism for how aminoglycosides

inhibit the recycling and translocation steps of protein synthesis.33, 46 However, the bactericidal
nature of 2-DOS aminoglycoside antibiotics is still poorly understood despite decades of clinical
use and biochemical studies. The emergence of strains with antibacterial resistance as well as
impaired hearing and kidney functions at high doses of aminoglycosides make them less
effective in clinical applications.314 Therefore, it is necessary to develop new and more specific
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drugs to combat bacterial infections. Understanding the underlying mechanism of action of this
class of antibiotics is significant for the development of unique antibiotics that target the
bacterial ribosome.

Figure 5.2 Binding of neomycin at the h44 and H69 regions of the ribosome. Neomycin
binds at the decoding site of h44 and major groove of H69. Drug binding induces conformational
changes of residues A1492 and A1493 of h44 and A1913 of H69 (PDB ID: 4V52).147
5.3 Objectives
The E. coli rluD gene encodes a pseudouridine synthase responsible for the 
modifications at positions 1911, 1915, and 1917 in H69 of 23S rRNA196 (Figure 5.3). These 
modifications are important for ribosome function and modulation of the loop structure.25
Previous work in our lab revealed that  modifications are important for efficient binding of
aminoglycosides to H69.237,239 It was also shown that structurally similar aminoglycosides had
different structural impacts on the modified and unmodified H69 RNAs.237
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Figure 5.3 Pseudouridylation of H69. Secondary structures and nucleotide sequences of modified and

unmodified H69 rRNA.
Previous observations with H69 model systems were further confirmed by doing
antibiotic footprinting studies in the context of modified and unmodified full ribosome.239
However, the effects of  modifications on the bactericidal activity of aminoglycosides have not
been examined. Considering previous observations, we hypothesized that lack of 
modifications would affect the antibacterial activity of aminoglycosides. Therefore, the objective
of the current study was to investigate the effects of  modifications of H69 on the bactericidal
activity of the 2-DOS class of aminoglycosides.
5.4 Results and discussion
5.4.1 Background information on the different E. coli strains
Four different strains of E. coli were utilized in our MIC experiments (Figure 5.4). First,
a brief background on the different bacterial strains used in the current study will be given.
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E. coli K-12 MG1655 RluD( ̶ ) strain
Most of the previously reported genetic and biochemical analyses of rluD function have
been carried out with E. coli K-12 strain MG1655.102,315 It was reported previously that deletion
of the rluD gene in E. coli K-12 strains led to extremely slow growth, increased read through of
stop codons, and defects in 50S ribosomal subunit assembly and subunit association.102,315
However, recent studies revealed that the RluD(–) mutant phenotype can be rescued by an
additional mutation in RF2 at a site adjacent to H69-interacting residues.316,317 Further genetic
analysis revealed that the slow growth and other defects associated with inactivation of rluD in
E. coli K-12 strains were due to a defective RF2 protein, with a threonine at position 246, which
is in contrast to the more typical alanine found at this position in most bacterial RF2s.318
E. coli K-12 MC415 (wild-type) and MC416 (RluD(–) ) strains
The suppressor mutations of RF2 link H69 residues with the termination phase of protein
synthesis.316,317 However, the role of  modifications in the translation termination process was
questionable. In order to study the role of  modifications of H69, several E. coli K-12 strains
with fully functional RF2 were generated by Michael O'Connor's lab.317 In E. coli strain MC415,
the K-12 prfB allele was replaced with the E. coli B prfB. Therefore, the strain has fully
functional RF2 (alanine at 246). Deletion of the rluD gene in the MC415 strain produces E. coli
strain MC416.317 O'Connor's lab showed that deletion of the rlud gene did not affect growth or
subunit association in these strains. This observation further confirmed that previously observed
slow growth and other defects associated with inactivation of rluD in E. coli K-12 strains are due
to a defective RF2 protein.315 These observations suggest that inactivation of RluD
pseudouridine synthase has minimal effects on bacterial growth and ribosome function.
However, the highly conserved nature of H69 pseudouridylation suggests that it plays a
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significant role in bacteria.196 Previous in vitro studies showed that  modifications play a role
in aminoglycoside binding to H69.237,239,319 Therefore, it was of interest to evaluate
aminoglycoside suceptibilities of wild-type and -deficient strains. E. coli MC415 (wild-type,
Ψm3ΨΨ) and E. coli MC 416 (RluD(–), Um3UU) from O’Connors’s lab were utilized in this
study. The only genetic variation of these two strains is the deletion of rlud gene in MC416.317
Therefore, direct comparisons of MICs of these two strains indicate the effects of modifications
on the antibacterial activities of the drugs we studied.
E. coli MRE600
MRE600 is an E. coli strain that was originally identified for its low RNase I activity.320322

The architecture of the MRE600 genome is distinct from that of E. coli K-12. However, the

MRE600 translational machinery is similar to that of E. coli K-12. The MRE600 strain carries
modified H69 with three  modifications in the loop region (1911, 1915 and 1917).321 Also, in
contrast to E. coli K-12 strain, MRE600 has an alanine at position 246 of RF2.323 Comparative
analyses between MRE600 and E. coli K-12 showed that these two strains exhibit nearly
identical ribosomal proteins, ribosomal RNAs, and highly homologous tRNA species.321
Considering these similarities, MRE600 and K-12 MG1655 RluD(–) were used in our previous
aminoglycoside footprinting experiments to isolate modified and unmodified ribosomes.239
However, the growth of these strains with aminoglycosides was not assessed. Therefore, the four
different E. coli strains were utilized in MIC experiments with a series of aminoglycosides that
are known to target H69 and the A site of ribosomes. MIC experiments were carried out
simultaneously with the four different strains and at least three independent experiments were
carried out with each antibiotic.
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Figure 5.4 E. coli strains used in the study. a) E. coli strain MC415 has modified H69 and RF2
with alanine at position 246. b) E. coli strain MC416 is the RluD( ̶ ) version of MC415. c) E. coli
strain MRE600 has modified H69 and RF2 with alanine at position 246. d) E. coli MG1655
RluD(–) strain has unmodified H69 and defective RF2 with threonine at position 246.
5.4.2 Comparison of MICs with different bacterial strains
MC415 vs. MC416
MC416 is the RluD( ̶ ) version of MC415 (Figure 5.4a & b). Other than absence of the
rluD gene in MC416, these two strains are genetically similar.317 Therefore, we can do direct
comparison of the MICs of these two strains. If there is any difference in MICs, we can consider
it as a consequence of the  modifications in H69.
MC416 vs. MG1655 RluD( ̶ )
Both of these RluD( ̶ ) strains are derived from E. coli K-12. However, MC416 has fully
functional RF2 with alanine at 246 position, whereas MG1655 has defective RF2 with threonine

130

at position 246.318 Previous studies showed that loss of  modifications affect RF2-ribosome
interactions and the effect is significant in E. coli K-12 strains carrying defective RF2.315
However, until now we did not know how defects in RF2-ribosome interactions affected drug
binding or antibacterial activities of aminoglycosides. Therefore, comparison of the MIC values
of MC416 and MG1655 RluD(–) strains reveals the effects of perturbed RF2-ribosome
interactions on the antibacterial activities of aminoglycosides.
MRE600 vs. MC415
Although both of these strains carry modified H69, we cannot do a direct comparison of
the MIC values because they are two different strains of E. coli. MRE600 is a divergent E. coli
strain that displays features of the closely related genus Shigella, whereas MC415 is an E. coli K12 strain derived from E. coli MG1655.321,323 However, comparative analyses between MRE600
and K-12 revealed that these two strains exhibit nearly identical ribosomal proteins, ribosomal
RNAs, and highly homologous tRNA species.321 Therefore, we hypothesized that these two
strains would show similar inhibition profiles for ribosome-targeting antibiotics. A recent study
investigating the genomes of 20 E. coli strains identified a total of 17,838 distinct genes, with
only 1,976 being common to all. Such genomic variation contributes to each strain’s distinct
physiological properties, such as their varied abilities to metabolize sugars, resistance to
particular antibiotics, and growth rate-temperature profiles.321,324 Therefore, in addition to drugtarget interactions, genomic variations of each bacteria strain would affect the in vivo potency of
the drug. This would give rise to unique inhibition and resistance profiles to these structurally
similar aminoglycosides.
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5.4.3 Neomycin shows better inhibition than paromomycin
Neomycin and paramomycin are structurally similar 4, 5-linked-2-DOS aminoglycosides.
Paromomycin differs chemically from neomycin at a single position in ring 1 (Figure 5.1).
Neomycin has a primary amine at the 6' position, whereas it is a hydroxyl group in
paromomycin. Recently, the crystal structures of neomycin and paromomycin bound with E. coli
70S ribosomes were solved. According to these crystal structures, both neomycin and
paromomycin interact with the major groove of h44 and H69, namely the intersubunit bridge
B2a region.146,147 However, crystal structures revealed that paromomycin induces a different H69
loop conformation compared to neomycin.140,146 These in vitro observed structural and binding
differences could affect the in vivo potency of the drug and this would give rise to unique
inhibition and resistance profiles to these aminoglycosides despite their structurally similarities.
Literature reports that neomycin is the most potent and toxic member of 4,5-linked
aminoglycoside class.325 This is in good agreement with the higher affinty binding of neomycin
to bacterial A site as well as H69 compared to paramomycin.319,326 The reported Kd values of
neomycin and paramomycin for the A site RNA range from 60 nm to 0.02 µM, depending on the
method and conditions.319,326 Previous biophysical studies showed that unmodified H69 has a
more than 10-fold higher affinity for neomycin (Kd = 0.3 (± 0.1) µM) than paramomycin (5.4 (±
1.1) µM).319 In our MIC experiments, neomycin showed better bactericidal activity compared to
paramomycin in both wild-type (MRE 600 and MC415) and -deficient (RluD(–)) strains
(MG1655 and MC416) (Table 5.1 and Figure 5.5). For both wild-type strains, neomycin
showed ~2-fold lower MIC value compared to paramomycin. For the RluD(–) strains, neomycin
showed ~4-fold lower MIC values compared to paramomycin (Table 5.1).
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Table 5.1 Comparison of the observed MIC values for different antibiotics tested.
Wild-type
Antibiotic
Neomycin
Paromomycin
Gentamicin
Kanamycin
Capreomycin
Carbenicillin

MRE600
> 0.7 mg/L
> 1.4 mg/L
> 0.7 mg/L
> 1.4 mg/L
> 43 mg/L
> 0.35 mg/L

MC415
> 0.7 mg/L
> 1.4 mg/L
> 0.045 mg/L
> 0.045 mg/L
> 43 mg/L
> 0.35 mg/L

RluD(–)
MG1655
> 11 mg/L
> 43 mg/L
> 0.7 mg/L
> 1.4 mg/L
> 43 mg/L
> 0.35 mg/L

MC416
> 0.7 mg/L
> 2.8mg/L
> 0.7 mg/L
> 1.4 mg/L
> 43 mg/L
> 0.35 mg/L

MIC experiments were carried out simultaneously with the four different strains and at least
three independent experiments were carried out with each antibiotic.
Similar MIC values were observed for both wild-type strains, MRE600 and MC415, for
both aminoglycosides, despite the fact that they are two distinct strains of E. coli. The MRE600
genome is distinct from that of E. coli K-12, however, their translational machinery is similar to
that of E. coli K-12.321 Comparative analyses between MRE600 and E. coli K-12 show that these
two strains exhibit nearly identical ribosomal proteins, ribosomal RNAs, and highly homologous
tRNA species.321 Therefore, we can assume that these two strains would show similar inhibition
profiles to ribosome-targeting antibiotics. Indeed, the observed MIC values for the wild-type
E. coli strains are similar to literature reported values for neomycin and paramomycin.189,327
Therefore, our MIC data are in a good agreement with the literature, with greater activity of
neomycin compared to paromomycin. The inhibition profiles of neomycin and paromomycin for
three E. coli K-12 strains, MC415, MC416 and MG1655 RluD(–), are shown in Figure 5.5.
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Figure 5.5 Growth inhibition profiles of neomycin and paromomycin in E. coli K-12.
Inhibition data for the MIC experiments done with neomycin and paromomycin in a) & c)
MC415 (wild-type,m3), b) and d) MC416 (RluD(–),Um3UU) and e) and f) MG1655
RluD(–). Percent inhibition of bacterial growth in the presence of different drug concentrations
was calculated and normalized to the growth control as described in Chapter 2, Methods,
Section 2.6.
5.4.4 Loss of pseudouridylation of H69 confers resistance to paromomycin compared to
neomycin
The main objective of the current study was to evaluate the effects of  modifications on
the antibacterial activity of 2-DOS-class aminoglycosides, which are known to target H69.
Previous studies suggested that  modifications are important for modulation of H69 loop
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structure.328,329 Previous studies also showed that structurally similar aminoglycosides had
different structural impacts on the modified and unmodified H69 RNAs.237 These observations
with H69 model systems were further confirmed by doing antibiotic footprinting studies on
modified and unmodified ribosomes.239 However, the effects of  modifications on the
bactericidal activity of aminoglycosides had not been examined. Considering previous
observations, we hypothesized that lack of  modifications would affect the antibacterial activity
of aminoglycosides.
For direct comparison of the effects of rlud gene deletions on the antibacterial activities,
two strains of E. coli K-12, generated by Michael O'Connor's lab, MC415 (wild-type, m3 )
and MC416 (RluD(–), Um3UU), were utilized in MIC experiments. Although typical E. coli K12 strains have defective RF2 with an Ala246Thr mutation, the two strains utilized in this study
have corrected RF2 with alanine at position 246. For neomycin, the observed MIC values for
wild-type and RluD(–) strains were both > 0.7 mg/L (Figures 5.5 a &b, Table 5.1). In contrast,
for paromomycin the observed MIC value for the RluD(–) strain was 2-fold higher than that of
the wild-type strain (Figures 5.5 c & d, Table 5.1). These data indicate that the  modifications
on H69 affect the antibacterial activity of paromomycin, but not neomycin. Considering the
structural similarities of these aminoglycosides, it was surprising to observe such different
behavior in the RluD(–) strain. To understand this result, we examined the crystal structures of
neomycin and paromomycin bound to 70S ribosomes. According to crystal structures, both
neomycin and paromomycin interact with the major groove of h44 and H69, namely the
intersubunit bridge B2a region.147 However, the crystal structures revealed that paromomycin
induces a different H69 loop conformation compared to neomycin. According to these structures,
residue A1913 located at the apical tip of H69 forms hydrogen bonding interactions with the 6'
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hydroxyl group of paramomycin (Figure 5.6), which was not observed with neomycin.140
Further single-molecule FRET studies revealed that neomycin and paromomycin drive subunit
rotation in opposite directions, which may be the result of differing interactions with H69.146

Figure 5.6 Crystal structures of 70S E. coli ribosomes bound a) neomycin (PDB ID:
4V9C)140 and b) paromomycin (PDB ID: 4WOI).146 Neomycin and paromomycin induce
distinct H69 loop conformation. In contrast to neomycin, paromomycin bound within the h44decoding site contacts the apical tip of H69 via ring I (6'-OH) and the universally conserved base
A1913 (N6) of H69 from its canonical h44 site of binding. The potential formation of a Hbonding interaction is shown in black dotted lines.
Information from crystal structures and single-molecule FRET studies suggests that
A1913 remains dynamic when neomycin is bound and relatively static when paromomycin is
bound.140,146 It is interesting that previous biochemical studies in our lab also suggested similar
behavior of H69 with neomycin and paromomycin.237 Previous work using H69 model systems
as well as antibiotic footprinting experiments in the context of full ribosomes revealed that
neomycin and paromomycin induce different structural impacts on the ribosome despite their
structural similarity.237,239 It was also shown that these structural impacts are influenced by 
modifications. The different conformational changes induced by neomycin would help to
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maintain its strong binding interactions with the ribosome, and it is not affected as greatly by the
perturbations caused by the loss of  modifications. In contrast, paromomycin was more
susceptible to H69 perturbations caused by the loss of s. Therefore, we concluded at this point
that different binding patterns within the ribosome give unique inhibition and resistance profiles
to

paromomycin

and

neomycin,

despite

their

structural

similarities

as

4,5-linked

aminoglycosides.
5.4.5 Defective RF2 in RluD(–) confer resistance to both neomycin and paromomycin
Previous studies have shown that the H69 is indispensable for efficient termination by
RFs and its conformational dynamics are likely to be important to facilitate a stable RF
interaction with the ribosome.330-332 However, the role of  modifications in H69 in the
translation termination process is questionable. Recent studies revealed that the RluD(–) mutant
phenotype in E. coli K-12 can be rescued by an additional mutations in RF2 at a site adjacent to
H69-interacting residues.316 This suppressor mutation links H69  residues with the termination
phase of protein synthesis. However, the role of H69-RF2 interactions in translation termination
is still not understood clearly. In another study, Kipper and co-workers investigated the role of
H69 s in peptide release by class 1 release factors in an in vitro system consisting of purified
components of the E. coli translation apparatus.333 In this study, they showed that lack of all
three s compromised the activity of RF2, but did not affect the activity of RF1.333 Altogether
these previous observations suggest that H69-RF2 interactions play an important role in
translation termination. Therefore, it is of interest to see how defective RF2 affects the RF2-H69
interaction. Residue 246 in E. coli RF2 is threonine in strain K12, whereas it is a conserved
alanine or serine in other known bacterial sequences of RF2, including other strains of E. coli.318
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Amino acid residue 246 in RF2 is four positions towards the N-terminus, and very close to the
universally conserved GGQ motif (Figure 5.7).318,323

Figure 5.7 Crystal structure of RF2 bound ribosome. Residue 246 is in close proximity to the
universally conserved GGQ motif. Q121 of RF2 is within H-bonding distance to C1914 and
U1915 of the loop region of H69 (PDB ID: 4V5E).334
Previous studies revealed that amino acid residue 246 plays a crucial role in stop codon
recognition and polypeptide release during translation termination.318 In these studies, it was
shown that Thr246 decreases RF2-dependent translation termination efficiency compared with
Ala246.318,323 Further studies revealed that effects of decrease in translation efficiency are
significant in RluD(–) bacterial strains.317 From these observations, it is clear that
pseudouridylation and Ala246 play important roles in the H69-RF2 interaction. Moreover, work
in the O'Connor lab revealed that inactivation of the rluD gene in E. coli strains containing the
prfB allele from E. coli B or in Salmonella enterica, both carrying a fully functional RF2 (with
Ala246), had negligible effects on growth, termination, or ribosome function.317 According to the
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crystal structure, residue 246 of RF2 does not have direct interactions with the H69 region
(Figure 5.7).334,335 However, an Ala246Thr mutation might cause indirect effects on the H69RF2 interaction, which might be enhanced in the RluD(–) background since H69 has a less
ordered loop conformation.329
The 2-DOS class of aminolglycosides is known to target the H69 region and inhibit the
ribosome recycling step.147 Since ribosome recycling and termination are sequential steps in the
translation process, defects in the termination step may affect drug binding as well as the
inhibition profiles of these drugs. On the other hand, it is still not clearly understood how the E.
coli K-12 strain with defective RF2 (Thr246) would respond to aminoglycosides compared to
strains with fully functional RF2. In addition to decreased translation termination efficiency,
defective RF2 may play a role in antibiotic resistance, specially under an RluD(–) background.
Considering these facts we thought it would be of interest to compare the inhibition profiles of
MG1655 RluD(–) (UUU, Thr246) and MC416 (UUU, Ala246) strains. Both of these strains are
E. coli K-12 strains and the only genetic variation is the single mutation in RF2, which results in
fully functional RF2 in MC416 and defective RF2 in MG1655. Comparison of the inhibition
profiles of MG1655 RluD(–) with MC416 could reveal the importance of the fully functional
RF2 on the antibacterial activity. For the MG1655 RluD(–) strain, the observed MICs for
neomycin and paromomycin are 11 and 43 mg/L, respectively. The observed MICs are 16-fold
higher than those with the MC416 strain (Figure 5.5 b, e & d, f). This result indicates that the
defective RF2 in MG1655 confers resistance to both neomycin and paromomycin. From these
data, we suggest that RF2-H69 interactions may play direct or indirect roles in drug binding and
antibacterial activities of these structurally related aminoglycosides. With these observations, we
propose that bacterial strains carrying partially defective RF2 show resistance to neomycin and
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paromomycin in the RluD(–) background. Further, we suggest that aminoglycoside resistance
could arise through defects in pseudouridylation or RF2 mutations. The observed results could be
a combined effect of defective RF2 and loss of s on MG1655 strain that perturbs the RF2-H69
interactions.
5.4.6 Loss of  modifications confers resistance to 4, 6-substituted 2-DOS aminoglycosides
Kanamycin and gentamicin have a 4,6-substituted 2-DOS moiety instead of the 4,5substituted 2-DOS found in neomycin and paromomycin (Figure 5.1). Both of these antibiotics
are known to bind the A site of the 30S ribosomal subunit and inhibit protein synthesis.147
However, crystal structures revealed that gentamicin also interacts with the H69 region as a
secondary binding site.147 Considering their different binding modes with H69, it was of interest
to see how pseudouridylation affects the antibacterial activities of these drugs. Previous
biochemical data showed that structural differences of gentamicin impact the binding to
H69.237,239 For example, previous antibiotic footprinting studies in our lab revealed that at the
higher concentrations, gentamicin appears to have a secondary binding site on H69 or an altered
binding mode that leads to different interactions with H69 compared to neomycin and
paromomycin.239 Similar differences were obtained previously with A-site RNA constructs, in
which the 4,6-linked aminoglycoside displayed binding stoichiometries greater than 1:1.141 Since
Ψ modifications in the H69 loop region are associated with modulation of the conformational
states, studies were carried out previously to see how the modifications affect the binding of
gentamicin to H69. In previous antibiotic footprinting experiments, a lower level of DMS
protection at G1922 of unmodified H69 compared to the wild-type suggested that Ψ
modifications play a role in aminoglycoside binding to H69.239 However, the level of protection
by gentamicin was much lower compared to neomycin and paromomycin. These data also
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supported that gentamicin has different binding interactions with H69, and Ψ modifications are
important for those interactions. Even though gentamincin and kanamycin are structurally related
aminoglycosides, kanamycin targets the h44 region and has not been shown to interact with
H69.336 Therefore, despite their structural similarity, kanamycin might recognize different RNA
structural motifs. In this study, MIC experiments were carried out with the 4,6-linked
aminoglycosides and wild-type (MC415, Ψm3ΨΨ) and RluD(–) strains (MC416 (Um3UU)
(Figure 5.8).
As mentioned previously, both strains have fully functional RF2 (Ala 246) and the only
genetic variation is the rluD gene deletion in MC416.317 For gentamicn, the observed MICs for
wild-type and RluD(–) strains are 0.045 mg/L and 0.7 mg/L, respectively (Figure 5.8a & b).
Interestingly, the RluD(–) mutant shows a 16-fold higher MIC value compared to the wild-type
strain with modified H69. This observation is in good agreement with our antibiotic footprinting
studies with unmodified RNA and gentamicin.239 Interestingly, we observed similar behavior for
the structurally-related kanamycin. (0.045 mg/L and 1.4 mg/L for wild-type and RluD(–) strains
(Figure 5.8c & d). Compared to wild-type the RluD(–) strain showed a ~30-fold higher MIC for
kanamycin. Considering the close proximity of h44 and H69 in the 70S ribosome, we
hypothesize that modifications on H69 could affect the mechanism of action of A-site binding
antibiotics.
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Figure 5.8 Effects of H69 pseudouridylation on antibacterial activity of 4,6-linked
aminoglycosides. Inhibition data for the MIC experiments done with gentamicin and kanamycin
in a) and c) wild-type MC415 and in b) and d) RluD(–) MC416 strains and e) and f) MG1655
RluD(–). Percent inhibition of bacterial growth in the presence of different drug concentrations
was calculated and normalized to the growth control as described in Chapter 2, Methods,
Section 2.6.
Our data with kanamycin suggest that conformational changes of H69 upon loss of
modifications could affect the binding and/or antibacterial activity of kanamycin, although we
cannot determine whether this effect is direct (H69 binding) or indirect (h44 binding). Altogether
our data indicate that absence of pseudouridylation confers resistance to 4,6-linked-2-DOS

142

aminoglycosdies. Future structure studies may reveal how these different binding interactions
might lead to the differing inhibition and resistance profiles of these aminoglycosides.
5.4.7 Defective RF2 in RluD(–) does not confer resistance to 4,6-linked-2-DOS
aminoglycosides
We also determined MICs of gentamicin and kanamycin in the MG1655 RluD(–) strain,
which lacks fully functional RF2. Comparison of the MIC values of MC416 and MG1655 RluD( ̶
) strains reveals the effects of perturbed RF2-ribosome interactions on the antibacterial activities
of aminoglycosides. In contrast to our observations with neomycin and paromomycin (Section
5.4.5), we did not observe any differences in MICs in the MG1655 strain compared to MC416
with fully functional RF2 (Figure 5.8e & f). The different trends with structurally similar
aminoglycosides, 4,5- vs. 4,6-linked, are consistent with their different binding interactions with
the ribosome.147,336 From these observations, we conclude that perturbations caused by defective
RF2 and lack of s do not equally affect all aminoglycosides. Perhaps the H69 conformational
changes induced by Ψ or RF2 do not affect or are not significant enough to impact the in vivo
activities of 4,6-linked aminoglycosides, but are important for the 4,5-linked compounds. These
results provide further evidence for the secondary role of H69 in aminoglycoside antibiotic
activity.
5.4.8 Loss of Ψ modifications do not affect the antibacterial activity of peptide antibiotic
capreomycin
Capreomycin is a cyclic peptide antibiotic that belongs to the tuberactinomycin family. 148
Viomycin was the first peptide antibiotic identified in this family. However, the secondgeneration drug capreomycin is the only member being clinically used for Mycobacterium
tuberculosis infections.148,149 These cyclic peptide antibiotics do not effectively inhibit E. coli
cell growth and their mechanism of action is not clearly understood. Such peptide antibiotics are
proposed to inhibit ribosome translocation by stabilizing the A-site tRNA binding interaction,
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while allowing EF-G binding and GTP hydrolysis.337 Capreomycin was recently found to bind at
the interface of the ribosomal subunits and interact with H69 of the 50S subunit and h44 of the
30S subunit simultaneously (Figure 5.9).149

Figure 5.9 Crystal structures of a) neomycin (PDB ID: 4V9C)140 and b) capreomycin (PDB
ID: 4V7M)149 bound 70S ribosomes. Capreomycin bind at the interface of the ribosomal
subunits and interact with H69 of the 50S subunit and h44 of the 30S subunit simultaneously. In
contrast, two neomycin molecules bind at the decoding site of h44 and major groove of H69.
Capreomycin binds to a site that lies between the large and small subunit in a cleft
formed between h44 of the 16S rRNA and the tip of H69 of 23S rRNA. According to a crystal
structure, the binding mode of capreomycin to H69 is different than aminoglycoside
antibiotics.149 This was further confirmed in antibiotic footprinting studies, in which
capreomycin did not show any interactions with H69.239 Considering its different binding mode
with H69 compared to aminoglycosides, it was of interest to examine the effect of H69
pseudouridylation on the antibacterial activity of capreomycin.
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Figure 5.10 Effect of H69 pseudouridylation on antibacterial activity of peptide antibiotic,
capreomycin. Inhibition data for the MIC experiments done with capreomycin in a) a) wild-type
MC415, b) RluD(–) MC416 c) MRE600 and d) MG1655 RluD(–) strains. Percent inhibition of
bacterial growth in the presence of different drug concentrations was calculated and normalized
to the growth control, as described in Chapter 2, Methods, Section 2.6.
Previously it was proposed that the 2'-OH methylation at C1409 of h44 and C1920 of
H69 are important for the antimicrobial activity of peptide antibiotics. Since these modifications
are naturally absent in E. coli strains, these cyclic peptide antibiotics do not effectively inhibit E.
coli cell growth.148 For capreomycin, the observed MIC is 43 mg/L for both wild-type and
RluD(–) strains (Figure 5.10). The higher MIC value of capreomycin is consistent with its poor
activity against E. coli strains. In addition, our result indicates that loss of Ψ modificatons on the
H69 loop does not affect the already poor bactericidal activity of capreomycin. We observed the
same trend with the E. coli MRE600 and E. coli K-12 RluD(–) strains (Figure 5.10 c & d),
which were previously used in antibiotic footprinting experiments. Because of the weak binding
of capreomycin to E. coli H69, the bactericidal activity of the drug may result from interactions
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with h44. Therefore, changes in H69 may not have significant effect on the bactericidal activity
of capreomycin. The close proximity of H69 and h44 in the ribosome suggests that structural
changes of H69 caused by modifications may have impacts on h44 as well. Our in vivo data
suggest this could be impacting aminoglycosides binding differently than capreomycin. We also
determined the MIC of capreomycin in the MG1655 RluD(–) strain, which lacks fully functional
RF2. Comparison of the MIC values of MC416 and MG1655 RluD( ̶ ) strains reveals the effects
of perturbed RF2-ribosome interactions on the antibacterial activities of capreomycin. However,
we did not observe any differences in MICs in the MG1655 strain compared to MC416 with
fully functional RF2 (Figure 5.9d). From these observations, we can conclude that perturbations
caused by defective RF2 and lack of s does not affect the antibacterial activity of capreomycin.
Perhaps the H69 conformational changes induced by Ψs or RF2 do not affect or are not
significant enough to impact the in vivo activities of peptide antibiotic capreomycin. These
results provide further evidence for the existence of a distinct mechanism of action of peptide
antibiotics compared to .aminoglycosides.
5.4.9 Wild type and RluD(–) strains showed similar suceptibility to non-ribosomal targeting
antibiotics
To determine whether wild-type and RluD(–) E. coli strains have similar or different
suceptibilities to other antibiotics, we did MIC experiments with the non-ribosomal targeting
antibiotc carbenicillin as a control experiment. Carbenicillin is a bectericidal antibiotic that
targets bacteria cell wall synthesis. It belongs to the carboxypenicillin subgroup of β-lactam
antibiotics.

146

Figure 5.11 Effects of H69 pseudouridylation on antibacterial activity of the non-ribosome
targeting antibiotic carbenicillin. Inhibition data for the MIC experiments done with
carbenicillin in a) wild-type MC415, b) RluD(–) MC416, c) MRE600 and d) MG1655 RluD(–)
strains. Percent inhibition of bacterial growth in the presence of different drug concentrations
was calculated and normalized to the growth control as described in Chapter 2, Methods.
The only genetic variation between MC415 (m3) and MC416 (Um3UU) is abscence
of the rlud gene in MC416.317 Previous studies in the O’Connor lab showed that these two strains
have similar growth rates despite absence of the rlud gene. In this work, E. coli MC415 and
MC416 displayed the same MIC values and similar inhibition profiles with carbenicillin (Figure
5.11a & b). This observation suggests that the unique inhibition profiles observed with
aminoglycosides with wild-type (MC415) and -deficient (MC416) strains results from
interactions of the drug with the ribosome. Although we cannot do direct comparisons of MICs
of MRE600 () and MG1655 (UUU) strains, it was satisfying that these two strains showed
the same MIC value and similar inhibition profiles with carbenicillin (Figure 5.5c & d).
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5.5 Overall summary and conclusions
Aminoglycosides are one of the most clinically important classes of antibiotics, which
inhibit bacterial protein translation by targeting the 70S ribosome.311 Aminoglycosides with a 2DOS motif are known to inhibit protein translation by binding to the h44 region of the small
subunit adjacent to the decoding site.137,139 However, recent x-ray crystal structures have shown
that neomycin, paromomycin, and gentamicin are able to interact with the major groove of H69
of 23S rRNA as well.

138,146,147

The observed interactions with H69 provide a possible

mechanism for how aminoglycosides inhibit the recycling and translocation steps of protein
synthesis. 147 However, the bactericidal nature of 2-DOS aminoglycoside antibiotics is still poorly
understood despite decades of clinical use and biochemical studies. The emergence of resistance
strains to prevailing aminoglycoside antibiotics and impaired hearing and kidney functions at
high doses made them less effective in clinical applications.314 Therefore, understanding the
underlying mechanism of action of this class of antibiotics is important for the development of
unique antibiotics that target the bacterial ribosome. Pseudouridylation is the most frequent
single-base modification in ribosomal RNA. Helix 69 contains three s at positions 1911, 1915,
and 1917.196 Previous work showed that these  modifications are important for ribosome
function and modulation of the loop structure.237,239 However, few studies were done previously
to understand the role of s in aminoglycoside-ribosome interactions.237,239,319 Previous work in
our lab revealed that  modifications are important for efficient binding of some
aminoglycosides to H69.237,239 This work also showed that structurally similar aminoglycosides
have different structural impacts on the modified and unmodified H69 RNAs. However, all of
these previous studies were confined to in vitro systems. In contrast, the main goal of the work
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presented in this thesis was to investigate the effects of  modifications in H69 on the
bactericidal activity of 2-DOS class aminoglycosides.
Data from our MIC experiments with wild-type (MC415, m3) and -deficient
(MC416, Um3UU) bacterial strains revealed that loss of  modifications conferred resistance to
paromomycin with much smaller impacts on neomycin activity despite its structural similarity to
paromomycin. This effect might be due to the different binding interactions of neomycin with
H69 compared to paromoycin, which was previously reported.146 Interestingly, the observed
antibiotic resistance was even higher for gentamicin and kanamycin, which belong to the 4,6linked aminoglycoside class.

Figure 5.12 Loss of pseudouridylation and defective RF2 (Thr246) confer resistance to 2DOS aminoglycosides. The most notable finding of this chapter is the aminoglycoside resistance
showed by MG1655 strain. This might be a combined effect of defective RF2 and loss of s on
MG1655 strain that perturb RF2-H69 interactions, which may cause decreased ribosomeaminoglycoside (AMN) binding leading to drug resistance.
Compared to wild-type, the -deficient strain showed ~2, ~16, and ~30-fold higher MIC
values, respectively, for paromomycin, gentamicin, and kanamycin. Moreover, our data showed
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that H69-pseudouridylation did not affect antibacterial activity of the peptide antibiotic
capreomycin, in which we observed the same MIC values for wild-type and -deficient strains.
In addition, comparison of the inhibition profiles of MC416 (RF2, Ala246) and MG1655 (RF2,
Thr246) strains gave us the opportunity to evaluate the effects of defective RF2 (Thr246) protein
on the antibacterial activities of aminoglycosides in an RluD(–) background (summarized in
Figure 5.12). Our data reveal that defective RF2 (Thr246) confers resistance to 4,5-linked-2DOS-aminoglycosides neomycin and paromomycin in the RluD(–) background. For both
neomycin and paromomycin, the observed MIC values in the RluD(–) strain (MC416) increased
by 16-fold in RluD(–) and Ala246Thr double mutant strain (MG1655). This might be a
combined effect of defective RF2 and loss of s on MG1655 strain that perturb RF2-H69
interactions. However, we did not see this behavior with 4,6-linked-2-DOS aminoglycosides
gentamicin and kanamycin or peptide antibiotic capreomycin.
Previous observations suggest that H69-RF2 interactions play an important role in
translation termination. It was also shown that Thr246 decreases RF2-dependent translation
termination efficiency compared with Ala246.318,323 However, it is still not clearly understood the
exact role of Ala246Thr mutation in E. coli K-12 strain. In addition to decreased translation
termination efficiency, defective RF2 may play a role in antibiotic resistance, specially under an
RluD(–) background. The 2-DOS class of aminoglycosides is known to target the H69 region
and inhibit the ribosome recycling step.147 Since ribosome recycling and termination are
sequential steps in the translation process, defects in the termination step may affect drug binding
as well as the inhibition profiles of these drugs. Although neomycin, paromomycin, gentamicin,
and capreomycin are known to interact with H69, crystal structures revealed that each of these
antibiotics has unique binding interactions with H69. Our in vivo data suggest that, these
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different interaction patterns of antibiotics with H69 play a role in the in vivo potency of the
drug, giving rise to unique inhibition and resistance profiles to these structurally similar
aminoglycosides. The information gained from these studies provides deeper insight into the
underlying mechanism of action of aminoglycosides, which is important for the development of
unique antibiotics that target the bacterial ribosome at novel sites such as H69.
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CHAPTER 6 OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Overall conclusions
Antibiotics have been used for the past 70 years to treat infectious diseases.161 Although
antibiotics were thought to be the perfect solution to bacterial infections, the emergence of
resistance has become a global health issue.132,163 The development of short peptides that
specifically bind to higher-order structures of ribosomal RNA is one promising way to address
the problem of antibiotic resistance. These peptides could potentially be developed into small
molecule drugs. Recent studies in several laboratories including ours have identified short
peptide sequences targeting rRNA motifs.191,192,215,216,221-223 Most of these studies were confined
to in vitro systems, including binding studies with small model rRNAs,191,192 in vitro chemical
footprinting studies with isolated ribosomes,221 or elucidation of crystal structures of peptidebound ribosomes.221-223 The poor correlation between in vitro and in vivo activities of these
peptides is one of the major questions in antibiotic peptide research. Therefore, in contrast to
these in vitro methods, one of the main objectives of my dissertation work was to utilize a
plasmid-based system to in vivo express ribosome-targeting peptides and study their direct
inhibitory effects on bacteria.
In Chapter 3, I optimized a specific plasmid system to in vivo express a proline-rich
AMP oncocin and studied its direct inhibitory effects on bacteria. The 19-mer, oncocin peptide
sequence was cloned into a plasmid vector and in vivo expressed as a free peptide. The
antibacterial activity of the peptide was confirmed by doing a bacterial growth assay. After
induction of the peptide complete inhibition of (< 80%) bacterial growth was observed. Data of
our growth assay supported the strong antibacterial activity of oncocin. Since the system allows
us to synthesize peptides inside bacteria it has several other downstream applications. The
system was utilized to in vivo express alanine mutants of oncocin and study their inhibitory
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activities. Results of our in vivo alanine scan experiment are in a good agreement with previously
reported structural and biochemical data and support the critical roles of Lys3, Tyr6, Leu7, and
Arg11 residues of oncocin in ribosome binding and antibacterial activity. One additional
application of our plasmid system is in vivo probe ribosome-peptide interactions. In vivo
chemical footprinting studies were carried out using dimethyl sulfate (DMS) as the chemical
probe to study the oncocin-ribosome interactions. Data of our footprinting experiments
confirmed the interaction of oncocin with the PTC region of the ribosome. To the best of our
knowledge this is the first effort to use in vivo DMS footprinting technique to study ribosomepeptide interactions.
In my dissertation research, the main focus was on H69 of the 50S subunit. H69 is
proposed to be a potential drug target based on its pivotal role in ribosome protein synthesis at
multiple stages and its unique higher-order RNA structure.50,195,196 In previous studies, the phagedisplay method was used to identify peptides that target the H69 region.192,236 In vitro binding
studies have shown that these selected peptides have moderate affinity towards H69.191,192 In a
second approach, peptide variants with higher affinity and enhanced selectivity were identified
by doing alanine and arginine scans of the parent peptide sequence derived from phage
display.191 Specificity, stoichiometries, and binding affinities of these peptides to H69 were
determined by using in vitro methods. Our working hypothesis was that the selected peptides
will bind to H69 and disrupt ribosome function. However, the in vivo activity of these peptides
was not determined. In Chapter 4 of this dissertation work, we utilized the optimized-plasmid
system to in vivo express H69-targeting peptide sequences, NQAANHQ, TARHIY, and
RQVANHQ. We hoped that in vivo expression of these peptides would allow us to study their
behavior of selected peptides in the actual cellular environment. In the first approach, peptides
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were expressed as GFP fusion proteins, and in the second approach they were expressed as free
peptides. In both systems, we found that the NQAANHQ peptide had slightly better inhibition
compared to other H69-targeting peptides. Based on in vivo and in vitro data, we can consider
NQAANHQ as a potential drug lead, but it will need considerable modifications or alterations to
improve its activity.
Another important type small molecule considered in this thesis work is the
aminoglycoside, a well-known antibiotic that targets the bacterial ribosome. The previously
identified primary binding site of the 2-deoxystreptamine (2-DOS) family of antibiotics was h44
of the small subunit adjacent to the decoding site.132,139 Recent x-ray crystal structures have
shown that neomycin, paromomycin, and gentamicin are able to interact with the major groove
of H69.138,140,146,147 However, the bactericidal nature of 2-DOS aminoglycoside antibiotics is still
poorly understood.140,146 Previous work in our lab revealed that  modifications are important
for efficient binding of aminoglycosides to H69.237,238
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However, the effects of 

modifications on the bactericidal activity of aminoglycosides have not been examined. The work
presented in the Chapter 5 of this thesis discusses the effects of s in H69 on the bactericidal
nature of 2-DOS aminoglycoside antibiotics. Antibacterial activities were assessed by
performing minimum inhibitory concentration (MIC) studies using wild-type and -deficient
bacterial strains. Our data reveal that loss of  modifications in the MC416 strain confer
resistance to 4,6-2-DOS-linked aminoglycosides, gentamicin and kanamycin, whereas the effect
was not significant with 4,5-2-DOS-linked aminoglycosides, neomycin and paromomycin. In
addition, comparison of the inhibition profiles of MC416 (RF2, Ala246) and MG1655 (RF2,
Thr246) strains gave us the opportunity to evaluate the effects of defective RF2 (Thr246) protein
on the antibacterial activities of aminoglycosides in an RluD(–) (pseudouridine-deficient)
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background. Our data reveal that defective RF2 (Thr246) confers resistance to 4,5-linked-2DOS-aminoglycosides, neomycin and paromomycin. However, we did not see this behavior with
4,6-linked-2DOS

aminoglycosides,

gentamicin

and

kanamycin,

or

peptide

antibiotic

capreomycin. With this observation, we suggest that bacterial strains carrying partially defective
RF2 show resistance to 4,5-linked-2-DOS aminoglycosides and this might be a combined effect
of defective RF2 and loss of s on the MG1655 strain, which likely perturb RF2-H69
interactions. Altogether our data confirm that in vitro observed structural and binding differences
affect the in vivo potency of the drug and give rise to unique inhibition and resistance profiles to
these structurally similar aminoglycosides. The information gained from these studies provides
deeper insight into the underlying mechanism of action of aminoglycosides, which is important
for the development of unique antibiotics that target the bacterial ribosome at novel sites such as
H69. In contrast to in vitro methods, most of the work that I did for my dissertation is focused on
the in vivo activity of antibacterial drugs targeting the bacterial ribosome. In fact, the methods
that I developed are not confined to ribosome-targeting drugs. We can expand this work to study
the in vivo activity of other peptide-based as well as other classes of drugs.
6.2 Future directions
6.2.1 In vivo expression of peptide libraries
The poor correlation between in vitro antimicrobial activity and in vivo efficacy is one of
the major obstacles that has limited the progression of AMP candidates towards clinical
development.228,229 Most commonly, the identification of therapeutic peptides starts with in vitro
screening of peptide libraries. This can be done with a random peptide library or peptide library
derived from a known AMP.191,215 For example, with the phage display technique, random
phage-displayed peptide libraries are incubated with a target of interest to select for those
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specifically binding to the target.230 Typically the target is immobilized on a solid support before
addition of the phage library. However, in these in vitro screening techniques, the most crucial
peptide-target interaction step occurs in a simulated environment, which is very different than the
actual cellular environment.228,229 This process also requires identification and synthesis or
isolation of the target prior to the experiment, as well as the assumption that the target is in its
bioactive conformation under these in vitro conditions. Another important concern is that targets
such as DNA, RNA, or proteins have numerous conformations in vivo that are influenced by
their environment. Peptides are also highly sensitive to their environmental conditions, which
results in discrepancies between their in vitro and in vivo activity. On the other hand in vitro
peptide library screens entirely depend on SPPS, which is expensive and time consuming.
Therefore, the development of in vivo peptide libraries would be an alternative approach to
overcome the limitations of in vitro peptide library screens.231-234
In a recent study, an oncocin-based in vitro peptide library was synthesized in order to
identify analogs with improved antibacterial activity against gram-positive bacterial strains.338 A
library of singly substituted oncocin analogs was produced by replacing each residue with all 20
canonical amino acids, yielding a set of 361 individual peptides. In this work, a peptide array
technology was employed to synthesize monosubstituted oncocin analogs on cellulose
membranes using cleavable linkers to release the free individual peptides for further
antimicrobial tests.338 Thirteen substitutions appeared promising and their improved antibacterial
activities were confirmed for different bacterial strains after larger scale synthesis of these
analogs. By combining two favorable substitutions into one peptide, they finally obtained an
oncocin analog that was ten times more active against P. aeruginosa and even 100-fold more
active against S. aureus compared to the original oncocin peptide. However, these kind of studies
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are entirely dependent on SPPS. In addition, the chemical synthesis of proline-containing
peptides is difficult because of the low reactivity of secondary amines. Therefore, the in vivo
peptide expression approach will have several advantages over SPPS. Considering these facts, as
the next immediate step of this project, we have already expressed an oncocin-based in vivo
peptide library in our laboratory. The ultimate goal of this project is to identify oncocin analogs
with improved antibacterial activity. Our system is not confined to AMPs. Therefore, we can
utilize our plasmid system to generate peptide libraries, or study a variety of other biologically
interesting peptides (e.g., anti-freeze peptides).
6.2.2 In vivo and in vitro chemical footprinting studies with H69-targeting peptides
In Chapter 3 of this dissertation work, I optimized an in vivo DMS footprinting protocol
to study oncocin-ribosome interactions. Our data in this footprinting experiment are in good
agreement with previously reported information on oncocin-ribosome interactions. This implies
that the in vivo footprinting protocol that I optimized is useful for studying peptide-ribosome
interactions in cellular environments. Therefore, we can use this optimized protocol to study a
variety of other ribosome-targeting peptides. Since the H69-targeting peptide NQAANHQ
showed comparatively higher inhibitory activity in our bacterial growth assays, it is of interest do
in vivo as well as in vitro DMS footprinting experiments with our H69-targeting peptides to
confirm their interactions with H69 region. In addition, we are currently using the in vivo DMS
footprinting technique to examine h31-targeting peptide-ribosome interactions.
6.2.3 Synthesis of peptide-aminoglycoside conjugates with enhanced antibacterial activity.
Based on our in vivo and in vitro data, we can consider NQAANHQ as a potential drug
lead, but it will need considerable modifications or alterations to improve its activity. Since 2DOS aminoglycosides also target the H69 region, a fragment-based drug design approach for
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producing peptide-aminoglycoside conjugates would be an interesting approach to improve the
antibacterial activity of H69-targeting peptides. There are several previous reports on
aminoglycoside-peptide conjugates.339-341 In most of these studies, click-chemistry was used to
synthesize the aminoglycoside-peptide conjugates, and the new classes of compounds showed
enhanced antibacterial activities against aminoglycoside-resistant bacterial strains.339,340 Docking
studies using PDB files of known crystal structures of the bacterial ribosome can be used to
study possible conjugation profiles between the neamine core of aminoglycosides and H69targeting peptides. This modeling approach could provide the best information for synthesizing
compounds containing peptide and aminoglycoside compounds.
6.2.4 Chemical footprinting studies with 2-DOS aminoglycosides
The work presented in Chapter 5 of this thesis focused on the effects of s in H69 on
the bactericidal nature of 2-DOS aminoglycoside antibiotics. The antibacterial activities of
different antibiotics in wild-type (MC415,) and RluD(–) (MC416, UUU) bacteria strains
were assessed by performing MIC studies. Even though MIC is a very good indication of the in
vivo activities of antibiotics, it does not entirely depend on the drug-target interaction. Therefore,
in order to gain further information about aminoglycoside-H69 interactions it is of interest to do
in vitro chemical footprinting experiments with 2-DOS aminoglycosides. Chemical footprinting
is considered as a powerful technique to study RNA-drug interactions.248-250 The chemical
footprinting technique was explained in detail in Chapter 2. However, for footprinting
experiments we have to isolate modified and unmodified ribosomes from MC415 and MC416
strains, respectively. Comparison of the antibiotic footprinting patterns of modified and
unmodified ribosomes will provide more information about the effects of  modifications on the
binding of aminoglycosides. Previous studies in our laboratory had employed ribosomes with a
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mutant RF2 (Thr 246). The information gained from these studies in conjunction with the wildtype RF2 protein will provide deeper insight into the underlying mechanism of action of
aminoglycosides, which is important for the development of unique antibiotics that target the
bacterial ribosome at novel sites such as H69.
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ABSTRACT
INVESTIGATION OF THE IN VIVO ACTIVITY OF RIBOSOME-TARGETING
PEPTIDES AND AMINOGLYCOSIDES IN ESCHERICHIA COLI
by
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August 2018
Advisor: Dr. Christine S Chow
Major: Chemistry (Biochemistry)
Degree: Doctor of Philosophy
The development of short peptides that specifically bind to higher-order structures of
ribosomal RNA is one promising way to address the problem of antibiotic resistance. However,
the poor correlation between in vitro and in vivo activities of these peptides is one of the major
questions in antibiotic peptide research. Therefore, one of the main objectives of this dissertation
work was to utilize a plasmid-based system to in vivo express ribosome-targeting peptides and
study their direct inhibitory effects on bacteria. A specific plasmid system was optimized to in
vivo express oncocin, a proline-rich antimicrobial peptide and its variants in bacteria. Our data
showed that the in vivo-expressed peptide completely inhibited bacterial growth and displayed
bactericidal activity. The in vivo dimethyl sulfate (DMS) footprinting data revealed interactions
of oncocin with the PTC region of the bacterial ribosome. The optimized plasmid system was
utilized to in vivo express short peptides that are known to target the helix 69 (H69) region of the
ribosome. In the first approach, peptides were expressed as GFP-fusion proteins, and in the
second approach they were expressed as free peptides. In both systems, we found that the
NQAANHQ peptide had slightly better inhibition compared to other H69-targeting peptides.
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Based on in vivo and in vitro data, we consider NQAANHQ as a potential drug lead, but it will
need considerable modifications or alterations to improve its activity.
The bactericidal nature of 2-deoxystreptamine aminoglycoside antibiotics is still poorly
understood despite decades of clinical use and biochemical studies. Previous work showed that
 modifications are important for efficient binding of aminoglycosides to H69. However, the
effects of  modifications on the bactericidal activity of aminoglycosides have not been
examined. Antibacterial activities of 2-deoxystreptamine aminoglycosides were assessed by
performing minimum inhibitory concentration (MIC) studies using wild-type and -deficient
bacterial strains. Our data revealed that loss of  modifications conferred resistance to 4,6linked-2-DOS aminoglycosides, gentamicin and kanamycin, whereas the effect was not
significant with 4,5-linked-2-DOS aminoglycosides, neomycin and paromomycin. However,
bacterial strains carrying mutant release factor 2 (RF2, Ala246Thr) showed resistance to
neomycin and paromomycin in the -deficient background. The observed results could be a
combined effect of loss of s and defective RF2 that perturb the ribosome-drug interactions.
Collectively, the information gained from these studies provides deeper insight into the
underlying mechanism of action of ribosome-targeting drugs, which is important for the
development of unique antibiotics that target the bacterial ribosome at novel sites such as H69.
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